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The pulsatile release of luteinising hormone (LH) induced by intermittent release 
of the gonadotrophin-releasing hormone (GnRH) is essential for initiating 
puberty and maintaining normal reproductive functions. Many neuropeptides 
including neurokinin B (NKB), substance P, kisspeptin (Kiss1) and 
gonadotrophin-inhibiting hormone (GnIH) have been implicated in regulating 
the secretion of LH. However, few studies have demonstrated the effects of 
those neuropeptides on pulsatile LH release and the dynamic changes of LH 
secretion in different gonadal hormone conditions. Studies outlined in this thesis 
have shown that antagonism of NKB receptor inhibits the pulsatile release of LH 
and delays the timing of puberty onset in female rats. Furthermore, NKB 
receptor agonism suppresses pulsatile LH release in ovariectomised (OVX) adult 
rats, but stimulates LH secretion in OVX rats replaced with 17β-oestradiol (E2). 
Likewise, intra-arcuate nucleus (ARC) administration of substance P, a 
neuropeptide belonging to the same family of NKB, suppresses pulsatile LH 
release in OVX rats, but stimulates LH secretion in OVX rats replaced with E2. 
Kiss1, a potent stimulator of the hypothalamo-pituitary-gonadal (HPG) axis, has 
been studied extensively within the hypothalamus, but little is known about its 
extra-hypothalamic effects. Current studies have shown that administration of 
Kiss1 into the medial amygdala (MeA), a key limbic brain structure involved in 
reproduction, stimulates LH secretion in OVX rats. Furthermore, intra-MeA 
administration of Kiss1 receptor antagonist inhibits the pulsatile LH release in 
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OVX rats and spontaneous LH surges in intact female rats. Unlike Kiss1, GnIH 
is a major inhibitor of the reproductive axis. Central administration of 
RFamide-related peptides-3 (RFRP-3), the mammalian orthologue of GnIH, 
suppresses the pulsatile LH release in OVX rats. This effect is partially mediated 
through the endogenous opioid peptides. RFRP-3 is also implicated in 
stress-induced suppression of pulsatile LH secretion. Furthermore, antagonism 
of RFRP-3 receptor in the ARC and the medial preoptic area (mPOA) stimulates 
LH secretion in OVX rats with E2 replacement, indicating that RFRP-3 may also 
regulate the E2-induced negative feedback control of LH release. Taken together, 
the present study has demonstrated that various neuropeptides signaling systems 
including NKB, substance P, Kiss1 and RFRP-3 regulate pulsatile LH secretion 
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CHAPTER ONE: GENERAL INTRODUCTION 
1.1 The hypothalamo-pituitary-gonadal axis 
Reproduction is essential for the evolution and survival of all life forms on earth. 
This process is biologically complex, particularly in higher organisms such as 
mammals. The reproductive system of mammals is tightly regulated by the 
hypothalamo-pituitary-gonadal (HPG) axis. Generally, this axis consists of a 
feedback loop that incorporates hypothalamic neurones, endocrine cells of the 
anterior pituitary and the gonads, which are in communication via hormonal 
signals. 
The major hypothalamic effector of the HPG axis is the neuropeptide 
gonadotrophin-releasing hormone (GnRH), which is secreted from a group of 
hypothalamic neurones. In rats, the majority of GnRH neuronal cell bodies are 
located in the medial preoptic area (mPOA) (Witkin et al. 1982). The GnRH 
neurones project to the median eminence (ME) and release GnRH in a pulsatile 
fashion into the pituitary portal blood system (Belchetz et al. 1978, Witkin et al. 
1982). In the anterior pituitary gland, GnRH binds with GnRH receptors on 
specialised gonadotroph cells, which leads to the secretion of the gonadotrophins 
luteinising hormone (LH) and follicle-stimulating hormone (FSH) into the 
systemic circulation (Amoss et al. 1971, Schally et al. 1971a). GnRH pulse 
frequency determines LH pulse frequency but is not tightly coupled to that of 
FSH (Clarke and Pompolo 2005). Furthermore, basal levels of LH and the 
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amplitude of LH pulses are affected by the frequency of GnRH/LH pulses 
(Clarke and Cummins 1985). High frequency of GnRH or LH pulses lead to 
lower amplitude of LH pulses, whereas low frequency lead to higher amplitude 
(Clarke and Cummins 1985, Wu et al. 1987). 
In females, gonadotrophins stimulate the synthesis of progesterone (P4) and 
oestrogens, the most notable of which is 17β-oestradiol (E2). The female HPG 
axis is subject to feedback stimulation or inhibition by these gonadal steroids 
produced mainly in the ovary. The female ovary is characterised by spontaneous 
cycles of ovarian follicle development, ovum selection and ovulation. After the 
initiation of puberty in the rat, a number of follicles commence growth every day 
to form a continuous source of developing follicles. The immature primordial 
follicles contain immature oocytes surrounded by a single layer of granulosa cell. 
At the beginning of each cycle this single cell layer proliferates to form the outer 
thecal cell layer and inner granulosa cell layer surrounding the developing 
oocytes. LH stimulates thecal cells via LH receptor to synthesize androgens, 
which are aromatized by granulosa cells to produce E2 (Makris and Ryan 1977, 
Magoffin and Erickson 1982). This aromatization is stimulated by FSH. The E2 
can bind to receptors in the granulosa cells, which are then stimulated to 
proliferate and produce more E2 (Chakravorty et al. 1993). This positive 
feedback of E2 synthesis leads to high circulating levels of E2, whch are 
stimulatory to the activity of the GnRH neural network. The resultant increase in 
GnRH secretion induces an LH surge (Sarkar et al. 1976), which triggers 
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domiant follicles to release ova, while others undergo atresia. The collapsed 
follicles are transformed into corpus lutea which secret P4 and E2. Low levels of 
E2 have been implicated in the inhibition of GnRH pulse frequency in rats 
(Nishihara et al. 1994). P4 enhances E2-induced negative feedback control of LH 
release in rats (Goodman 1978). During the oestrous cycle, the pulsatile release 
of GnRH is present and highly sensitive to the effects of gonadal steroid 
signalling. In rats, the lowest frequency and amplitude of LH pulses were 
observed in oestrus phase of the cycle (Gallo 1981). 
In males, LH and FSH control the release of testosterone from the Leydig cells 
of the testes, some of which is aromatized into E2. P4 synthesis by the testis is 
also stimulated by the gonadotrophins. The collective functions of gonadal 
steroids in males include restraint of GnRH secretion, maintenance of 
spermatogenesis, thermoregulation and modulation of behaviour.  
 
1.2 The GnRH pulse generator 
The development of radioimmunoassays for LH and FSH levels (Midgley 1966, 
Midgley and Jaffe 1966) enabled the measurement of circulating levels of these 
hormones. LH is released from the anterior pituitary in a pulsatile fashion and 
the basal frequency of LH pulses differs between species. LH pulses are 
observed approximately every 75 minutes (min) in ovariectomised (OVX) 
monkeys (Dierschke et al. 1970) and every 20 min in OVX rats (Gay and Sheth 
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1972). The discovery of GnRH as the hypothalamic neuropeptide responsible for 
the release of gonadotrophins (Schally et al. 1971b) energised the field to 
understand the underlying mechanisms. It was suggested that a pulsatile 
secretion of GnRH is required to induce the pulsatile LH release into the 
peripheral circulation (Osland et al. 1975, Schuiling and Gnodde 1976). This 
was verified after the development of a radioimmunoassay for GnRH (Nett et al. 
1973), which enables the detection of the pulses of GnRH through sampling of 
the portal blood. It was shown that not only is GnRH released in a pulsatile 
fashion into the portal blood, but that each GnRH pulse is tightly coupled to a 
pulse of LH (Carmel et al. 1976, Clarke and Cummins 1982, Levine and Duffy 
1988). Therefore, the pulsatile release of GnRH determines the episodic LH 
pulses. The term ‘GnRH pulse generator’ has been used to describe the neural 
construct responsible for this rhythmic discharge of GnRH since the 1970s 
(Dierschke et al. 1970), even though the exact neural structure of this construct 
is still unknown. 
The GnRH pulse generator is thought to be located in the mediobasal 
hypothalamus which includes the arcuate nucleus (ARC). Indeed, lesions of the 
ARC in OVX rats (Blake and Sawyer 1974, Soper and Weick 1980) have been 
shown to abolish pulsatile LH release. Furthermore, synchronised bursts, or 
‘volleys’, of multiunit electrical activity (MUA), were shown to coincide 
invariably with LH pulses in OVX ewes (Thiery and Pelletier 1981), rats 
(Kawakami et al. 1982), monkeys (Wilson et al. 1984) and goats (Mori et al. 
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1991). Since a large population of GnRH neurones reside in the ARC of 
monkeys (Silverman et al. 1982), it was postulated that the GnRH neurones 
might possess this inherent rhythmicity. Indeed, cultured GnRH cells are capable 
of releasing GnRH at a comparable frequency to that observed in both rats and 
monkeys in vivo (Krsmanovic et al. 1992, Martinez de la Escalera et al. 1992, 
Wetsel et al. 1992, Terasawa et al. 1999a). This process was coupled with 
spontaneous synchronized oscillations of intracellular calcium concentrations 
and resultant firing of action potentials (Terasawa et al. 1999b, Nunez et al. 
2000, Richter et al. 2002). Rhythmic calcium current synchrony was also 
observed in non-neuronal cells between GnRH neurones (Richter et al. 2002), 
which might explain how GnRH neurones are able to synchronize their activity 
despite their diffuse distribution in the mammalian brains (King et al. 1982). 
However, GnRH neurones were not found to be located in the ARC of rats (King 
et al. 1982), yet abrupt increase of MUA, reflecting the activity of the GnRH 
pulse generator, are recorded from this region (Kawakami et al. 1982, Kimura et 
al. 1991, Nishihara et al. 1991, Goubillon et al. 1995, McGarvey et al. 2001, 
Kinsey-Jones et al. 2008). Furthermore, the frequency of spontaneous calcium 
oscillations in cultured mouse GnRH neurones was inconsistent with that of 
GnRH pulses in the mouse (Jasoni et al. 2007). Normal pulsatile LH release 
persists in OVX rats with mediobasal hypothalamus (no GnRH neurones reside 
within this region) isolated from the rest of brain (Blake and Sawyer 1974, 
Ohkura et al. 1991). This indicates that the neural construct that constitutes the 
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rodent GnRH pulse generator does not necessarily include the GnRH neurones. 
In line with this, recent in vivo studies using optogenetic approaches have shown 
that synchronizing GnRH neurones of mice to fire together in their normal 
bursting pattern fails to generate LH pulses (Campos and Herbison 2014). In 
contrast, optogenetic activation of GnRH neurones at the GnRH neuron cell 
bodies or their terminal projections at ME can induce LH pulses (Campos and 
Herbison 2014). 
 
1.3 The KNDy signalling systems 
Recent studies have identified the neuropeptide, kisspeptin (Kiss1), and Kiss1 
receptor (Kiss1r; previously known as G protein-coupled receptor 54, GPR54), 
as a major regulator of the HPG axis. Kiss1 is encoded by Kiss1 gene and 
cleaved into different forms including 54, 14, 13 and 10 (Kp-10) amino acid 
peptides (Harms et al. 2003). All Kiss1 proteins and truncated forms contain a 
C-terminal 10 amino acid motif which is highly conserved across species 
(Stafford et al. 2002, Terao et al. 2004) and has the same affinity and efficacy on 
the rat receptor (Kotani et al. 2001). Unless specifically mentioned, all Kiss1 
fragments will be referred to as Kiss1. 
Kiss1 was initially described as a suppressor of metastasis in malignant 
melanoma (Lee et al. 1996). In 2003, inactivating mutations of gene KiSS1r 
were found to cause hypogonadotrophic hypogonadism in humans associated 
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with the delay or absence of puberty onset (de Roux et al. 2003, Seminara et al. 
2003). In addition, humans with activating mutations of gene KiSS1r 
experienced precocious puberty (Teles et al. 2008). Animal studies have further 
substantiated the above facts with Kiss1 or Kiss1r knockout mice showing low 
levels of gonadotrophins and delayed puberty onset (Funes et al. 2003, Seminara 
et al. 2003, d'Anglemont de Tassigny et al. 2007, Lapatto et al. 2007). 
Since the discovery of KiSS1r mutations as a cause of hypogonadotrophic 
hypogonadism, considerable evidence has been generated to show the 
stimulatory effects of Kiss1 on the gonadotrophins. It has been widely reported 
that central or peripheral administration of Kiss1 induces an increase in LH and 
FSH release in rats (Irwig et al. 2004, Matsui et al. 2004, Navarro et al. 2004, 
Thompson et al. 2004, Navarro et al. 2005a, Navarro et al. 2005b, Patterson et 
al. 2006, Tovar et al. 2006), mice (Gottsch et al. 2004, Messager et al. 2005), 
sheep (Messager et al. 2005, Arreguin-Arevalo et al. 2007), monkeys (Shahab et 
al. 2005, Plant et al. 2006, Seminara et al. 2006) and humans (Dhillo et al. 2005, 
Dhillo et al. 2007). Furthermore, Kiss1 has a more potent stimulatory effect on 
LH release than with FSH release (Navarro et al. 2005a, Dhillo et al. 2007). 
Kiss1-induced gonadotrophin release can be blocked by GnRH antagonists in 
many species, including rats (Irwig et al. 2004), mice (Messager et al. 2005) and 
monkeys (Shahab et al. 2005). Both central and peripheral administration of 
Kiss1 induces c-Fos expression (marker of neuronal activation) in GnRH 
neurones (Irwig et al. 2004, Matsui et al. 2004). In vitro studies have shown that 
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Kiss1 can induce a potent long-lasting depolarization in mouse GnRH neurones 
(Han et al. 2005, Liu et al. 2008). Therefore, Kiss1 appears to stimulate the HPG 
axis via activation of GnRH neurones directly. Indeed, expression of Kiss1r 
mRNA has been found in the majority of GnRH neurones in rats (Irwig et al. 
2004), mice (Han et al. 2005, Messager et al. 2005) and monkeys (Shahab et al. 
2005). Specific knockout of Kiss1r in GnRH neurones nullifies the stimulatory 
effect of Kiss1 on the electrical activity of GnRH neurones (Kirilov et al. 2013). 
In addition, Kiss1 neurones project to GnRH perikarya (Clarkson and Herbison 
2006b, Yeo and Herbison 2011, Yip et al. 2015) and axon terminals (Decourt et 
al. 2008, Ramaswamy et al. 2008, Yip et al. 2015), providing anatomical 
evidence of direct innervations of GnRH neurones by Kiss1 neurones. 
Kiss1 and Kiss1r are widely expressed throughout the brain, particularly in the 
hypothalamus. Two principal populations of Kiss1 neurones are located in 
anteroventral periventricular area (AVPV) and ARC in rodents (Clarkson et al. 
2009, Oakley et al. 2009). In the ARC, Kiss1 neurones co-express dynophin 
(Dyn) and neurokinin B (NKB). In 2009, patients with severe congenital 
gonadotrophin deficiency and pubertal failure were found to have inactivating 
mutations in TAC3 or TACR3, the genes encoding NKB or its receptor 
neurokinin 3 receptor (NK3R), respectively (Topaloglu et al. 2009). It revealed 
the key role of NKB in the central control of reproduction. However, 
pharmacological studies investigating the effect of NKB on gonadotrophin 
release have yielded conflicting results, with some showing stimulatory effects 
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(Billings et al. 2010, Ramaswamy et al. 2010, Navarro et al. 2011a) and others 
showing inhibitory effects (Sandoval-Guzman and Rance 2004, Navarro et al. 
2009a, Kinsey-Jones et al. 2012). Similarly, recent animal studies that generated 
Tacr3 knockout mice (in rodents, NKB and NK3R were encoded by Tac2 and 
Tacr3, respectively) or administered antagonists to NK3R failed to recapitulate 
the symptoms presented in human patients caused by inactivating genetic 
mutations (Gill et al. 2012, Navarro et al. 2012, Yang et al. 2012). Compared 
with Kiss1, NKB appears to be a less potent driving force in the HPG axis. 
Indeed, it has been proposed that the stimulatory effect of NKB on the HPG axis 
is dependent on Kiss1 signalling (Navarro 2013). 
Dyn is an endogenous opioid peptide that preferentially signals through the 
κ-opioid receptor (Wuster et al. 1980). Dyn is involved in the suppression of LH 
release (Kinoshita et al. 1982, Navarro et al. 2009a). Furthermore, this inhibitory 
effect appears to be modulated through the GnRH pulse generator, since central 
administration (intracerebroventricular, icv) of Dyn antagonist increased LH 
pulse frequency in rats (Gallo 1990) and reduced the interval between MUA 
volleys in the ARC of goat (Wakabayashi et al. 2010). Indeed, intra-ARC 
administration of an agonist of the κ-opioid receptor decreased LH pulse 
frequency in OVX rats (Grachev et al. 2012a), indicating that ARC Dyn 
signalling is inhibitory to the GnRH pulse generator. 
Across species, Kiss1 neurones in the ARC have been found to be co-expressed 
with NKB and Dyn, and are therefore named the Kiss1/NKB/Dyn (KNDy) 
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neurones (Lehman et al. 2010). Furthermore, KNDy neurones in the ARC 
co-express NK3R and project to one another forming an interconnected network 
(Krajewski et al. 2010). It has been speculated that NKB exerts stimulatory 
effects on KNDy neurones via NK3R to evoke synchronized bursting activities 
among KNDy neurones. The resultant release of Dyn extinguishes these bursting 
activities and imposes a prolonged inhibitory effect on KNDy neurones, until the 
next episodic oscillation. Each NKB/Dyn oscillation could induce a Kiss1 pulse 
which activates the GnRH neurones to produce the pulsatile mode of GnRH 
secretion into the pituitary portal blood. Therefore, the KNDy neurones could 
represent at least part of the neuronal construct of the GnRH pulse generator 
(Okamura et al. 2013). 
 
1.4 Steroid hormone feedback to KNDy signalling systems 
Prior to the discovery of Kiss1 as a driving force in the HPG axis, the 
mechanisms by which gonadal steroids exert their feedback control on GnRH 
release were unknown. GnRH neurones per se do not express the androgen 
receptor, oestrogen receptor α (ERα) or P4 receptor (Shivers et al. 1983, Skinner 
et al. 2001). It has been shown that Kiss1 neurones express androgen receptor, 
ERα and ERβ which indicates that Kiss1 neurones may regulate steroids 
feedback control on GnRH release (Smith et al. 2005a, Smith et al. 2005b, Kim 
et al. 2011). Furthermore, different populations of Kiss1 neurones are under 
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different control by gonadal steroids. In both male and female mice, expression 
of Kiss1 mRNA in the ARC is increased by gonadectomy, but reduced by the 
replacement of gonadal steroids (Smith et al. 2005a, Smith et al. 2005b). 
Conversely, treatment with gonadal steroids increases the expression of Kiss1 
mRNA in the AVPV in both male and female mice (Smith et al. 2005a, Smith et 
al. 2005b). Similarly, in both male and female rodents, gonadal steroids increase 
the expression of Kiss1 mRNA in the medial amygdala (MeA), a region 
implicated in social and emotional behaviours as well as various aspects of 
reproduction (Kim et al. 2011). Although the physiological relevance of Kiss1 
neurones in the MeA remains unknown, there is abundant evidence to suggest 
that AVPV and ARC Kiss1 neurones are involved in distinct attributes of 
gonadal steroids feedback control of GnRH release. 
In female rodents, AVPV Kiss1 neurones have been proposed to relay the 
positive feedback effects of E2 on GnRH neurones during the generation of the 
preovulatory LH surge. The expression of Kiss1 mRNA in the AVPV in females 
peaked during the afternoon of the proestrus stage, and the AVPV Kiss1 
neurones were strongly activated during the LH surge, measured by the c-Fos 
expression in these neurones (Smith et al. 2006, Adachi et al. 2007, Clarkson et 
al. 2008). Central administration of Kiss1 antagonist into the mPOA where 
GnRH neurones reside blocked the spontaneous and E2-induced LH surges in 
female rats (Kinoshita et al. 2005, Adachi et al. 2007). Similarly, chronic 
administration (icv) of specific Kiss1r antagonist abolished the spontaneous LH 
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surges (Pineda et al. 2010a). Kiss1 or Kiss1r knockout female mice also failed to 
generate preovulatory LH surges, accompanied with decreased GnRH neuronal 
activities during that time (Clarkson et al. 2008). Furthermore, ERα knockdown 
in Kiss1 neurones blocked ovulation in female mice, substantiating the 
hypothesis that the positive feedback control of E2 on GnRH secretion are 
mediated by Kiss1 neurones in the AVPV through ERα signalling (Mayer et al. 
2010). 
Contrary to Kiss1 neurones in the AVPV, ARC Kiss1 neurones regulate the 
negative feedback control of gonadal steroids. The up-regulating of Kiss1 
mRNA expression in the ARC following OVX corresponded with an increase in 
circulating levels of gonadotrophins (Smith et al. 2005a). This increase was 
significantly attenuated in female mice lacking ERα in Kiss1 neurones (Mayer et 
al. 2010). In the ARC, Kiss1 neurones co-express NKB and Dyn. Like Kiss1, 
NKB and Dyn are both involved in the negative feedback control of gonadal 
steroids. The expression of Tac2 mRNA in the ARC was elevated after OVX 
and reduced after E2 treatment in female rats (Dellovade and Merchenthaler 
2004). The reduction in Tac2 mRNA levels by E2 was nullified in ERα knockout 
female mice (Dellovade and Merchenthaler 2004). This indicates that ERα 
signalling is also involved in NKB modulated E2 negative feedback control. Dyn 
has been involved in P4-induced inhibition of pulsatile GnRH release. Dyn 
neurones in the ARC express receptors for P4 (Foradori et al. 2002) and central 
administration of Dyn antagonist blocked P4-induced inhibition of pulsatile LH 
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release in sheep (Goodman et al. 2004). As expected, gonadectomy decreased 
the Dyn mRNA expression in the ovine ARC (Foradori et al. 2005). However, 
the expression of Dyn mRNA in the ARC remained unchanged by P4 treatment 
or inhibited by E2 treatment (Foradori et al. 2005, Gottsch et al. 2009, Navarro et 
al. 2009a), despite its suppressive effects on LH release. Nevertheless, the ERα 
signalling seems to be involved in the E2 negative feedback control by Dyn, 
since the inhibition of Dyn mRNA by E2 treatment was abolished in female mice 
lacking ERα (Gottsch et al. 2009). In summary, KNDy neurones in the ARC are 
the principal mediators regulating gonadal steroids-induced negative feedback 
control of the gonadotrophins. 
 
1.5 KNDy signalling in reproductive development 
Puberty is defined as acceleration of growth, achievement of reproductive 
competence and development of secondary sexual characteristics (Grumbach 
2002). The vaginal opening, an external marker of puberty onset, usually occurs 
a day after the first ovulation in most laboratory rats (35-45 d after birth) (Heger 
and Ojeda 2007). In female rhesus monkeys, menarche and first ovulation occurs 
at approximately 30 and 42 month of age, respectively (Plant 2007). Although 
rodent puberty is different from the the monkeys due to an absent juvenile brake 
on the pulsatile GnRH release, the basic mechanisms underlying the process of 
sexual maturation are well conserved across species. The nature of puberty is an 
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activation of the HPG axis with an accelearated pulsatile release of GnRH 
(Wildt et al. 1980, Urbanski and Ojeda 1985), which in turn increases the 
circulating levels of the gonadotrophins and gonadal steroids. It has been shown 
that both the frequency and amplitude of GnRH pulses increases peripubertally 
in both rats and monkeys (Watanabe and Terasawa 1989, Sisk et al. 2001, Harris 
and Levine 2003). Furthermore, a reduction in the sensitivity of the E2-induced 
negative feedback control of gonadotrophin release during the peripubertal 
period might facilitate this activation of the HPG axis (Bronson 1981, Rapisarda 
et al. 1983). Although the exact mechanisms underlying the initiation of puberty 
are still unknown, many studies have implicated the KNDy signalling systems in 
the acceleration of GnRH release during puberty onset. 
During the peripubertal period, expression of Kiss1 mRNA in the ARC increases 
significantly in both male and female rats (Takase et al. 2009, Bentsen et al. 
2010). Chronic administration (icv) of Kiss1 advances the onset of puberty 
(Shahab et al. 2005, Clarkson and Herbison 2006b), whereas Kiss1r antagonism 
results in pubertal delay in rats (Pineda et al. 2010a). Furthermore, inactivating 
mutations of Kiss1 impairs reproductive maturation in both male and female 
mice (d'Anglemont de Tassigny et al. 2007). Likewise, levels of ARC Tac2 
mRNA expression increase gradually across sexual maturation and peak at 
puberty onset (Gill et al. 2012, Navarro et al. 2012). It has been postulated that 
KNDy neurones in the ARC play an important role in puberty onset simply 
because KNDy neurones compose part of neural construct of the GnRH pulse 
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generator (Terasawa et al. 2013). Indeed, the frequency and amplitude of Kiss1 
pulses measured at the level of the ME are gradually increased in prepubertal 
monkeys (Keen et al. 2008, Guerriero et al. 2012), in parallel to the prepubertal 
developmental changes in GnRH release. This increase of Kiss1 release is 
accompanied by an increasing sensitivity of GnRH neurones in response to 
Kiss1 (Castellano et al. 2006, Roa et al. 2008). 
It should be noted that E2-induced negative feedback control of ARC Kiss1 
signalling exists before the puberty onset. Treatment with E2 decreased the ARC 
Kiss1 and Tac2 mRNA in prepubertal mice (Gill et al. 2012). Furthermore, 
targeted knockdown of ERα expression in Kiss1 neurones increased ARC Kiss1 
mRNA and advanced puberty onset in mice (Mayer et al. 2010). However, both 
ARC Kiss1 and Tac2 mRNA expression increased gradually during sexual 
maturation, despite the increased circulating E2 levels during that period (Takase 
et al. 2009, Gill et al. 2012). The treatment with E2 in prepubertal monkeys did 
not inhibit the pulsatile release of Kiss1 at the level of the ME (Guerriero et al. 
2012). Therefore, the increased activity of ARC Kiss1 and NKB signalling seem 
to override the negative feedback control of the gonadal steroids peripubertally. 
However, the underlying mechanisms for up-regulated KNDy signalling 
peripubertally are still unknown. 
The pubertal activation of the HPG axis is influenced by metabolic signals. The 
timing of puberty onset is closely related to body weight (Kennedy and Mitra 
1963). Negative energy balance delays puberty onset, whilst over-nutrition 
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advances puberty onset. The KNDy signalling systems have been implicated in 
mediating the effects of metabolic signals on the developing HPG axis. Fasting 
induced a decrease of hypothalamic Kiss1 mRNA expression in prepubertal rats, 
with significantly delayed puberty onset (Castellano et al. 2005). Likewise, both 
ARC Tac2 and Tacr3 mRNA expression were down-regulated in prepubertal 
fasting rats (Navarro et al. 2012). Treatment of Kiss1 or NKB during the fasting 
period could restore the normal gonadotrophin release and puberty onset 
(Castellano et al. 2005, Navarro et al. 2012). In contrast, over-nutrition-induced 
precocious puberty in rats is related to the increased pulsatile LH release and 
up-regulated ARC Kiss1 and Tac2 expression (Li et al. 2012). This indicates that 
metabolic cues affect the timing of puberty onset by mediating the KNDy 
signalling systems. 
 
1.6 Neuropeptides regulate the KNDy signalling systems 
Kiss1 belongs to a peptide family named RFamide peptides which possess an 
Arg-Phe-NH2 motif at their C-terminus. RFamide peptides have recently been 
characterised as major regulators of GnRH neurones (Parhar et al. 2012). Among 
them, gonadotrophin-inhibitory hormone (GnIH) and its mammalian orthologue 
RFamide related peptides (RFRP) are emerging as important inhibitory 
neuropeptides on the HPG axis. 
In 2000, it was discovered that GnIH is able to directly inhibit gonadotrophin 
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secretion at the level of the anterior pituitary gland in the quail (Tsutsui et al. 
2000). In avian species, GnIH neurones were found in the paraventricular 
nucleus (PVN), with fibres projecting to the ME (Tsutsui et al. 2000, Ukena et al. 
2003). The receptor for GnIH exists in the avian pituitary and GnIH inhibits 
gonadal development and maintenance via the decrease of gonadotrophin 
synthesis and release in the pituitary (Ubuka et al. 2006). In mammals, the 
orthologous GnIH gene encodes a precursor polypeptide, the RFRP (Hinuma et 
al. 2000, Ukena et al. 2002). The expression of RFRP mRNA was detected in 
the dorsomedial hypothalamic area (DMH) in rodents (Kriegsfeld et al. 2006). 
The majority of RFRP mRNA expressing neurones were localised in the 
periventricular nucleus (IPe) in monkeys (Ubuka et al. 2009), and in the DMH 
and PVN in sheep (Clarke et al. 2008). In mammals, the projections of RFRP 
neurones were traced to multiple limbic and hypothalamic structures including 
the mPOA, ARC and amygdala (Kriegsfeld et al. 2006, Johnson et al. 2007, 
Ubuka et al. 2009, Ubuka et al. 2012). Across species, RFRP fibres were 
observed to innervate the GnRH neurone cell bodies in the mPOA (Kriegsfeld et 
al. 2006, Smith et al. 2008). This indicates that RFRP may exert a direct 
inhibitory effect on the GnRH neurones. Indeed, G protein-coupled receptor 147 
(GPR147), the receptor of RFRP, is expressed in GnRH neurones (Ubuka et al. 
2012) and central administration of RFamide related peptide-3 (RFRP-3) has 
been shown to decrease GnRH neuronal activities and induce an inhibition of 
gonadotrophin release (Kriegsfeld et al. 2006, Johnson et al. 2007, Anderson et 
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al. 2009, Pineda et al. 2010b). In addition, RFRP-3 decreased the firing rate of 
GnRH neurones in vitro (Ducret et al. 2009). Furthermore, species differences 
may exist with regard to the fibre projections of RFRP in the ME. RFRP fibres 
were observed in the external (neurosecretory) layer of ME in sheep, while no 
obvious RFRP fibres were found in the ME of rodents (Kriegsfeld et al. 2006, 
Johnson et al. 2007, Clarke et al. 2008). Furthermore, RFRP neurones failed to 
take up retrograde tract tracing dye injected peripherally in rodents (Rizwan et al. 
2009). Therefore, RFRP predominately regulates the HPG axis via central 
mechanisms in rodents. The recent findings that ARC Kiss1 neurones express 
GPR147 and receive projections from RFRP neurones (Poling et al. 2013) 
indicate that the KNDy signalling systems might be involved in this process. 
Like the KNDy signalling systems, RFRP has been involved in gonadal steroids 
feedback control of gonadotrophins. RFRP neurones express ERα receptors and 
peripheral treatment of E2 suppressed the hypothalamic RFRP mRNA in mice 
(Kriegsfeld et al. 2006, Poling et al. 2012). Furthermore, OVX induced a higher 
LH level in GPR147 knockout mice compared to wild type mice (Leon et al. 
2014). This indicates that RFRP could be involved in the E2-induced negative 
feedback control. However, this might not be the case in rats since OVX did not 
affect the expression of RFRP mRNA in DMH in rats (Quennell et al. 2010). 
RFRP has also been implicated in E2 positive feedback control of gonadotrophin 
release. RFRP-3 neuronal activities were reduced during the LH surge in 
hamsters (Gibson et al. 2008). Furthermore, central administration of RFRP-3 
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inhibited neuronal activities in AVPV and blocked the E2-induced LH surge in 
female rats (Anderson et al. 2009). However, normal pre-ovulatory LH surges 
were observed in GPR147 knockout mice, indicating that RFRP-3 may just play 
a permissive role in the positive feedback control (Leon et al. 2014). In summary, 
the gonadal feedback control of RFRP signalling is still not clear and merits 
further investigations. 
NKB belongs to a family of peptides termed tachykinins, which play an essential 
role in the regulation of HPG axis (Lasaga and Debeljuk 2011). The best known 
members of this family are substance P, neurokinin A (NKA) and NKB, which 
preferentially bind to three G protein-coupled receptors NK1R, NK2R and 
NK3R respectively (Almeida et al. 2004). Substance P can influence the HPG 
axis via acting at the level of hypothalamus, pituitary and gonads (Lasaga and 
Debeljuk 2011). There is considerable evidence that has implicated substance P 
in regulating the release of gonadotrophins and prolactin (Vijayan and McCann 
1979, Dees et al. 1985, Picanco-Diniz et al. 1990), although with conflicting 
results of either inhibitory or stimulatory effects reported. Furthermore, 
substance P has been shown to suppress LH surges in rats 
(Aslanowicz-Antkowiak and Traczyk 1992) and monkeys (Kerdelhue et al. 
1997). However, with the exception of NKB, research on the role of tachykinins 
on HPG axis in the last decade has been rather modest (Lasaga and Debeljuk 
2011). Recent studies have energised this field by showing that substance P is 
co-expressed with Kiss1 and NKB in KNDy neurones in the human 
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(Hrabovszky et al. 2013). This indicates that substance P might be a fourth 
player in the existing KNDy signalling systems. However, this was not 
replicated in mice (Navarro et al. 2015). Furthermore, substance P directly 
increases the excitability of mouse ARC Kiss1 neurones, which express NK1R 
(de Croft et al. 2013, Navarro et al. 2015). The stimulatory effect of substance P 
on LH release is abolished in Kiss1r knockout mice (Navarro et al. 2015). In 
summary, the role of substance P in central regulation of HPG axis involves the 
KNDy signalling systems. 
Glutamate and gamma-aminobutyric acid (GABA) are two principal 
neurotransmitters (stimulatory and inhibitory, respectively) of the central 
nervous system. Glutamate, acting through the N-methyl-D-aspartate (NMDA) 
receptor, and GABA, through GABAA and GABAB receptors, play an important 
role in many aspects of the reproductive system, including the onset of puberty, 
pre-ovulatory LH surges, and the pulsatile release of LH (Jarry et al. 1991, 
Meijs-Roelofs et al. 1991, Ping et al. 1995, Clarkson and Herbison 2006a). 
Although both glutamate and GABA appear to modulate GnRH neurones 
directly, since GnRH neurones express NMDA, GABAA and GABAB receptors 
(Jung et al. 1998, Adjan et al. 2008, Liu and Herbison 2011), recent studies have 
provide evidence to suggest that glutamate and GABA could regulate GnRH 
neurones indirectly through the Kiss1 signalling system. Fasting-induced 
decreased expression of Kiss1 mRNA in monkeys is associated with a reduction 
in glutamatergic inputs to Kiss1 neurones via NMDA receptors (Shamas et al. 
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2015). Furthermore, peripherally administered NMDA-induced LH secretion in 
mice is dependent on Kiss1 signalling (d'Anglemont de Tassigny et al. 2010). 
Likewise, antagonism of GABAA receptor in the ME/ARC in monkeys increased 
the release of Kiss1 and resultant GnRH, which can be blocked by a Kiss1r 
antagonist (Kurian et al. 2012). Similarly, knockout of GABAB receptor 
amplified the expression of Kiss1 mRNA in the MeA in mice with increased 
release of GnRH (Catalano et al. 2010, Di Giorgio et al. 2014). Taken together, 
Kiss1 signalling may function as a downstream effector of glutamatergic and 
GABAergic signalling on the GnRH neurones. 
 
1.7 Aims and objectives 
The discovery of KNDy and other related neuropeptide signalling systems have 
rapidly advanced our knowledge with regard to the central control of the HPG 
axis. However, ambiguous or even contradictory evidence has been produced 
regarding their roles in the control of puberty onset and gonadotrophin release. 
Furthermore, even less is known about their roles in regulating the pulsatile 
release of GnRH. Therefore, the general aim of the studies outlined within this 
thesis is to provide experimental evidence to address these questions. More 
specific objectives are listed below. 
 




 To determine the effects of central administered NK3R antagonist on 
the timing of puberty onset in female rats and whether it could affect the 
precocious puberty onset induced by over-nutrition status. 
 To test the hypothesis that NKB-NK3R signalling alters the dynamic of 
pulsatile GnRH release in prepubertal female rats to affect the timing of 
puberty onset. 
 
2. To interrogate the action of ovarian steroid hormone on gonadotrophin release 
in response to NKB-NK3R and NMDA signallings. 
 To determine the effects of NK3R agonist or NMDA on LH release in 
OVX rats replaced with different levels of E2. 
 To establish whether the biphasic effects of NMDA on LH release in 
different E2 conditions are mediated through the KNDy signalling 
systems. 
 
3. To investigate the role of the NK1R signalling system in the ARC in the 
regulation of gonadotrophin release. 
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 To test the effects of NK1R signalling in the ARC on pulsatile LH 
release in OVX rats. 
 To determine the modulatory influence of E2 on LH release in OVX rats 
administered with NK1R agonists into the ARC. 
 
4. To elucidate the role of RFRP-3 signalling in the central control of the HPG 
axis. 
 To determine whether RFRP-3 signalling interacts with endogenous 
opioid peptides to regulate GnRH pulse generator activity. 
 To examine the role of RFRP-3 signalling in stress-induced suppression 
of GnRH pulse generator frequency. 
 To determine the mechanism and site of action of RFRP-3 in the 
E2-induced negative feedback control of LH release. 
 
5. To investigate the role of Kiss1 and GABA signallings in the MeA in 
regulating LH secretion. 
 To determine the effects of intra-MeA administration of Kiss1 and 
Kiss1r antagonists on pulsatile LH secretion in OVX rats. 
 To examine the effects of chronic administration of Kiss1r antagonists 
on spontaneous LH surges and oestrous cyclicity in female rats. 
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 To determine whether the stimulatory effects of peripherally 
administered Kiss1 on LH secretion is mediated by GABAB receptor 




CHAPTER TWO: GENERAL MATERIALS AND 
METHODS 
2.1 Experiments on prepubertal animals 
2.1.1 Animals 
Adult Sprague-Dawley rats obtained from Charles River (Margate, UK) were 
allocated into breeding pairs. Once the female rats were suspected of pregnancy, 
they were separated from the male rat into an individual cage and fed with 
breeding diet (12% kcal fat, 27% kcal protein, 61% kcal carbohydrate; RM3; 
Special Diet Services). Litters were assessed every day (d) and the d of birth was 
considered postnatal d (pnd) 0. Excess male offspring were culled to reduce 
litters to 10-12 pups on pnd 2. Litters were weaned at pnd 21 and female 
offspring were housed in groups of four or six per cage under controlled 
conditions (12-h light, 12-h darkness, with lights on at 0700 h; controlled 
ambient temperature 22 ± 2 °C) and provided with food and water ad libitum.  
Litters were either assigned to standard chow diet (21% kcal fat, 17% kcal 
protein, 63% kcal carbohydrate; RM1; Special Diet Services) or a high fat diet 
(45% kcal fat, 20% kcal protein, 35% kcal carbohydrate; Special Diet Service). 
Litters were weighed every 3-d after pnd 25 and monitored daily for vaginal 
opening and first oestrous after pnd 28. All procedures were conducted in 
accordance with Animals (Scientific Procedures) Act UK, 1986 and were 
approved by the King’s College London Ethical Review Panel Committee. 
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2.1.2 Surgical procedures 
2.1.2.1  Anaesthesia and post-operative care 
All surgical procedures were carried out under a combination of ketamine 
(Vetalar, 600 mg/kg, ip; Pfizer, Sandwich, UK) and xylazine (Rompun, 60 mg/kg, 
ip; Bayer, Newbury, UK); supplementary injections of ketamine (600 mg/kg, ip) 
were administered to maintain anaesthesia as required. Each rat was injected 
subcutaneously with 0.8 ml/kg Duphamox LA antibiotic suspension (200 mg/ml 
procaine benzylpenicillin, 250 mg/ml dihydrostreptomycin-sulphate; Fort Dodge 
Animal Health, Southampton, UK) prior to surgery. Following each surgical 
procedure, animals were allowed to recover from anaesthesia on a heated pad 
until fully conscious. Post-operative analgesia was provided by means of 
subcutaneous administration of carprofen (Rimadyl; 4.4 mg/kg; Pfizer Animal 
Health, Tadworth, UK) daily for 3 d. 
 
2.1.2.2 Head screws for tether attachment 
In order to allow the anchorage of a metal spring to protect exteriorised 
chronically implanted intravenous (iv) catheters used for blood sampling, the 
animals were fitted with a tether screw on the skull. Under general anaesthesia, 
the scalp of the animal was shaved and the head was then placed in a stereotaxic 
frame (David Kopf Instruments, Tujunga, California, USA) by placing the ear 
bars into the external auditory meatus on each side of the skull, which was then 
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balanced and tightened. The incisors were placed over the incisor bar (ensuring 
the tongue clearance) and the nose was held firmly down with the nose bar. The 
skin of the scalp was sterilized by swabbing with povidoneiodine surgical scrub 
(Betadine; Seton Healthcare, Oldham, UK) followed by 75% ethanol. The eyes 
were protected by ad hoc topical application of ophthalmic gel (2mg/g Carbomer 
980; Viscotears; Novartis, Camberley, UK) and an opaque sterile shield. A 
midline incision (approximately 1.5 cm) was made with a scalpel and the skin 
was retracted. The periosteum was removed using a scalpel blade and the skull 
was dried with sterile gauze.  
Three screw holes, two in the occipital bone and a third on the right hand side of 
the frontal bone, were drilled with a dental bur (RdPC3, Ash® Instruments; 
Dentsply, Addlestone, UK) in a handheld cordless drill (Interfocus, Linton, UK). 
Three stainless steel cheese head screws (10BA × 1/32”; Allscrews, Reading, 
UK) were then screwed into the holes. The screws provide anchorage over 
smooth surface of the skull. The slotted screw was held inverted in a 
micro-manipulator (David Kopf Instruments) on the stereotaxic frame, and was 
then secured in a midline position just rostral to the two cheese head screws in 
the occipital bone. Dental cement, which was made from Simplex rapid acrylic 
powder (Associated Dental Products, Swindon, UK) containing streptomycin 
antibiotic (1:14; Sigma-Aldrich) and mixed with solvent (Associated Dental 
Products), was applied to the three small screws and the head of the tether screw 
until all screw heads were completely covered. Once the dental cement had dried, 
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the incision was closed around the shaft of the slotted screw using 5.0 
mercerised silk (Pearsalls, Taunton, Somerset, UK). The animal was then 
removed from the stereotaxic frame, and was allowed to recover on a heat pad. 
Once recovered, the animals were returned to their individual cages. All 
experimental surgical procedures were carried out with the aid of a surgical 
microscope (Carl Zeiss, Welwyn Garden City, UK) and a fibre-optic cold light 
source (KL 1500 LCD; Schott, Stafford, UK) if required. 
 
2.1.2.3 Unilateral cannulation of the internal jugular veins 
On pnd 31 (fed with normal chow diet) or pnd 29 (fed with high fat diet), the 
animals were implanted with iv catheters for collection of blood samples. The iv 
catheters were constructed from 42 cm lengths of polypropylene tubing (Portex 
PP50; Smiths Medical, Ashford, UK) inserted, allowing 15 mm overlap, into 4 
cm lengths of fine Silastic
TM 
medical grade tubing (STHT-C-020-0, Sanitech) at 
the proximal end and, with a 10 mm overlap, into 5 cm lengths of size 0.02 
Tygon tubing at the distal end, each transiently expanded immersion in xylene. A 
20 cm length of 5.0 mercerised silk was then tied in the middle of the overlap 
between the PP50 and Silastic
TM 
tubing and was held in place using a ring of 
silicone adhesive, such that the two ends of the silk ligature were of equal length. 
The catheters were then left overnight to allow the silicone adhesive to dry. The 
Silastic
TM
 tubing was cut to length of 19 mm, measured from the ring of silicone 
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adhesive. The resulting catheters were flushed with sterile saline and a 
saline-filled 2 ml syringe (Terumo, Egham, UK) was attached to the distal end of 
the catheter. 
The iv catheterisation was carried out under general anaesthesia, as described 
above. The ventral surface of the animal’s neck was shaved using electric hair 
clippers. The animal was placed on the dorsum on top of heat pad with the neck 
resting on a plastic support to facilitate catheter implantation. The shaved area 
was then sterilised with surgical scrub and ethanol as described above. A 1 cm 
longitudinal incision was made along the midline over the trachea and the skin 
was retracted with clamps. The right internal jugular vein was then exposed 
following the method of blunt dissection. Loops of 5.0 mercerised silk were 
placed around the vessel, proximal and distal to the exposed portion, lifting it 
slightly to allow ease of access. The proximal suture (but not the distal suture) 
was then tightened to close the vein and prevent back-flow. A transverse incision 
encompassing 25% of the vein’s circumference was made using Castroviejo 
micro-dissection scissors (Harvard Apparatus, Edenbridge, UK). The Silastic
TM 
end of the catheter was inserted into the vessel through the incision until the ring 
of silicone cement reached the incision. At this point the tip of the catheter is 
positioned at the junction between the cranial (superior) vena cava and the right 
atrium; this was confirmed by observation of effortless drawback and 
replacement of blood using the saline-filled syringe. The catheter was secured to 
the vein by the loops of 5.0 mercerised silk. The 5.0 mercerised silk attached to 
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the catheter by silicone adhesive was sutured to the pectoralis major muscle to 
keep the catheter in place. The syringe was replaced with a pin resembling a 10 
mm length of stainless steel wire (diameter = 0.65 mm; K.C. Smith, Potters Bar, 
UK). Crocodile forceps (Harvard Apparatus) were introduced at the posterior 
portion of the incision proximal to the slotted screw anchored to the animal’s 
cranium, tunnelled under the skin around the neck until their tips were exposed 
through the ventral incision. The distal end of the jugular catheter on the same 
side was then held firmly in the crocodile forceps and retracted under the skin 
until exteriorised through the incision on the head. This was repeated for the 
second catheter and the neck incision was sutured with 5.0 mercerised silk. The 
catheters were tunnelled through a 30 cm long protective spring tether (Instec), 
which was then anchored to the slotted screw. A small nut fixed with 
thread-locking adhesive (Henkel Loctite Adhesives, Welwyn Garden City, UK) 
was then used to secure the tether to the cranial attachment. Following surgery 
the animals were allowed to recover from anaesthesia on a heated pad until fully 
conscious. 
After the animals regained consciousness, catheters were filled with 0.2 ml 40% 
polyvinyl pyrolidone (Sigma-Aldrich) in heparinised (200 U/ml heparin sodium; 
CP Pharmaceuticals, Wrexham, UK) saline and 2 mg/ml streptomycin 
(Sigma-Aldrich). The stainless steel pins were then replaced. The solution acts 
as a flexible, removable physical barrier that helps to maintain cannula patency, 
and also has anti-bacterial and anti-fungal properties to improve cannula 
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longevity and minimise risk of infection. The animals were then returned to their 
individual cages, and the distal end of the spring tether was attached to a swivel 
(Instec), which rotates 360° in the horizontal plane, allowing the animals to 
move freely around the enclosure. The animals were left to recover from surgery 
for 2-d before experiments commenced. 
 
2.1.3 Collection of blood samples 
Blood collecting procedures were carried out on pnd 34 and 36 in rats fed with a 
standard chow diet, and on pnd 31 and 33 in rats fed with a high fat diet. The 
computer-controlled automated serial blood sampling system was based on a 
system described previously (Clark et al. 1986). The 8-channel system allows 
for the intermittent withdrawal of small blood samples (35 µl) from up to 8 rats 
simultaneously with minimal disturbance to the animals. On the morning of 
experimentation, the polyvinyl pyrolidone solution was aspirated from the 
indwelling iv catheter, the cannula was flushed with physiological saline and 
connected to one of the channels of a dual-channel swivel (Instec). Once 
connected, the animals were left undisturbed for 2 h. Blood sampling 
commenced at between 1100 and 1200 h, and samples were collected every 5 
min for up 4 h. 
A 5 cm length of size 0.02 Tygon tubing connected the distal end of the 
dual-channel swivel to the first port on a three-way solenoid valve (Lee Products, 
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Gerrards Cross, UK). A 162 cm length of polypropylene tubing (Portex PP10; 
Smith’s Medical) was attached to the second port of the solenoid valve, with the 
distal end connected to a modified hypodermic needle (25 gauge; Terumo) 
attached to a robotic fraction collector (222XL; Gilson, Middleton, WI, USA). 
Finally, a 176.5 cm length of polypropylene tubing (Portex PP30; Smith’s 
Medical) was used to connect the third port on the solenoid valve with a bag of 
heparinised (50 U/ml heparin sodium) saline via a length of peristaltic pump 
tubing (Gilson) mounted on an 8-channel peristaltic pump (Gilson). 
Custom-made software (provided by Mr D. Layman, King’s College London) 
controlled the system through a System Interface Module (Gilson) linked to the 
peristaltic pump, the fraction collector and the solenoid valves. The third port on 
the solenoid, leading to the saline reservoir, was always open whilst the 
computer switched between the first port (to the rat) and the second port (to the 
fraction collector). Figure 2.1 provides a schematic representation of the 
bleeding system. Each cycle started with the first port on the solenoid valve 
opening and saline from the reservoir being delivered to the rat for 4 seconds (s) 
to flush the iv cannula. The solenoid then switched to open the second port, 
closing the first port towards the animal, and saline was flushed to the fraction 
collector for 20 s to flush the associated tubing. After that, the valve to the 
fraction collector was closed, the valve to the rat opened, and the direction of the 
peristaltic pump was reserved to allow withdrawal of blood from the rat for 65 s. 
The solenoid valve was switched again to the fraction collector and the pump 
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direction again reversed. The pump then flushed the blood through the solenoid 
into the PP10 tubing leading to the fraction collector in 15 s. At the preset pump 
speed and the given internal diameters of tubing used, the rate of blood 
withdrawal from each prepubertal animal was 35 µl in 15 s. The second port on 
the solenoid valve, towards the fraction collector, was then closed and the first 
port opened for 88 s so that blood remaining within the iv cannulae could be 
returned to the animal and 35 µl heparinised saline was administered to maintain 
blood volume. The first port was closed and the second port opened to the 
fraction collector, and the 35 µl blood held in the PP10 tubing was pumped 
through to the fraction collector and delivered into one of a series of labelled 
LP-2 tubes (Thermo Life Sciences, Basingstoke, UK). In addition to the 35 µl of 
blood, heparinised saline from the reservoir was pumped through the fraction 
collector. This ensured that all of the blood was delivered into the tubes and that 
the fraction collector tubing was flushed at the end of each cycle. This final 
volume within each LP-2 tube was 185 µl (35 µl blood and 150 µl heparinised 
saline). The system then stood by for 28 s before starting the next cycle, in order 
to maintain a 5-min interval between each blood withdrawal. A schematic 
diagram summarising the stages of the automated blood sampling cycle is 
provided (Figure 2.2). 
After the completion of all of the sampling cycles, the iv cannulae were 
disconnected from the bleeding system, flushed with sterile saline, refilled with 
0.2 ml polyvinyl pyrolidone solution and plugged with stainless steel pins to 
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maintain patency, and the animals were removed from the system. The system 
was flushed with sterile water followed by 75% ethanol, each for 10 min, in 
order to maintain patency and reduce the risk of bacterial contamination. The 
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Fig. 2.1 Photographs of the automated blood sampling system components, 
showing the connections from ports 1, 2 and 3 on the solenoid valve to the 


































Fig. 2.2 Simplified schematic diagram of the automated blood sampling 
system cycle. (A), Blood is first withdrawn from the rat towards the pump. 
(B), 25 µl (or 35 µl) of blood is then pushed from the pump towards the 
fraction collector. (C), The remaining blood, together with 25 µl (or 35 µl) 
heparinised saline to maintain blood volume, is then returned to the animal. 
(D), The 25 µl (or 35 µl) blood sample is deposited via the fraction collector 





2.2 Experiments on adult animals 
2.2.1 Animals 
Experiments were carried out using adult Sprague-Dawley rats, weighing 
200-220 g, obtained from Harlan Laboratories (Oxfordshire, UK). All animals 
were housed under controlled conditions, as described above, provided with 
standard chow diet and water ad libitum. Animals were group-housed (maximum 
four per enclosure) prior to surgery and housed individually following surgery 
and during experimentation. All animal procedures were conducted legally and 
ethically, as described above. 
 
2.2.2 Surgical procedures 
2.2.2.1 Anaesthesia and post-operative care 
All surgical procedures were carried out under general anaesthesia induced by 
ketamine (Vetalar, 100 mg/kg, ip; Pfizer, Sandwich, UK) co-administered with 
and xylazine (Rompun, 10 mg/kg, ip; Bayer, Newbury, UK); supplementary 
injections of ketamine (100 mg/kg, ip) were administered to maintain 
anaesthesia as required. Each rat was injected subcutaneously with 0.4 ml/kg 
Duphamox LA antibiotic suspension (Fort Dodge Animal Health) prior to 
surgery. Animals were allowed to recover from anaesthesia on a heat pad after 
each surgical procedure until fully conscious. Post-operative analgesia was 
provided by means of subcutaneous administration of 4.4 mg/kg carprofen 
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(Pfizer Animal Health) daily for 3 d. 
 
2.2.2.2 Ovariectomy 
Rats were bilaterally OVX in order to remove fluctuating levels of gonadal 
steroids. Animals were anaesthetised and an appropriate area in the midline of 
the back, between the bottom rib and the top of the thigh was shaved with an 
electric razor. The shaved area was sterilised by Betadine surgical scrub 
followed by 75% ethanol as described above. An incision (approximately 2 cm 
in length) was made along the midline of the back, laterally over the estimated 
position of the ovaries. Scissors were then used to separate the abdominal 
muscle 1 cm left lateral to the spine, and the ovary was retrieved with blunt 
forceps. The fallopian tube was then clamped below the full ovary and the distal 
end of the uterine horn, tied off with a 3.0 mercerised silk suture and the ovary 
was removed with a scalpel. The remaining fallopian tube and uterus were then 
replaced in the abdominal cavity and the muscle incision was closed with a 3.0 
mercerised silk suture. The procedure was repeated to remove the contralateral 
ovary. In addition, animals receiving E2 replacement were implanted 
subcutaneously with either one or two Silastic
TM
 E2 capsules according to the 
experimental design. The E2 capsules were constructed from 5 cm lengths of 
Silastic
TM
 tubing (inner diameter [ID] 1.57 mm; outer diameter [OD] 3.18 mm; 
Sanitech, Havant, UK). The tubing was sealed at one end with implant grade 
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silicone adhesive (Silibione MED ADH 4100 RTV; Bluestar Silicones, Ventura, 
CA, USA) and then left to dry overnight. The following d, the tubing was filled 
to a length of 25 mm with 20 μg/ml E2 (Sigma-Aldrich) dissolved in arachis oil 
(Sigma-Aldrich), and the open end of the tubing was again sealed with silicone 
adhesive. Control animals without E2 replacement were replaced with two 5 cm 
lengths of Silastic
TM
 capsules filled with arachis oil (Sigma-Aldrich). Capsules 
were covered in foil and left to dry overnight. They were then stored in darkness 
until required. The E2 capsules were washed with 100% ethanol and bathed in 
sterile physiological saline overnight prior to implantation. The capsules were 
placed subcutaneously on the dorsum of the rat through the incision made for 
ovariectomy. A pair of blunt forceps was then used to create a pocket under the 
skin and place the capsule subcutaneously. Finally, the skin incision was closed 
with 3.0 mercerised silk sutures. The animal was then allowed to recover from 
anaesthesia on a heat pad. Once recovered, the animals were returned to their 
individual cages. 
 
2.2.2.3  Head screws for tether attachment 
Under general anaesthesia, the scalp of the animal was shaved and sterilised and 
the eyes were protected as described above. The head was placed in a stereotaxic 
frame (David Kopf Instruments) and a midline incision (approximately 2.5 cm) 
was made with a scalpel and the skin was retracted. The periosteum was 
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removed using a scalpel blade and the skull was dried with sterile gauze. 
Three screw holes, two in the occipital bone and a third on the right hand side of 
the frontal bone, were drilled with a dental bur (Ash® Instruments) in a 
handheld cordless drill (Interfocus). Three stainless steel cheese head screws 
(10BA × 3/32”; Allscrews) were then screwed into the holes. The slotted screw 
was secured rostral to the two cheese head screws by dental cement, as described 
above. The incision was closed around the shaft of the slotted screw using 3.0 
mercerised silk. The animal was allowed to recover on a heat pad and returned to 
their individual cages once recovered. 
 
2.2.2.4 Unilateral cannulation of the left lateral cerebral ventricle 
For experiments requiring icv administration of substances, rats were implanted 
with a chronically indwelling unilateral guide cannula (22 gauge; Plastics One, 
Roanoke, VA, USA) stereotaxically targeted towards the left lateral cerebral 
ventricle. The anaesthetised animal was placed in a stereotaxic frame, the scalp 
was shaved and sterilised, and the skull surface was exposed, as described above. 
A stereotaxic alignment tool (David Kopf Instruments) was used to align the 
surface of the skull to ensure that bregma and lambda are in the same horizontal 
plane (Paxinos and Watson, 1986). 
The guide cannula was fitted with an internal cannula (28 gauge; Plastics One), 
which was attached to a 20 cm length of Tygon tubing (size 0.02; Elkay 
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Laboratory Products, Basingstoke, UK). The Tygon tubing and internal cannula 
were filled with artificial cerebrospinal fluid (aCSF) and attached to a 25 µl 
syringe (Hamilton, Bonaduz, Switzerland) prefilled with sterile water. The guide 
cannula was secured within a cannula holder tool (David Kopf Instruments) 
attached to the micro-manipulator, which was then fitted onto the stereotaxic 
frame. Vertical alignment of the guide cannula was confirmed against a try 
square positioned on the base of the stereotaxic frame. The tip of the internal 
cannula was then aimed directly at the bregma to obtain the zero reference 
anterior-posterior (AP) and medio-lateral (ML) coordinates. The cannula was 
repositioned 0.6 mm posterior and 1.5 mm left lateral to bregma; coordinates 
corresponding to the position of the left lateral ventricle according to the Rat 
Brain Atlas (Paxinos and Watson 1986). Once in position above the left lateral 
ventricle, a pen mark was made on the skull directly below the internal cannula 
tip. The manipulator was then moved forward to clear the surface of the skull. A 
disk bur (FFXC7HP, Ash® Instruments, Dentsply) in a handheld drill was used 
to create a hole (diameter = 2 mm) in the skull at the above coordinates, and the 
remaining small piece of bone was carefully removed using watchmaker’s 
forceps (Holborn Surgical & Medical Instruments, Margate, UK). Additionally, 
two holes in the occipital bone and one hole in the right frontal bone were drilled 
and three stainless steel cheese head screws (10BA × 3/32”) were attached, as 
described previously. The manipulator arm was then moved back into position 
with the internal cannula tip aimed at the left lateral ventricle. The zero reference 
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dorso-ventral (DV) coordinates were obtained by lowering the manipulator until 
the tip of the internal cannula just made contact with the surface of the dura. The 
dura was pierced with a hypodermic needle for cannula entry. The cannula was 
then lowered to 4.5 mm below the zero reference DV coordinates and flushed 
with 1 µl saline to remove any debris from the tip, before being raised 0.5 mm to 
give a final cannula position of 4 mm below the surface of the dura. Correct 
cannula positioning within the lateral ventricle was confirmed by briefly 
disconnecting the syringe from the distal end of the Tygon tubing and visualising 
gravitational movement of the meniscus. The guide cannula was then fixed in 
place using dental cement, as described previously. A slotted screw was affixed, 
as described above, and dental cement was applied to the three cheese head 
screws, slotted screw head and guide cannula pedestal, forming a smooth unified 
assembly. Once the cement had set, the internal cannula was removed from the 
guide cannula and replaced with a dummy cannula (Plastic One) to maintain 
patency. The skin was then sutured around the shaft of the slotted screw and 
guide cannula using 3.0 mercerised silk. The animals were then allowed to 
recover from anaesthesia on a heat pad until fully conscious. 
 
2.2.2.5 Bilateral cannulation of the brain nuclei 
For experiments involving the bilateral administration of substances into the 
brain nuclei, rats were fitted with a chronically indwelling double guide cannula 
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(22 gauge; Plastics One) stereotaxically positioned 1 mm above the nuclei, 
including the mPOA, ARC and MeA. The position information is found in Table 
2.1. The procedure was carried out with the aid of a surgical microscope and a 
fibre-optic cold light source. Anaesthetised rats were prepared for surgery as 
described above. The guide cannula was fitted with a double internal cannula (28 
gauge; Plastics One), which extends 1 mm beyond the tips of the guide cannula 
to reach the target. The guide/internal cannula assembly was then secured within 
a cannula holder tool attached to a micro-manipulator, which was then fitted 
onto the stereotaxic frame. Vertical alignment of the guide cannula was 
confirmed against a try square positioned on the base of the stereotaxic frame. 
Coronal alignment was confirmed against the ear bar. The tip of the right internal 
cannula was positioned directly above the bregma to obtain the zero reference 
AP and ML coordinates. The cannula was then moved into the correct AP and 
ML coordinates for implantation (see Table 2.1 for coordinates), such that each 
guide of the cannula was equidistant from the midline, spanning the dorsal 
sagittal sinus. Once in position, pen marks were made on the skull directly below 
the internal cannula tips. The manipulator was then moved forward to clear the 
surface of the skull. Two overlapping holes or three holes (diameter = 2 mm) in 
the same coronal plane were drilled in the skull by means of disk bur driven by a 
handheld drill to expose the entry site for the bilateral cannulae and the dorsal 
sagittal sinus. The remaining disks of bone were carefully removed using 
watchmaker’s forceps. Three additional holes were drilled and fitted with 
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stainless steel screws for additional anchorage, as described above. The cannula 
was then moved back into position, with the right internal cannula positioned 
directly over the midline of the dorsal sagittal sinus, to obtain final zero 
reference ML and DV coordinates. The cannulae were then replaced at the 
specified coordinates such that the internal cannula tips were equidistant from 
the midline, and able to clear the dorsal sagittal sinus. The dura was lanced 
directly below the internal cannula tips. The cannula was then carefully lowered, 
until the tip of the internal cannula reached appropriate distance below the 
surface of the dura (see Table 2.1 for coordinates). The guide cannula and a 
slotted screw for later attachment of a metal spring tether were then cemented in 
place, as described above. Once the cement had set, the guide cannula was 
released from the micro-manipulator and the skin was sutured around the 
cannula pedestal and shaft of the slotted screw using 3.0 mercerised silk. The 
internal cannula was replaced with a dummy cannula and a crystal cap (Plastics 
One) to maintain patency. Following surgery the animals were allowed to 















ARC -3.3 ±0.5 -10.2 
mPOA -0.3 ±0.5 -8.6 
MeA -3.3 ±3.2 -8.6 
Table 2.1 Coordinates for bilateral cannulation of the ARC, mPOA and MeA. 
These measurements (mm) were derived from the Rat Brain Atlas by Paxinos 
and Watson (1986). 
 
2.2.2.6 Bilateral cannulation of the internal jugular veins 
After a 10-d post-operative recovery period following ovariectomy, if required, 
for the tether screw attachment and the cannulation of the left lateral cerebral 
ventricle, ARC, mPOA or MeA, the animals were implanted with iv catheters for 
collection of blood samples or systemic administration of injectable substance. 
The construction of iv catheters was the same as described above expect for the 
proximal end which was made of Silastic
TM
 medical grade tubing 
(STHT-C-025-0, Sanitech) suitable for adult rats. The Silastic tubing was cut to 
length of 28 mm (right side) or 27 mm (left side) measured from the ring of 
silicone adhesive. The resulting catheters were flushed with sterile saline and a 




Anaesthetised rats were sterilised and ventral surface of the animal’s neck was 
exposed for surgery. Bilateral jugular veins were exposed, incised and inserted 
by iv catheters. The distal end of the iv catheters were retracted and exteriorised 
above the head by the aid of the crocodile forceps (Harvard Apparatus). 
Catheters were later tunnelled through a 30 cm long spring tether (Instec) and 
filled with 0.2 ml polyvinyl pyrolidone (Sigma-Aldrich). Detailed surgical 
procedures were described in 2.1.2.3. The animals were left to recover from 
surgery for 3 d before experiments commenced. 
 
2.2.3 Experimental procedures 
2.2.3.1 Automated serial blood sampling 
Each rat was designed to be bled multiple times for the efficiency of animal 
usage. Rats were bled with administration of vehicle or different dosage of 
pharmacological agents one time each without repetition. There was a 3-4 d gap 
between each bleeding procedure and rats were not to be bled more than 4 times. 
On the morning of experimentation, the polyvinyl pyrolidone solution was 
aspirated from one of the two indwelling iv catheters, and the cannula was 
flushed with physiological saline and connected to one of the channels of a 
dual-channel swivel (Instec), as described above. Once connected, the animals 
were left undisturbed for 1 h. Blood sampling commenced at approximately 
1000 h, and samples were collected every 5 min for up 6 h. 
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The custom-made software (Mr D. Layman, King’s College London) has the 
option to collect a smaller amount of blood (25 µl) for adult rats compared with 
the prepubertal rats for each cycle. The detailed steps in each cycle is the same 
as the prepubertal one except when the pump flushed the blood through the 
solenoid into the PP10 tubing it took 10 s instead of 15 s. It caused 25 µl 
withdraw of blood samples for each cycle instead of 35 µl, making the final 
volume within each LP-2 tube 175 µl (25 µl blood and 150 µl heparinised 
saline). A schematic diagram summarising the stages of the automated blood 
sampling cycle is provided (Figure 2.2). 
After the completion of all of the sampling cycles, the iv cannulae were 
disconnected from the bleeding system and refilled with 0.2 ml polyvinyl 
pyrolidone, as described above. The system was flushed with sterile water 
followed by 75% ethanol, each for 10 min and the collected blood samples were 
frozen at -20°C. 
 
2.2.3.2 Stress paradigms 
Restraint stress 
Custom-built restraint devices were used for applying restraint stress to rats (Li 
et al. 2004). This was necessary since commercially available restraint devices 
would not be suitable for mobile animals with the head tether attachment used 
for the automated blood sampling in the experiment. The restraint devices were 
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built from strong transparent plastic, in the shape of a cylinder, 18.0 cm in length 
and 5.8 cm in diameter, with a hinged top to allow placement of the rat inside. 
The head of the rat protruded through a 3.2 cm diameter collar at one end of the 
device. At the tail end of the device was a fixture with a 1.5 cm diameter central 
hole to allow the rat’s tail to extend out from the device. The cylinder was 
equipped with air holes around the whole tube to avoid overheating. The rat was 
placed into the open restraint tube and the top half of the tube was then closed 
around the rat’s body. The rat was checked to ensure that no skin was caught in 
the edges of the device and that the head could move freely. The rear plate was 
pushed into the end of the restraint tube with a hole for the rat’s tail. The animal 
was kept in the device for 1 h. 
 
Immunological stress 
After 2-h of blood sampling, lipopolysaccharides (LPS; 15 µg/kg in 0.2 ml 
saline, Sigma-Aldrich) was administered via the second iv catheter; 0.2 ml 
sterile saline was flushed along the catheter after the LPS to ensure complete 






2.2.3.3  Central microinjections 
For the purpose of administration of drugs into the brain structures, including the 
lateral cerebral ventricular and the nucleus (nuclei), rats were attached by the 
guide cannulae to remote injection systems which were preloaded with drugs or 
vehicle control, thus allowing remote infusion without disturbing the rat during 
the experiment. The rat was equipped with a remote injection system at the same 
time as the attachment to the automated blood sampling system. 
Unless otherwise stated, all compounds infused into the brain were dissolved in 
aCSF, which was made up as follows: 
       100 ml deionised water              0.214 g NaHCO3                             
       0.724 g NaCl                      0.18 g D-Glucose 
       0.246 g KCl                       0.0368 g CaCl2 
       0.0163 g KH2PO4                  0.025 g MgSO4 
Each salt was added to the deionised water until the previous one had fully 
dissolved. The aCSF solution was then filtered through a sterile filter (Millipore, 
Watford, UK), aliquoted and stored at -20ºC. 
 
Unilateral infusion into the lateral cerebral ventricle 
For central administration of substance into the brain, animals were attached 
through the icv guide cannula to a remote injection system. A unilateral icv 
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internal cannula (Plastic One) was attached to a 30 cm length of Tygon tubing 
(ID: 0.51 mm, OD: 1.53 mm; Elkay). The distal end of the Tygon tubing was 
connected to the dual-channel swivel on the second channel not used for the 
automated blood sampling system. A 5 cm length 0.02 Tygon tubing was then 
attached to the distal side of the dual-channel swivel. The whole system was 
filled with aCSF using a 1 ml syringe. Approximately 2 µl air was placed in the 
extensive Tygon tubing to determine whether fluid was in fact passing down the 
cannula. The 1 ml syringe was then replaced by a 25 µl Hamilton syringe 
(Waters International, UK) primed with sterile water. Air (1 µl) was drawn into 
the internal cannula to separate the drug and aCSF, followed by 4 µl of the 
solution to be administered and another 1 µl of air. The position of the 2 µl air 
bubble within the extension tubing was then marked to indicate the pre-injection 
reference point. The dummy cannula was gently removed from the guide 
cannula and replaced with the internal cannula, which was held in place using a 
plastic applicator cap with a hole to allow the 30 cm Tygon tubing to pass 
through it. The Tygon tubing was then taped to the tether spring out of the 
animal’s reach. Injections were performed manually at a constant speed over 5 
min, and the displacement of the 2 µl air bubble was used to track the progress 
of the injections. At the end of the experiment, the internal cannula was removed 





Bilateral infusion into the nuclei 
For bilateral administration of drugs into the brain nuclei, the rat was attached by 
the double guide cannulae to a remote injection system. The system comprised a 
bilateral internal cannula (Plastics One), each channel of which was attached to 
an 80 cm length of extension tubing (Portex PP50 tubing); the distal ends of 
PP50 tubing were attached to a 5 cm length of Tygon tubing transiently 
expanded by immersion in xylene. The system was filled with aCSF and a 5 µl 
syringe (Hamilton) primed with sterile water was connected to each distal end of 
the assembly via the Tygon tubing. 1 µl air bubbles were loaded into the 
extension tubing to monitor progress of administration in response to fine 
movement of the syringe plungers. Air (0.2 µl) was drawn into the internal 
cannula to separate the drug from the upstream aCSF, followed by 0.4 µl of the 
solution to be administered and another 0.2 µl air. The Hamilton syringes were 
taped together and then securely taped to the front of the cage at approximately 
the same level as the rat to prevent premature leakage of the solution into the 
brain due to gravity. The dummy cap and cannula were gently removed from the 
guide cannula and the internal cannula was then fully inserted into the guide 
cannula. The internal cannula was held in place using a plastic applicator cap 
with a hole to allow passage of PP50 tubing. The PP50 tubing was then taped to 
the tether spring out of the animal’s reach. Injections were performed manually 
at a constant speed over 5 min, and the displacement of the 1 µl air bubble was 
used to track the progress of the injections. At the end of the experiment, the 
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internal cannula was removed and replaced with a dummy cannula and crystal 
cap. 
 
2.3 Radioimmunoassay for determination of LH levels 
A double-antibody radioimmunoassay supplied by the National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK, Bethesda, MD, USA) 
was used to determine LH concentrations in the whole blood samples. The 
sensitivity of the assay was 0.093 ng/ml. 
 
2.3.1 Reagents used in the radioimmunoassay 
General Diluent:    1400 ml  Deionised water 
              8.09 g   Na2HPO4 (anhydrous) (Sigma-Aldrich) 
              2.03 g   NaH2PO4·2H2O (Sigma-Aldrich) 
              0.14 g   Thimerosal (Sigma-Aldrich) 
              7.00 g   Bovine Serum Albumin (BSA; Sigma-Aldrich) 
 
The above components were dissolved in 1000 ml water in order, with each 
component only added once the previous had fully dissolved. A further 400 ml 
of water was then added to bring the total volume to 1400 ml and give a 0.05 M 
phosphate buffer (pH 7.4) with 0.5% BSA. This buffer was then used for 
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iodination, preparation of standards, primary antibody diluent, label and 
precipitating antibody buffer. 
 
Primary antibody diluent:    45 ml    General diluent 
                         0.84 g   EDTA 
                         149.5 μl  Normal Rabbit Serum 
 
Primary antibody: 
The lyophilised antibody NIDDK-anti-ratLH-S-11 was used as a primary 
antibody for the LH radioimmunoassay. The lyophilised protein was 
reconstituted in 1 ml of deionised water to give a buffered solution with an 
antibody dilution of 1:40. The antibody was then split into 25 μl aliquots and 
stored at –20˚C. For use in the assay aliquots were thawed and diluted with 1 
aliquot per 45 ml of primary antibody diluent. 
 
Precipitating antibody: 
Anti-rabbit gamma globulin raised in the donkey was used (IDS, Boldon, UK). 








Rat LH was labelled with radioactive iodine-125 (
125
I) by means of an iodination 
procedure similar to that described previously (Markwell and Fox 1978) (See 
sections 2.3.2 and 2.3.3). 
 
Rat LH standards: 
The referenced preparation used for the standard curve was NIDDK-rLH-RP-3 
(5 μg ampoule) supplied in lyophilised form. The protein was dissolved in 1 ml 
of deionised water. The protein was then stored in 40 μl aliquots (containing 200 
ng LH) at -20°C until required. The highest concentration standard (16 ng/ml) 
was produced by diluting one aliquot of rat LH in 12.46 ml general diluent. The 
resulting 16 ng/ml standard was then split into 400 μl aliquots and stored at 
-20°C until required. On the first d of an assay, one aliquot of the 16 ng/ml 
standard was removed from the freezer. 200 μl of the standard was then used to 
in a 1/2 dilution series to produce the remaining standards containing 8, 4, 2, 1, 
0.5, 0.25, 0.125, 0.0625, 0.03125, 0.01562 and 0 ng/ml rat LH. Three LP2 tubes 
were then labelled S1 to S12, for each of the 12 standard curve concentrations. 
50 μl each of the 12 dilutions of rat LH standard was dispensed in triplicate into 
pre-labelled LP-2 tubes. A further 50 μl of saline was then added to all standard 





In order to calculate the coefficient of variation across multiple repetitions of the 
LH RIA, samples of pooled plasma, obtained by centrifugation of whole blood 
from OVX rats, were aliquoted into 25 μl,12.5 μl, 6.25 μl volumes and made up 
to 100 μl with general diluent. These control samples were run in triplicate in 
each LH RIA, with one set of plasma pools added to the assay approximately 
every 500 tubes to account for potential drift. 
 
Washing solution:    1000 ml   Deionised water 
              40 g      Polyethylene glycol (PEG; Sigma-Aldrich) 
              9 g       NaCl (Sigma-Aldrich) 
              2 ml      Triton® X-100 (Sigma-Aldrich) 
 
The above components were dissolved in 800 ml water in the specified order, 
with each component only added once the previous had fully dissolved. A further 
198 ml water was then added to bring the total volume to 1000 ml. The resulting 






2.3.2 Reagents used in the iodination of rat LH 
Purified rat LH: 
Iodination grade protein NIDDK-rLH-1-9 was supplied by the NIDDK in 
lyophilised form. It was reconstituted with 200 µl of 0.5 M phosphate buffer. 
Aliquots of 10 µl (containing 5 µg rat LH) were then stored at -80°C until 
required for iodination. 
 
Idoine-125: 
37 MBq iodine-125 (
125
I) was supplied by Perkin-Elmer (Cambridge, UK) in the 




Phosphate Buffer (PB) 0.5 M (pH7.4):     140 ml  Deionised water 
                                    7.1 g   Na2HPO4 (anhydrous)                               
3.12 g  Na2HPO4·2H2O 
Phosphate Buffer (PB) 0.05 M (pH7.4):  1400 ml Deionised water 
                                    7.1 g   Na2HPO4 (anhydrous)                               
3.12 g  Na2HPO4·2H2O                              
 
Iodination vials: 
The catalytic matrix formed within the iodination vials was used as a reducing 
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substrate for the 
125
I. 1 mg Iodo-Gen® (1,3,4,6-Tetrachloro-3a, 
6a-diphenylglyvouril: Sigma-Aldrich) was dissolved in 10 ml chloroform 
(Sigma-Aldrich). This solution (50 µl) was then placed into the bottom of small 
glass test tubes (Thermo Life Sciences). The tubes were left at room temperature 
until the chloroform had evaporated away leaving the matrix of iodogen at the 
bottom of the tube. The iodogen coated vials were then sealed with a small 
rubber stopper and stored at -20°C until required. 
 
2.3.3 Procedure for iodination of rat LH 
This procedure was carried out behind a Perspex shield positioned within a 
ventilated cupboard certificated for work involving radioactivity. 5 g Sephadex 
G-75 (Sigma-Aldrich) was soaked overnight in 150 ml deionised water at 4°C. 
On the morning of the iodination, the Sephadex was allowed to warm to room 
temperature. The top of a 10 ml polystyrene serological pipette (BD Falcon, 
Oxford, UK) was sawn off. The tapered end of the pipette was then plugged with 
approximately 2 cm of glass wool (Surechem Products, Needham Market UK). 
One aliquot (5/10 µl) of rat LH was diluted with 20 µl of 0.5 M PB and mixed.  
The entire 30 µl was then added to the bottom of the iodination vial. 5 µl 
125
I 
(equivalent to 17.5 MBq) was then immediately added to the iodination vial. The 
mixture was then left for 30-40 min to allow the reduction of molecular Na
125
I to 
125I‾, and the subsequent binding of the ionic iodine-125 to tyrosine residues of 
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the rat LH protein. During the 30-40 min reaction period the elution column was 
made.  
The prepared 10 ml plastic pipette was fixed vertically in a clamp stand with the 
tapered end plugged with glass wool at the bottom. Soaked Sephadex G-75 was 
slowly added to the pipette with deionised water in order to prevent the 
Sephadex from drying. Soaked Sephadex was added to the column and allowed 
to settle, while the water fraction was allowed to flow out of the column. More 
water was constantly added to the column to prevent the Sephadex from drying. 
Once the Sephadex had settled and formed a distinct meniscus, at least 10 ml of 
general diluent was run through the column, still ensuring the Sephadex was not 
exposed to air. After 30-40 min the reaction between 
125
I and rat LH was 
quenched by the addition of 150 µl 0.05 M PB. General diluent was allowed to 
run through the elution column until the meniscus of the buffer had reached the 
top of the Sephadex layer. At this point, whilst being careful not to allow the 
Sephadex to come into contact with air, the reaction product was transferred 
from the iodination vial to the elution column. The position of the radioactivity 
within the column was judged using a hand-held Geiger counter (Mini 900; 
Perspective Instruments, Shaw, UK). Once the radioactivity reached 
approximately halfway through the column, a series of 40 500 µl fractions of 
eluent were collected into pre-labelled 1.5 ml tubes (Eppendorf, Stevenage, UK). 
During this collection period the column was constantly topped up with general 
diluent. 10 µl from each collected fraction was transferred into clean pre-labelled 
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LP-3 tubes, which were counted for 1 min using an automatic gamma counter 
(WIZARD
2




Figure 2.3 illustrates a typical iodination profile. The fractions represented by 
the first peak contain 
125
I-rLH. Any tubes from the first peak with counts per 
minute over approximately 1,000,000/10 µl were mixed and diluted with general 
diluent to give approximately 85,000 cpm/µl. Aliquots of 100 µl were then 
placed into 0.5 ml Eppendorf tubes and stored at -20°C until required. 
 
 
Fig. 2.3 Representative examples of an elution profile from a Sephadex G-75 































2.3.4 Procedure for the radioimmunoassay 
The assay was carried out over 4 consecutive d. Reagents were added at room 
temperature, but otherwise samples were stored at 4°C. The sequence of samples 
assayed was as follows: 
 
Tubes 1-3: Total counts tubes 
Tubes 4-6: Non-specific binding tubes 
Tubes 7-42:  Standard curve; 12 standard concentrations, run in triplicate, 
starting with the standard of lowest concentration 
Tubes 43-51: Plasma pools 
Tubes 52-end: Blood samples of unknown LH concentration. Additional 
sets of plasma pools were added approximately every 500 samples. 
 
D 1: 
1. 50 µl primary antibody diluent was added to each of the three 
non-specific binding tubes in the standard curve. 
2. All other tubes, with the exception of the total counts tubes, received 50 
µl of primary antibody diluted in primary antibody, as described above. 




D 2:  
4. An aliquot of 
125
I-rLH was diluted with general diluent to 150-200 
cpm/µl. 50 µl of the resulting solution was dispensed into the total counts 
tubes, which were then counted using an automatic gamma counter to 
confirm adequate radioactivity levels (7,500-10,000 cpm/tube).  
5. Each tube received 50 µl 
125
I-rLH diluted to 150-200 cpm/µl. 
6. All tubes were vortexed and stored overnight at 4°C. 
 
D 3: 
7. All tubes, with the exception of total counts tubes, received 50 µl 
precipitating antibody diluted with general diluent, as described above. 
8. All tubes were vortexed and stored overnight at 4°C. 
 
D 4: 
9. All tubes were centrifuged at 3,500 rpm for 60 min at 4°C. 
10. Excluding the three total counts tubes, the supernatant in each tube was 
aspirated away using a water suction aspirator, without disturbing the pellet, 
and discarded. 
11. Excluding the three total counts tubes, each tube received 200 µl 




12. Excluding the three total counts tubes, the supernatant in each tube was 
again aspirated using a water suction aspirator, without disturbing the pellet, 
and discarded.  
13. The radioactivity in the remaining pellets at the bottom of each tube 
was then counted for 1 min per tube using an automatic gamma counter. 
Tubes were counted in the order previously specified. The standard curve 
was automatically plotted by the computer software, and the unknown 
concentrations of LH were calculated from this curve.  
 
The detection limit of the LH RIA was 0.093 ng/ml and the three plasma 
pool concentrations were 8.41 ± 0.07, 4.64 ± 0.18 and 2.05 ± 0.20 ng/ml 
(mean ± SEM). The intra-assay variation was 5.8%, and the inter-assay 
variation was 7.2%. 
 
2.3.5 LH pulse detection 
The algorithm ULTRA was used to aid the detection of LH pulses (Van Cauter 
1988). Two intra-assay coefficients of variation of the assay were used as the 
reference threshold for the pulse detection. Briefly, ULTRA functions by 
comparing each data point to the two points before and after it, and determining 
if a significant rise and fall has occurred in the profile; this is consistent with a 
pulse. To allow for the fact that a pulse may occur over several data points, the 
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data is filtered so that only absolute troughs and peaks are present; any 
intermediate points are disregarded. If the difference between any trough and 




CHAPTER THREE: NK3R ANTAGONISM DECREASES 
LH PULSE FREQUENCY AND AMPLITUDE AND 
DELAYS PUBERTY ONSET IN FEMALE RATS 
3.1 Introduction 
The reproductive system is regulated by an intricate network of central and 
peripheral factors; however, the precise mechanisms triggering critical 
reproductive events, such as puberty onset, remain mostly unknown. Recently, a 
plethora of studies have revealed Kiss1 and NKB as gatekeepers of puberty and 
essential components of normal reproductive function. Humans with inactivating 
mutations in TAC3 or TACR3, the genes encoding NKB or its receptor NK3R, 
respectively, present with severe congenital gonadotrophin deficiency and 
pubertal failure (Topaloglu et al. 2009). Individuals with this rare recessive 
mutation disorder show low levels of sex steroids, LH and underdeveloped 
gonads (Young et al. 2010). Analysis of gonadotrophin concentrations in patients 
with TAC3 or TACR3 mutations showed very weak LH secretion with reduced 
frequency and amplitude of LH pulses, whereas the FSH concentrations is 
preserved (Francou et al. 2011). In those patients, normal LH pulses were 
induced by pulsatile administration of exogenous GnRH (Young et al. 2010, 
Francou et al. 2011). 
Thus, the interest in deciphering the role of NKB-NK3R signalling in the central 
control of the reproductive system arose. However, initial studies involving the 
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action of NKB upon gonadotrophin release has been controversial, with some 
showing the suppressive effect on LH secretion (Sandoval-Guzman and Rance 
2004, Navarro et al. 2009a, Wakabayashi et al. 2010, Kinsey-Jones et al. 2012), 
with others showing the opposite effect with NKB or its agonist stimulating LH 
release across species (Billings et al. 2010, Ramaswamy et al. 2010, Navarro et 
al. 2011a, Navarro et al. 2011b). Although speculative, this discrepancy might be 
due to the differences in the species, sex and gonadal status. Nonetheless, in 
prepubertal stage, acute administration of senktide induced LH pulses in 
monkeys (Ramaswamy et al. 2011), rats (Grachev et al. 2012b) and sheep 
(Nestor et al. 2012), suggesting NKB-NK3R signalling as a stimulative 
component before puberty onset, which is in accordance with human genetic 
studies. 
In rodents, Tac2 and Tacr3 (encoding NKB and NK3R) mRNA is widely 
expressed throughout the brain including amygdala, bed nucleus of the stria 
terminalis and ARC. In adult rodents, NKB-NK3R signalling in the ARC has 
been implicated in gonadal steroids negative feedback control by virtue of 
up-regulated Tac2 mRNA in the presence of gonadal steroids and 
down-regulated Tac2 mRNA in gonadal steroids deprivation situations, such as 
post-gonadectomy (Danzer et al. 1999, Dellovade and Merchenthaler 2004, 
Navarro et al. 2009a, Navarro et al. 2011a). Similarly, in the prepubertal stage, 
NKB-NK3R signalling is also involved in gonadal steroids negative feedback 
control, at least in female mice (Kauffman et al. 2009). Despite of that, the major 
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regulation pathway that drives the stimulation of NKB expression prior to 
puberty onset seems to dominate over the rising levels of gonadal steroids that 
occur during puberty onset. It is supported by the fact that the level of expression 
of Tac2 in ARC increases gradually across sexual maturation and peaks at 
puberty onset, despite the increased circulating E2 levels during that period (Gill 
et al. 2012, Li et al. 2012, Navarro et al. 2012). Furthermore, to determine 
whether the NKB-NK3R signalling has a stimulatory role on puberty onset, the 
effects of pharmacologic blockade with an NK3R antagonist (SB222200) on 
puberty onset were investigated (Gill et al. 2012, Navarro et al. 2012). Central 
administration of SB222200 tends to modestly delay puberty onset in rats 
(Navarro et al. 2012), whereas peripheral administration of SB222200 has no 
significant impact on puberty onset in mice (Gill et al. 2012). This discrepancy 
could be due to differences in species and methodologies between studies. 
Surprisingly, the latter study is consistent with a finding of genetic knockout 
mice lacking the Tacr3 genes that displayed normal timing of puberty onset 
(although with abnormal oestrous cycles and other reproductive phenotypes) 
(Yang et al. 2012). Thus, the role of NKB-NK3R signalling in the developmental 
reproductive system remains to be further investigated in animal studies. 
Furthermore, the precise mechanisms by which NKB-NK3R signalling exerts its 
effects on the central control of the reproductive system remain to be established. 
A necessity for the initiation of puberty is the acceleration of the GnRH pulse 
generator, resulting in the concomitant increase in LH pulse frequency (Sisk and 
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Foster 2004, Plant 2008, Mayer et al. 2010, Li et al. 2012). The exact neuronal 
component of the GnRH pulse generator and the mechanisms underlying its 
acceleration are still unknown. The discovery of Kiss1 and its receptor, Kiss1r, 
has yielded substantial evidence that Kiss1-Kiss1r signalling plays a critical role 
in initiating puberty and maintaining normal reproductive function (de Roux et 
al. 2003, Seminara et al. 2003, Kirilov et al. 2013). Across many species, Kiss1 
neurones in the ARC co-express NKB and Dyn and are named the KNDy 
neurones (Lehman et al. 2010). It is proposed that NKB is stimulatory to KNDy 
neurones, whereas Dyn is inhibitory (Navarro et al. 2009a, Wakabayashi et al. 
2010). It has been shown that KNDy neurones in the ARC express NK3R and 
project to one another forming a network where they communicate via this 
receptor (Krajewski et al. 2010). This network may represent part of the 
neuronal component of the GnRH pulse generator (Rance et al. 2010, Okamura 
et al. 2013). Thus, it is reasonable to speculate that ARC NKB-NK3R signalling 
is involved in the acceleration of pulsatile GnRH release triggering puberty 
onset.  
Reproduction is an energy-demanding function which is subjected to regulation 
by metabolic cues. Previous studies have implicated Kiss1 in this process, with 
reduced hypothalamic Kiss1 gene expression and LH secretion in prepubertal 
rats in acute fasting (Castellano et al. 2005). Given the fact that NKB-NK3R 
signalling is highly integrated with Kiss1 signalling in the context of KNDy 
neurones, it is reasonable to assume that NKB is also involved in metabolic 
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stress-induced reproductive dysfunction. In this sense, negative energy balance 
decreases NKB and NK3R expression in the hypothalamus and delays puberty 
onset in female rats, which can be rescued by administration of NKB (Navarro et 
al. 2012). Furthermore, in this study, the stimulative effect of NKB on LH 
secretion in prepubertal rats is not only preserved but augmented, indicating a 
sensitized effect of NKB in negative energy balance (Navarro et al. 2012). 
However, less attention has been paid to neural mechanisms in over-nutrition 
states, which induce obesity and advance puberty onset. Childhood obesity, 
which has escalated in recent decades (Ogden et al. 2002, Wang and Lobstein 
2006, Ogden et al. 2012), is not only related to cardiovascular and metabolic risk 
and to adulthood obesity, but can also lead to earlier onset of puberty, which in 
girls is a risk factor for anti-social behaviour, anxiety and other mental health 
disorders, in additions to gynaecological disorders and cancers consequent to 
earlier sexual activity and first pregnancy (Apter and Vihko 1983, Michaud et al. 
2006, De Leonibus et al. 2012). In animal models, for example, rats fed a high 
fat diet, demonstrate increased body weight gain and earlier sexual maturation 
(Li et al. 2012, Fungfuang et al. 2013). This precocious puberty may be related 
to the premature activation of the GnRH pulse generator and hence increased LH 
pulse frequency (Li et al. 2012). The up-regulation of Tac2 expression in the 
ARC of rats fed a high fat diet suggests that NKB-NK3R signalling may also be 
involved in obesity-induced puberty advancement and premature activity of 




To test the hypothesis that endogenous NKB-NK3R signalling regulates the 
timing of puberty onset and the dynamic pulsatile release of LH during the 
prepubertal stage in female rats. 
a) To investigate the role of endogenous NKB-NK3R signalling in the timing 
of puberty onset in female rats, including the precocious puberty onset 
induced by over-nutrition status. 
b) To investigate the mechanisms of endogenous NKB-NK3R signalling 
involved in the process of puberty onset by determining changes in LH 
pulse frequency in prepubertal female rats administered NK3R antagonist, 
in both normal and over-nutrition status. 
 
3.3 Materials and methods 
3.3.1 Animals and surgical procedures 
Adult Sprague-Dawley rats were allowed to mate to produce litters (see section 
2.1.1). Litters were either assigned to a standard chow diet or a high fat diet after 
weaned at pnd 21 (see section 2.1.1). 
All surgeries were carried out under a combination of ketamine and xylazine 
(see section 2.1.2). On pnd 24 (Fig. 3.1), standard chow diet fed female rats were 
chronically implanted with icv cannulae. Animals were fitted with a 28 gauge 
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cannula (Plastics One, Roanoke, VA, USA) directed towards the left lateral 
cerebral ventricular: the coordinates for implantation were 1.2 mm lateral, 1 mm 
posterior to bregma, and 4.5 mm below the surface of the dura according to the 
Rat Brain Atlas of Paxinos and Watson (Paxinos G 1986). An osmotic 
mini-pump (Model 2002, Alza Corp, Mountain View, CA, USA) was attached to 
the cannula with silicone tubing, and implanted subcutaneously in the 
interscapular space. The NK3R antagonist SB222200 (dissolved in aCSF/15% 
DMSO/20% cyclodextrin) (Sarau et al. 2000) or aCSF (contains 15% DMSO 
and 20% cyclodextrin) was delivered via the osmotic mini-pump at 0.5 µl/h for a 
14-d period. The dose of SB222200 used was 2 nmol/µl (24 nmol/d). On pnd 31 
(Fig. 3.1), female rats were fitted with an indwelling cardiac catheter via the 
right jugular vein (see section 2.1.2.3). The free end of the catheter was 
exteriorised at the back of the head. A small metal screw was fixed by two small 
screws anchored to the occipital bones with dental cement (see section 2.1.2.3). 
A 30 cm long lightweight spring tether (Instec Laboratories Inc., Boulder, CO) 
was connected to the metal screw to protect exteriorised cardiac catheters. The 
distal end of the tether was attached to a fluid swivel (Instec Laboratories), 
which allowed the rat freedom to move around the enclosure. Rats were housed 
separately after surgery and allowed 3-d of recovery before experimentation (Fig. 
3.1). 
Female rats fed the high fat diet were also fitted with icv cannulae on pnd 23 and 
received SB222200 or aCSF (as above) via an osmotic mini-pump for 14 d. On 
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pnd 29, rats were fitted with an indwelling cardiac catheter via the right jugular 
vein and experiments started 2 d later (Fig. 3.1). 
 
Fig. 3.1 Timeline diagram of experimentation with prepubertal rats fed with 
either standard chow diet or high fat diet. 
 
3.3.2 Experiment 1: Effects of NK3R antagonism on the timing of 
puberty onset in female rats fed a standard chow diet or a high 
fat diet  
Litters were weaned on pnd 21 and housed in groups of 3 to 4 per cage until they 
underwent surgical procedures, after which they were individually caged. Rats 
provided with the standard chow diet were implanted with icv cannulae 
connected to osmotic mini-pumps filled with either aCSF or SB222200 (n = 
9-12 per group) on pnd 24, as described above. Similarly, rats provided with the 
high fat diet were implanted with icv cannulae connected to osmotic mini-pumps 
filled with either aCSF or SB222200 (n = 10-12) on pnd 23. Rats were weighed 












34 36 Puberty 
onset
Termination

















every 3 d after pnd 25. They were also monitored daily for vaginal opening and 
the first vaginal oestrus (markers of puberty onset) after pnd 28. Vaginal opening 
were assessed approximately at 0900 hour (h) every d. Once vaginal opening 
occurred, vaginal smears were taken daily at 0900 h to detect the stage of the 
oestrous cycle (Goldman et al. 2007) until the first oestrous cycle was detected. 
 
3.3.3 Experiment 2: Effects of NK3R antagonism on LH pulse 
parameter in female rats fed a standard chow diet 
Blood collecting procedures were carried out on pnd 34 and 36 in rats fed with a 
standard chow diet (n = 6-7 per group), in an attempt to capture a changing LH 
pulse frequency leading to puberty (Li et al. 2012). On the morning of 
experimentation, rats were attached via the cardiac catheter to a 
computer-controlled automated blood sampling system, which allows for the 
intermittent withdrawal of small blood samples (35 µl) without disturbing the 
animals. Once connected, animals were left undisturbed for 2 h before sampling 
commenced. Blood sampling commenced between 1100 h and 1200 h. Samples 
were collected every 5 min for 4 h for LH measurement. After removal of each 
35 µl blood sample, an equal volume of heparinized saline (50 U/ml normal 
saline; CP Pharmaceuticals, Wrexham, UK) was automatically infused into the 
animal to maintain patency of the catheter and blood volume. Blood samples 
were frozen at -20°C for later assay to determine LH concentrations. After each 
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bleeding procedure, rats were replaced with 1.5 ml whole blood, iv over 15 min. 
A further 1 ml of whole blood was administered iv over 10 min the following d 
to preserve the hematocrit and maintain blood volume. 
 
3.3.4 Experiment 3: Effects of NK3R antagonism on LH pulse 
parameter in female rats fed a high fat diet 
In rats fed a high fat diet, blood collecting procedures were carried out on pnd 31 
and 33 (n = 7-9 per group), in keeping with the advanced timing of puberty onset 
in the over-nutrition status (Li et al. 2012). The rest of the experimental 
procedures were identical to the ones with standard chow diet described above. 
Rats were continuously bled for 4 h without disturbance. Small amounts of 
blood (35 µl each) were intermittently collected for later LH assays to determine 
the LH pulses. 
 
3.3.5 Statistical analysis 
Detection of LH pulses was established by use of the algorithm ULTRA. Two 
intra-assay coefficients of variation of the assay were used as the reference 
threshold for pulse detection. The effect of SB222200 on parameters of LH 
secretion was calculated by comparing the mean number of LH pulses or mean 
amplitude of LH pulses within the 4-h experimental period between the two 
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groups. Comparisons between SB222200 and control groups on body weight, 
time of vaginal opening, and first oestrus were made by subjecting data to 
one-way ANOVA and the Dunnett’s test. Comparisons between SB222200 and 
control groups on LH pulse frequency and amplitude, as well as the comparisons 
between the body weight of standard chow diet and high fat diet on pnd 31 were 
made using a two-way ANOVA and the Holm-Sidak post-hoc test. All data are 
shown as mean ± S.E.M. P < 0.05 was considered statistically significant. 
 
3.4 Results 
3.4.1 Experiment 1: Effects of NK3R antagonism on the timing of 
puberty onset in female rats fed a standard chow diet or a high 
fat diet 
To investigate the role of NKB-NK3R signalling in the control of pubertal 
timing, we examined the effect of centrally administered NK3R antagonist via 
osmotic mini-pumps on the timing of vaginal opening. In female rats fed a 
standard chow diet, central (icv) administration of the NK3R antagonist 
(SB222200, 24 nmol/d) significantly delayed the d of vaginal opening compared 
with that in the control group by approximately 4 d (aCSF vs. SB222200: 37.4 ± 
0.5 vs. 41.2 ± 0.6 d; P < 0.05) (Fig. 3.2, B). The d of first oestrus was also 
significantly delayed in the treatment group (aCSF vs. SB222200: 37.6 ± 0.5 vs. 
41.9 ± 0.9 d; P < 0.05). In rats fed a standard chow diet, chronic infusion of 
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SB222200 had no effect on body weight gain compared to controls (Fig. 3.2, A). 
In rats fed a high fat diet, icv administration of SB222200 (24 nmol/d) 
significantly delayed the d of vaginal opening compared to controls by 
approximately 2 d (aCSF vs. SB222200: 33.4 ± 0.4 vs. 35.1 ± 0.6 d; P < 0.05) 
(Fig. 3.2, D). The d of first oestrus was also significantly delayed in the 
treatment group (aCSF vs. SB222200: 33.7 ± 0.6 vs. 35.9 ± 0.5 d; P < 0.05). In 
rats fed a high fat diet, chronic infusion of SB222200 had no effect on body 
weight gain compared with controls (Fig. 3.2, C). Furthermore, on pnd 31, the 
body weight of rats fed with high fat diet was significantly higher than that of 
rats fed with standard chow diet (aCSF + standard chow diet vs. aCSF + high fat 
diet: 91.2 ± 2.6 vs. 113.0 ± 3.5; P < 0.05; SB222200 + standard chow diet vs. 
SB222200 + high fat diet: 93.1 ± 3.1 vs. 117.0 ± 3.5; P < 0.05).  
 
3.4.2 Experiment 2: Effects of NK3R antagonism on LH pulse 
parameter in female rats fed a standard chow diet 
To further determine the mechanisms of NKB-NK3R signalling involved in the 
timing of puberty onset, serial blood samples were collected from prepubertal 
female rats fed a standard chow diet to measure LH pulses. The number of LH 
pulses in the 4-h sampling period increased between pnd 34 and 36 in the control 
group (Figs. 3.3, A, C and E) and was significantly reduced in rats administered 
with SB222200 (Figs. 3.3, B, D and E) (number of LH pulses on pnd 36, aCSF 
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vs. SB222200: 2.5 ± 0.2 vs. 1.6 ± 0.2; P < 0.05). LH pulse amplitude was 
significantly reduced in SB222200-treated rats compared with controls on both 
pnd 34 and 36 (amplitude of LH pulses on pnd 34, aCSF vs. SB222200: 3.2 ± 
0.4 vs. 1.8 ± 0.4; P < 0.05; amplitude of LH pulses on pnd 36, aCSF vs. 
SB222200: 2.8 ± 0.2 vs. 1.8 ± 0.3; P < 0.05) (Fig. 3.3, F). 
 
3.4.3 Experiment 3: Effects of NK3R antagonism on LH pulse 
parameter in female rats fed a high fat diet 
Serial blood samples were also collected in prepubertal female rats fed a high fat 
diet. The number of LH pulses in the 4-h sampling period increased between pnd 
31 and 33 in the control group (Figs. 3.4, A, C and E) and was significantly 
reduced in rats administered with SB222200 compared with controls on pnd 33 
(number of LH pulses on pnd 33, aCSF vs. SB222200: 3.6 ± 0.6 vs. 2.1 ± 0.4; P 
< 0.05) (Figs. 3.4, C-E). LH pulse amplitude was significantly reduced in 
SB222200-treated rats compared with the control on pnd 31 (amplitude of LH 
pulses on pnd 31, aCSF vs. SB222200: 3.0 ± 0.4 vs. 1.9 ± 0.2; P < 0.05) (Figs. 
3.4, A, B, and F). 
  
Fig. 3.2 Effects of a NK3R antagonist (SB222200) on body weight and d of 
vaginal opening in female rats fed with a standard chow or a high fat diet 
(45% kcal fat intake) after weaned on pnd 21. In rats fed a standard chow diet, 
the central administration of SB222200 (24 nmol/d, 12 µl/d, icv) had no 
affect on body weight gain (A) but delayed puberty onset (B) compared to 
controls (aCSF, 12 µl/d).  In rats fed a high fat diet, the central administration 
of SB222200 (24 nmol/d, 12 µl/d, icv) did not affect the body weight gain (C) 
but delayed puberty onset (D) compared to controls (aCSF, 12 µl/d).  *P < 
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Fig. 3.3 Effects of a NK3R antagonist (SB222200) on LH pulses in 
prepubertal female rats fed a standard chow diet. (A, C) Representative 
examples of LH profiles on pnd 34 and 36, respectively, in animals 
administered aCSF (12 µl/d, icv) as vehicle. (B, D) Representative examples 
of LH profiles on pnd 34 and 36 in animals administered SB222200 (24 
nmol/d). (E) Summary showing that the administration of SB222200 
significantly reduced the number of LH pulses in the 4-h sampling period on 
pnd 36. Note that the number of LH pulses in the 4-h sampling period in 
control rats significantly increased between pnd 34 and 36. (F) Summary 
showing that the administration of SB222200 significantly reduced the 
amplitude of LH pulses on both pnd 34 and 36.  #P < 0.05 vs. aCSF group on 
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Fig. 3.4 Effects of a NK3R antagonist (SB222200) on LH pulses in 
prepubertal female rats fed a high fat diet (45% kcal of fat intake) starting 
from pnd 21. (A, C) Representative examples of LH profiles on pnd 31 and 
33 in animals administered aCSF (12 µl/d, icv) as vehicle. (B, D) 
Representative examples of LH profiles on pnd 31 and 33 in animals 
administered SB222200 (24 nmol/d, icv). (E) Summary showing that the 
administration of SB222200 significantly reduced the number of LH pulses 
in the 4-h sampling period on pnd 33. Note that the number of LH pulses in 
the 4-h sampling period in control rats significantly increased between pnd 
31 and 33. (F) Summary showing that the administration of SB222200 
significantly reduced the amplitude of LH pulses in the 4-h sampling period 
on pnd 31.  #P < 0.05 vs. aCSF group on the same pnd; *P < 0.05 vs. aCSF on 
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It is well established from studies in humans with inactivating mutations that 
NKB-NK3R signalling plays a critical role in pubertal development (Topaloglu 
et al. 2009, Gianetti et al. 2010, Francou et al. 2011, Tusset et al. 2012). The 
present study further confirms the physiological importance of endogenous 
NKB-NK3R signalling for the initiation of puberty in an animal model by 
showing that the timing of puberty is profoundly delayed in prepubertal female 
rats receiving continuous chronic central administration of SB222200, a 
selective NK3R antagonist. Furthermore, we have demonstrated a role for 
NKB-NK3R signalling in precocious puberty consequent to an obesogenic diet 
by showing that the advanced puberty onset in female rats fed with a high fat 
diet is also delayed by continuous administration of SB222200. Our findings are 
consistent with, and extend, recent studies (Gill et al. 2012, Navarro et al. 2012, 
Nakahara et al. 2013) that have shown that peripheral daily administration of 
SB222200 caused a modest, non-significant delay of puberty in female mice 
(Gill et al. 2012). Although the ability of SB222200 to cross the blood-brain 
barrier was tested in that study, the lack of significant developmental timing 
delay may be due to the limited duration of blockade produced by daily mode of 
administration (Gill et al. 2012). In the same vein, this rationale could also apply 
to the aforementioned study by Navarro et al. that intermittent central 
administration of SB222200 only induced a modest delay in timing of puberty 
(Navarro et al. 2012). In this sense, a study published recently by Nakahara et al. 
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showed that continuous peripheral administration (via osmotic mini-pump) of 
senktide, a NK3R agonist, advances puberty in female rats (Nakahara et al. 
2013); adding further support to the critical role of NKB-NK3R signalling in 
initiating the puberty onset. 
Reproduction is an energy-demanding process which is mediated by metabolic 
cues that eventually contribute to the regulation of GnRH release. Positive 
energy balance leads to precocious puberty onset while negative energy balance 
delays the timing of puberty onset. The present study demonstrates for the first 
time that a NK3R antagonist retard precocious puberty in overfed female rats, 
which would appear to be in agreement with the observation that chronic 
administration of a NK3R agonist partially reversed the pubertal failure in 
underfed prepubertal female rats (Navarro et al. 2012). Tac2 mRNA expression 
in the ARC is up-regulated in overfed rats with advanced puberty (Li et al. 2012), 
whereas Tac2 mRNA expression is down-regulated in the ARC of underfed rats 
with delayed puberty (Navarro et al. 2012). Thus, NKB gene expression is 
subjected to modulation of metabolic cues, which is in keeping with the notion 
that NKB may be a prepubertal signalling system of the metabolic status 
(Navarro 2013). Collectively, these studies support the idea that NKB-NK3R 
signalling plays a pivotal role in pubertal development and the altered timing of 
puberty, irrespective of nutritional status. However, a major conundrum 
regarding this role of NKB-NK3R signalling arose due to the recent finding that 
genetic Tacr3 knockout mice achieve a normal timing of sexual maturation, 
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although they presented with lower uterine weight, abnormal oestrous cyclicity 
and subfertility (Yang et al. 2012). It is possible these Tacr3 null mice retain 
residual NK3R activity, or in the absence of NK3R, NKB activates other 
tachykinin receptors to stimulate GnRH release (Steiner and Navarro 2012, de 
Croft et al. 2013). 
It is well established that puberty onset is associated with an acceleration of LH 
pulse frequency (Sisk and Foster 2004, Plant 2008, Mayer et al. 2010, Li et al. 
2012). It has been shown in the present study that pubertal delay in response to 
NK3R antagonism was accompanied by a reduction in LH pulse frequency and 
amplitude in both normal and high fat diet fed rats. Before the onset of puberty 
there is an up-regulation of ARC Tac2 and Tacr3 mRNA expression (Gill et al. 
2012, Navarro et al. 2012), which suggests potential involvement of 
NKB-NK3R signalling in the acceleration of the GnRH pulse generator during 
this critical developmental stage. In the present study, we demonstrate for the 
first time that NK3R antagonism delays the increase in LH pulse frequency 
during pubertal development in female rats. This is consistent with studies 
showing that chronic administration of SB222200 tends to decrease basal LH 
levels (Navarro et al. 2012), and chronic administration of the NK3R agonist, 
senktide, tends to increase the frequency of pulsatile LH release in prepubertal 
female rats (Nakahara et al. 2013). Additionally, acute injections of senktide 
induced LH pulses in prepubertal macaques (Ramaswamy et al. 2011), rats 
(Grachev et al. 2012b) and sheep (Nestor et al. 2012). In the present study, 
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NK3R antagonism was also shown to reduce the amplitude of LH pulses; 
however, the mechanisms underlying this are not known. Interestingly, this 
phenomenon is reminiscent of the LH profiles in patients with TAC3 or TACR3 
mutations that the LH pulse frequency and amplitude is both significantly 
reduced (Francou et al. 2011, Young et al. 2013). Furthermore, central 
administration of NKB increased the frequency and amplitude of MUA volleys 
in the ARC (mirroring the LH pulses) in goat, which would appear to be in 
keeping with the present findings (Wakabayashi et al. 2010). Thus, NKB-NK3R 
signalling may involve not only in the regulation of the LH pulse frequency, but 
also LH pulse amplitude, although the underlying mechanisms remain to be 
investigated. Furthermore, we have previously shown that precocious puberty 
associated with over-nutrition is accompanied by an earlier onset of accelerated 
LH pulse frequency and concomitant up-regulation of ARC Tac2 mRNA 
expression (Li et al. 2012). The results from the present study suggest that 
endogenous NKB-NK3R signalling may underlie the acceleration of LH pulse 
frequency associated with precocious puberty in overfed rats. 
The neural mechanisms underlying modulation of LH pulse frequency by 
NKB-NK3R signalling is unclear, particularly because the neural construct 
comprising the GnRH pulse generator per se remains enigmatic. There is 
increasing evidence that the network of KNDy neurones in the ARC may 
represent a significant component of the GnRH pulse generator (Lehman et al. 
2010, Wakabayashi et al. 2010). It is speculated that reciprocal stimulatory and 
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inhibitory interactions between KNDy neurones mediated by NKB and Dyn, 
respectively, result in pulsatile Kiss1 release to drive pulsatile release of GnRH 
(Navarro et al. 2009a, Lehman et al. 2010, Wakabayashi et al. 2010). In studies 
supporting this mode of action, Goodman et al. (Goodman et al. 2013) recently 
demonstrated that intra-ARC administration of SB222200 or the selective 
κ-opioid receptor antagonist, nor-BNI, decreased or increased LH pulse 
frequency, respectively, in the ovariectomised ewe. Although the failure of 
NK3R antagonism to reduce LH pulse frequency in the ovariectomised rat 
(Grachev et al. 2012a) remains an unexplained and unexpected observation, the 
activation of this receptor in the gonadal intact adult or prepubertal rat evokes 
LH pulses (Navarro et al. 2011a, Grachev et al. 2012b, Kinsey-Jones et al. 2012). 
Thus, it is reasonable to suggest that the suppression of LH pulses and pubertal 
delay observed in the present study may reflect antagonism of the ARC 
population of NK3R; more specifically, the NK3R expressed on KNDy neurones. 
It is speculated that NKB act on ARC KNDy neurones to release Kiss1 which, in 
turn, act on Kiss1r expressed GnRH neurones (Navarro 2013). This speculation 
is supported by various evidence including: (a) senktide-induced pulsatile LH 
secretion is dependent on Kiss1r (Ramaswamy et al. 2011, Garcia-Galiano et al. 
2012b, Grachev et al. 2012b); (b) isolated mouse GnRH neurones are insensitive 
to NKB, while Kiss1 neurones are robustly activated and reversed by NKB 
antagonist (Navarro et al. 2011a, Kirilov et al. 2013, Ruka et al. 2013); (c) 
GnRH neurone-specific deletion of Kiss1r is associated with a failure to go 
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through puberty and infertility (Kirilov et al. 2013). Together, these data strongly 
suggest an action of NKB upon KNDy neurones; however, we cannot rule out 
any additional action of NKB on other brain areas since: (a) it has been reported 
that NKB causes GnRH secretion in GT1-7 GnRH neurones (Glidewell-Kenney 
et al. 2013); (b) earlier morphologic evidence indicated that NKB could 
influence GnRH secretion at the level of the median eminence via interaction 
with NK3R on GnRH terminal fibres (Krajewski et al. 2005); (c) activation of 
NK3R at the level of GnRH terminals in the median eminence stimulates GnRH 
release and this effect is independent of Kiss1 (Gaskins et al. 2013). Further 
research is necessary to establish the precise site and mechanism by which 
NKB-NK3R signalling regulates pulsatile GnRH secretion. 
In conclusion, the present study demonstrates that endogenous NKB-NK3R 
signalling plays a role in controlling the timing of puberty and the associated 




CHAPTER FOUR: TRIPHASIC EFFECTS OF NKB AND 
NMDA ON LH SECRETION IN FEMALE RATS 
4.1 Introduction 
GnRH neurones, located within the hypothalamus, form the final common 
pathway for the control of the reproductive system. GnRH neurones secrete 
GnRH to prompt the release of LH and FSH from the anterior pituitary. This 
process is influenced by several factors, including neuropeptides (e.g. Kiss1 and 
NKB), neurotransmitters (e.g. glutamate) and sex steroids (e.g. E2). A close 
interplay exists among those factors allowing fine control of GnRH release. 
Recent discoveries of Kiss1-Kiss1r and NKB-NK3R signalling have extensively 
expanded our knowledge of hypothalamic control of GnRH release (de Roux et 
al. 2003, Topaloglu et al. 2009). A plethora of studies have indicated Kiss1 as a 
predominant stimulatory neuropeptide on GnRH/LH secretion regardless of the 
sex steroids conditions (Roa et al. 2006, Pielecka-Fortuna et al. 2008, Navarro et 
al. 2009b). In contrast, stimulatory, inhibitory, or even null effects of the agonist 
of NK3R, senktide, on LH secretion have been reported: central administration 
of senktide stimulates LH release in intact rodents (Navarro et al. 2011b, 
Kinsey-Jones et al. 2012), castrated male monkeys (Ramaswamy et al. 2010) 
and intact female sheep (Billings et al. 2010). Other studies have shown the 
opposite effects, with senktide decreasing the circulating LH levels in OVX 
rodents (Sandoval-Guzman and Rance 2004, Navarro et al. 2009a, Navarro et al. 
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2011a), and suppressing pulsatile LH release in OVX goats and OVX rats 
(Wakabayashi et al. 2010, Kinsey-Jones et al. 2012, Grachev et al. 2014a). 
Interestingly, no effect on LH secretion was shown in other studies in OVX mice 
primed with E2 and in intact male rats (Navarro et al. 2009a, Corander et al. 
2010). The discrepancies among the above studies might be due to the 
differences in the species, sex and gonadal status. Indeed, an ensuing study 
regarding the sex differences has shown that NKB stimulated LH release in a 
sexually dimorphic fashion: NKB stimulated LH release in female rats, 
regardless of the stage of development, but failed to stimulate LH release in 
male rats after puberty onset, and this phenomenon was independent of the sex 
steroid milieu (Ruiz-Pino et al. 2012). This finding helped to resolve a small part 
of the above discrepancies. In addition, other studies addressing the gonadal 
status/sex steroid milieu have yielded complicated results, with some showing 
the reverse effects of NKB on LH secretion in OVX rats after E2 treatment, and 
others displaying the same inhibitory effects with or without E2 treatment 
(Navarro et al. 2011a, Grachev et al. 2012a). The basis underlying these remains 
to be further investigated. 
The neurotransmitter glutamate is another important regulator of GnRH release. 
Glutamate, acting through the NMDA receptor, a glutamate receptor subtype that 
is required for GnRH release, plays an important role in many aspects of the 
reproductive system, including the onset of puberty (Urbanski and Ojeda 1990, 
Meijs-Roelofs et al. 1991), pre-ovulatory LH surge (Brann and Mahesh 1991, 
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Meijs-Roelofs et al. 1991) and the maintenance of pulsatile LH release 
(Bourguignon et al. 1989, Ping et al. 1995). Similar to NKB-NK3R signalling, 
the sex steroid milieu appears to be very important for the LH releasing ability 
of NMDA, an agonist of NMDA receptor. NMDA has either null or inhibitory 
effects on LH secretion in OVX animals without exogenous E2 treatment 
(Estienne et al. 1990, Reyes et al. 1990, Reyes et al. 1991, Brann and Mahesh 
1992, Arias et al. 1993). In contrast, NMDA stimulates LH secretion in animals 
with intact gonadal status across various species, which is in keeping with the 
general excitatory role of glutamate (Schainker and Cicero 1980, Wilson and 
Knobil 1982, Gay and Plant 1987, Jansen et al. 1991, Brann and Mahesh 1992, 
d'Anglemont de Tassigny et al. 2010, Garcia-Galiano et al. 2012a). Furthermore, 
the inhibitory or null effects of NMDA on LH release in OVX rats, sheep and 
monkeys are shifted to stimulatory effects in the presence of high levels of E2 
(Estienne et al. 1990, Reyes et al. 1991, Arias et al. 1993). 
It appears that NMDA increases LH release in the presence of physiological 
relevant levels of sex steroids when gonads are intact, whereas it inhibits LH 
release in the presence of low levels of sex steroids when gonads are removed; 
effects reminiscent of NKB-NK3R signalling described above. A large number 
of studies have indicated that instead of direct actions on GnRH neurones, NKB 
acts through other signalling systems such as Kiss1 and Dyn to affect GnRH 
release (Ramaswamy et al. 2011, Garcia-Galiano et al. 2012b, Grachev et al. 
2012b, Kinsey-Jones et al. 2012). Similar to NKB, NMDA does not seem to act 
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on GnRH neurones directly, since either central or peripheral treatment of 
NMDA failed to induce c-Fos expression in GnRH neurones in rodents (Saitoh 
et al. 1991, Lee et al. 1993, d'Anglemont de Tassigny et al. 2010). Alternatively, 
it is suggested that peripheral administration of NMDA could cross the 
blood-brain barrier to activate ARC Kiss1 neurones since the stimulatory effects 
of peripheral NMDA on LH release were lost in Kiss1 knockout mice 
(d'Anglemont de Tassigny et al. 2010). Therefore, the stimulatory effects of 
NMDA in the presence of high levels of sex steroids may be due to the 
activation of Kiss1 neurones in the ARC. Furthermore, NKB-NK3R signalling in 
the ARC exerts an inhibitory effect on pulsatile LH release in OVX rats, which 
may involve Dyn signalling (Grachev et al. 2012a). Thus, it is reasonable to 
speculate that peripheral administration of NMDA act through KNDy neurones 
to affect LH release, that is, via Kiss1-Kiss1r signalling to stimulate LH release 
or via NKB-NK3R signalling to inhibit LH release, depending on the prevailing 
sex steroids milieu. 
 
4.2 Aims and objectives 
To test the hypothesis that the effects of NKB-NK3R and NMDA signalling 
systems on LH release in OVX rats are dependent on the circulating levels of E2 
and that the different effects of NMDA on LH release are mediated via the 
KNDy signalling systems. 
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a) To determine the effects of senktide or NMDA on LH release in OVX rats 
in the presence of different levels of E2 replacement. 
b) To establish whether the suppressive effect of NMDA on LH release in low 
E2 condition is through NKB-NK3R signalling. 
c) To establish whether the stimulatory effect of NMDA on LH release in high 
E2 condition is through Kiss1-Kiss1r signalling. 
 
4.3 Materials and methods 
4.3.1 Animals and surgical procedures 
Under general anaesthesia, adult Sprague-Dawley rats were OVX. In addition, 
animals receiving E2 replacement were implanted subcutaneously with either 
one or two Silastic
TM
 E2 capsules, while animals without E2 replacement were 
replaced with two Silastic
TM
 capsules filled with arachis oil (see section 2.2). 
Meanwhile, animals were also implanted with unilateral icv guide cannulae 
directed towards the left lateral cerebral ventricle (see section 2.2.2.4). After a 
10-d recovery period, rats were fitted with two indwelling cardiac catheters via 
the jugular vein, as described in section 2.2.2.6. Experimentation commenced 3 





Fig. 4.1 Timeline diagram of various surgical and experimental procedures for 
investigating the effects of NKB-NK3R and NMDA signalling on LH release in 
OVX rats replaced with different levels of E2. 
 
4.3.2 Experiment 1: Effects of senktide on LH secretion in OVX rats 
replaced with different levels of E2 
An icv injection cannula (Plastics One) with extension tubing preloaded with 
senktide (Tocris Bioscience) was inserted into the guide cannula, with 1 µl of air 
separating the fluid in the tubing from the lateral ventricle system before the 
actual injection. The tip of injection cannula extended 1 mm beyond the guide 
cannula to reach the ventricle. The distal end of the tubing was extended outside 
of the cage and connected to a 25 µl Hamilton syringe (Waters International), 
thereby allowing remote infusion without disturbing the rat during the 
experiment (see section 2.2.3.3). Rats were also attached via one of the two 
cardiac catheters to a computer-controlled automated blood sampling system, 
which allows for the intermittent withdrawal of small blood samples (see section 
2.2.3.1). Once connected, animals were left undisturbed for 1 h before sampling 
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h. At the end of the experiment, 150 µl blood was withdrawn from the cardiac 
catheter and centrifuged at 800 rpm for 15 min in a refrigerated centrifuge. The 
plasma was aspirated and stored in a -20°C freezer for later assay to determine 
E2 concentration. 
To examine the effects of senktide on LH secretion in the presence of different 
E2 levels, senktide (600 pmol in 4 µl aCSF) was administered (icv) over 5 min 
after 2-h controlled blood sampling into OVX rats without E2 replacement 
(OVX+0×E2, n = 7), into OVX rats implanted with one E2 capsule (OVX+1×E2, 
n = 10), and into OVX rats implanted with two E2 capsules (OVX+2×E2, n = 8). 
The dose of senktide was adopted from Kinsey-Jones et al. (2012). 
 
4.3.3 Experiment 2: Effects of NMDA on LH secretion in OVX rats 
replaced with different levels of E2 
On the morning of experimentation, the rats were attached to the automated 
blood sampling system, as described above. After 2 h of controlled blood 
sampling, NMDA (30 mg/kg in 0.2 ml saline, Sigma-Aldrich) was infused (iv) 
via one of the cardiac catheters over the period of 5 min into OVX+0×E2 rats (n 
= 6), into OVX+1×E2 rats (n = 8), and into OVX+2×E2 rats (n = 8). The dose of 





4.3.4 Experiment 3: Effects of NMDA on LH secretion in OVX+0×E2 
rats in the presence of a NK3R antagonist 
On the morning of experimentation, OVX+0×E2 rats were attached to the 
automated blood sampling system and equipped with the icv injection system, as 
described above. After 1 h 45 min of blood sampling, SB222200 (15 nmol in 4 
µl aCSF/15% DMSO/20% cyclodextrin, n = 7, Tocris Bioscience), a NK3R 
antagonist (Sarau et al. 2000), or aCSF/15% DMSO/20% cyclodextrin (4 µl, n = 
6) was administered (icv) over 5 min into OVX+0×E2 rats. 15 min later, NMDA 
(30 mg/kg) was infused (iv) via one of the cardiac catheters over 5 min. 
Additional controls were administered (icv) with SB222200, followed by iv 
infusion of saline 15 min later (n = 6). The dose of SB222200 was deduced from 
one of our previous studies with intra-ARC administration of 0.5 nmol 
SB222200 (Grachev et al. 2012a). A preliminary dose (5 nmol SB222200) failed 
to block the inhibitory effects of NMDA on LH release (data not shown), which 
prompted us to adopt a higher dose of 15 nmol. 
 
4.3.5 Experiment 4: Effects of NMDA on LH secretion in OVX+2×E2 
rats in the presence of a Kiss1r antagonist 
OVX+2×E2 rats were attached to the automated blood sampling system and 
equipped with the icv injection system on the morning of experimentation, as 
described above. After 1 h 45 min of blood sampling, peptide-234 (3 nmol in 4 
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µl aCSF; n = 5, Sigma-Aldrich), a Kiss1r antagonist (Roseweir et al. 2009), or 
aCSF (4 µl, n = 5) was infused (icv) into the rats. Fifteen minutes later, NMDA 
(30 mg/kg) was infused (iv) via one of the cardiac catheters. Additional controls 
were administered (icv) with peptide-234, followed by iv infusion of saline 15 
min later (n = 4). The dose of peptide-234 was adopted from Roseweir et al. 
(2009). 
 
4.3.6 Experiment 5: Effects of implantation of different numbers of E2 
capsules on circulating levels of E2 in OVX rats, comparing to 
intact female rats 
Blood samples for the measurement of plasma E2 were obtained as described 
above (n = 7, 8, 8, for OVX+0×E2, OVX+1×E2 and OVX+2×E2 groups, 
respectively). An additional group of ovary-intact Sprague-Dawley rats from 
Harlan Laboratories (Oxfordshire, UK) were monitored daily for normal ovarian 
cyclicity by means of vaginal cytology. Rats with normal ovarian cyclicity (n = 4) 
were implanted with cardiac catheters to enable collection of blood samples (150 
µl) for measurement of E2 levels at oestrus and proestrus stages that would be 
used respectively as physiological low and high E2 controls. Blood samples (150 
µl) were taken at 0900 h on proestrus and 1800 h on oestrus since E2 levels reach 
peak and nadir around these times respectively (Smith et al. 1975, Nequin et al. 
1979). Normal ovarian cyclicity in those studies was defined as having at least 2 
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consecutive normal cycles, which last for 4 d with 1 d of oestrus. Rats with 5 d 
of cycles were excluded since they had a different fluctuation dynamic of E2 
levels (Nequin et al. 1979). 
A double-antibody radioimmunoassay (ImmuChem; MP Biomedicals, 
Orangeburg, NY) was used to estimate the E2 content of the plasma samples (50 
µl) following the manufacturer’s protocol. The sensitivity of the assay was 7.2 
pg/ml. The intraassay variation was 9.6%, and the interassay variation was 
10.1%.  
5.3.4 Statistical analysis 
The effect of pharmacological agents on LH secretion was calculated by 
comparing the area under the LH profile [area under the curve (AUC); 





 1-h post-treatment period with that in the 1-h pre-treatment period, using 
SigmaPlot version 11 (Systat Software, San Jose, CA). LH pulses in experiment 
3 were established by use of the algorithm ULTRA (Van Cauter 1988). The 
effects of pharmacological agents on pulsatile LH secretion were analysed by 
comparing the mean LH pulse interval in the 2-h period preceding treatment 
with that in two consecutive 2-h post-treatment periods. The duration (min) of 




 2-h post-treatment periods, was divided 
by the number of LH pulses detected in each of these periods to give the 
appropriate LH pulse interval. The effect of the baseline of LH secretion in 
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different levels of E2 was calculated by comparing the AUC in the 1-h 
pre-treatment period. E2 levels in OVX+0×E2, OVX+1×E2 and OVX+2×E2 were 
calculated from means of E2 levels detected 10 d after OVX. E2 levels in oestrus 
or proestrus rats were calculated from means detected during oestrus or proestrus 
phases in three consecutive oestrous cycles. Statistical significance was tested 
using one-way ANOVA followed by Dunnett’s test. All data were shown as 
mean ± S.E.M. P < 0.05 was considered statistically significant. 
 
4.4 Results 
4.4.1 Experiment 1: Effects of senktide on LH secretion in OVX rats 
replaced with different levels of E2 
To investigate the effects of NKB on LH secretion in different E2 levels, we 
examined the effects of centrally administered senktide, a NK3R agonist, on LH 
secretion in OVX rats replaced with different numbers of E2 capsules. Central 
administration of senktide inhibited LH secretion in OVX+0×E2 rats (AUC in 
1-h pre-injection vs. AUC in 2
nd
 1-h post-injection: 283.5 ± 23.3 vs. 188.0 ± 13.9 
ng/ml.min; P < 0.05) (Fig. 4.2). In contrast, senktide briefly stimulated LH 
secretion in OVX+2×E2 rats (AUC in 1-h pre-injection vs. AUC in 1
st
 1-h 
post-injection: 169.6 ± 6.0 vs. 207.3 ± 15.0 ng/ml.min; P < 0.05) and this 
stimulation effect was not seen in the second h (AUC in 1-h pre-injection vs. 
AUC in 2
nd
 1-h post-injection: 169.6 ± 6.0 vs. 146.8 ± 7.9 ng/ml.min; P > 0.05) 
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(Fig. 4.2). Most interestingly, senktide had no effects on LH secretion in 
OVX+1×E2 rats (AUC in 1-h pre-injection vs. AUC in 1
st
 1-h post-injection vs. 
AUC in 2
nd
 1-h post-injection: 216.6 ± 19.7 vs. 229.4 ± 20.6 vs. 218.4 ± 22.3 
ng/ml.min; P > 0.05) (Fig. 4.2). Of note, the baseline of LH secretion was 
significantly inhibited in the E2 replaced rats (AUC in 1-h pre-injection, 
OVX+0×E2 vs. OVX+1×E2 vs. OVX+2×E2: 283.5 ± 23.2 vs. 216.6 ± 19.7 vs. 
169.6 ± 6.0 ng/ml.min; P < 0.05). 
 
4.4.2 Experiment 2: Effects of NMDA on LH secretion in OVX rats 
replaced with different levels of E2 
To investigate the effects of NMDA on LH secretion in different E2 levels, we 
examined the effects of peripherally infused NMDA, a NMDA receptor agonist, 
on LH secretion in OVX rats replaced with different numbers of E2 capsules. 
Peripheral infusion of NMDA inhibited LH secretion in OVX+0×E2 rats (AUC 
in 1-h pre-injection vs. AUC in 2
nd
 1-h post-injection: 285.0 ± 8.7 vs. 232.2 ± 
10.6 ng/ml.min; P < 0.05) (Fig. 4.3). In contrast, NMDA briefly stimulated LH 
secretion in OVX+2×E2 rats (AUC in 1-h pre-injection vs. AUC in 1
st
 1-h 
post-injection: 163.8 ± 16.4 vs. 222.1 ± 17.6 ng/ml.min; P < 0.05) and this 
stimulation effect was not seen in the second h (AUC in 1-h pre-injection vs. 
AUC in 2
nd
 1-h post-injection: 163.8 ± 16.4 vs. 146.3 ± 17.5 ng/ml.min; P < 0.05) 
(Fig. 4.3). NMDA had no effects on LH secretion in OVX+1×E2 rats similar to 
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that of senktide (AUC in 1-h pre-injection vs. AUC in 1
st
 1-h post-injection vs. 
AUC in 2
nd
 1-h post-injection: 231.3 ± 23.5 vs. 236.8 ± 29.6 vs. 203.8 ± 29.5 
ng/ml.min; P > 0.05) (Fig. 4.3). The baseline of LH secretion was significantly 
inhibited in E2 capsules implanted rats as described before (AUC in 1-h 
pre-injection, OVX+0×E2 vs. OVX+1×E2 vs. OVX+2×E2: 285.0 ± 8.7 vs. 231.3 
± 23.5 vs. 163.8 ± 16.4 ng/ml.min; P < 0.05). 
 
4.4.3 Experiment 3: Effects of NMDA on LH secretion in OVX+0×E2 
rats in the presence of a NK3R antagonist 
To investigate whether NMDA-induced LH suppression in OVX+0×E2 rats was 
through the NKB-NK3R signalling, we examined the effects of peripherally 
administered NMDA on LH secretion in the presence of a NK3R receptor 
antagonist. Peripheral administration of NMDA-induced LH suppression was 
blocked by pre-treatment of SB222200, a NK3R antagonist (AUC in 2
nd
 1-h 
post-injection, vehicle + NMDA group vs. SB222200 + NMDA group: 228.9 ± 
7.5 vs. 262.4 ± 12.5 ng/ml.min; P < 0.05) (Fig. 4.4). Administration of aCSF (icv) 
with NMDA (iv) inhibited the LH secretion similar to the LH response of 
NMDA alone, whereas administration of SB222200 (icv) with saline (iv) had no 
effects on LH secretion (Fig. 4.4). Furthermore, peripheral administration of 
NMDA suppressed the pulsatile release of LH (LH pulse interval, 2-h 
pre-injection vs. 1
st
 2-h post-injection: 25.0 ± 2.1 vs. 37.8 ± 1.8 min; P < 0.05). 
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This suppression was blocked by co-administration of SB222200 (LH pulse 
interval in 1
st
 2-h post-injection, vehicle + NMDA vs. SB222200 + NMDA: 37.8 
± 1.8 vs. 30.8 ± 1.5 min; P < 0.05). SB222200 co-administered with saline had 
no effects on pulsatile LH release.  
 
4.4.4 Experiment 4: Effects of NMDA on LH secretion in OVX+2×E2 
rats in the presence of a Kiss1r antagonist 
To investigate whether NMDA-induced LH release in OVX+2×E2 rats was 
through the Kiss1-Kiss1r signalling, we examined the effects of peripherally 
administered NMDA on LH secretion in the presence of a Kiss1r antagonist. 
Peripheral administration of NMDA-induced LH release was blocked by 
pre-treatment of peptide-234, a Kiss1r antagonist (AUC in 2
nd
 1-h post-injection, 
vehicle + NMDA group vs. peptide-234 + NMDA group: 218.8 ± 12.2 vs. 172.7 
± 15.0 ng/ml.min; P < 0.05) (Fig. 4.5). Administration of aCSF (icv) with 
NMDA (iv) stimulated the LH secretion similar to the response of NMDA alone, 
while administration of peptide-234 (icv) with saline (iv) had no effects on LH 





4.4.5 Experiment 5: Effects of implantation of different numbers of E2 
capsules on circulating levels of E2 in OVX rats, comparing with 
intact female rats 
The circulating levels of E2 were significantly increased in OVX rats implanted 
with one E2 capsule compared with that without E2 capsule (OVX+0×E2 vs. 
OVX+1×E2: 12.7 ± 1.5 vs. 23.8 ± 2.0 pg/ml; P < 0.05) (Fig. 4.6). The E2 levels 
were further increased in OVX rats implanted with two E2 capsules (OVX+1×E2 
vs. OVX+2×E2: 23.8 ± 2.0 vs. 36.8 ± 2.4 pg/ml; P < 0.05) (Fig. 4.6). Compared 
with the physiological controls, the circulating levels of E2 in OVX+2×E2 rats 
were not different to that in intact female rats in oestrus stage (36.8 ± 2.4 vs. 45.2 
± 6.6; P > 0.05) but significant lower to that in proestrus stage (36.8 ± 2.4 vs. 
96.4 ± 6.9; P < 0.05) (Fig. 4.6). Furthermore, the E2 levels in both OVX+0×E2 
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Fig. 4.2 Effects of senktide on LH secretion in OVX rats replaced with 
different levels of E2. Representative LH profiles illustrating the effect of icv 
administration (arrow) of senktide (600 pmol) on LH secretion in OVX rats 
without E2 replacement (labelled as 0×E2) (A), with one E2 capsule 
replacement (labelled as 1×E2) (B), or with two E2 capsules replacement 
(labelled as 2×E2) (C). Central administration of senktide inhibited LH 
secretion in OVX+0×E2 rats, but stimulated LH secretion in OVX+2×E2 rats 
and had no effects on LH secretion in OVX+1×E2 rats, as summarised in D. 
*P < 0.05 vs. 1 h baseline within the same group; #P < 0.05 vs. 1-h baseline 
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Fig. 4.3 Effects of NMDA on LH secretion in OVX rats replaced with 
different levels of E2. Representative LH profiles illustrating the effect of iv 
infusion (arrow) of NMDA (30 mg/kg) on LH secretion in OVX rats without 
E2 replacement (labelled as 0×E2) (A), with one E2 capsule replacement 
(labelled as 1×E2) (B), or with two E2 capsules replacement (labelled as 2×E2) 
(C). Peripheral administration of NMDA inhibited LH secretion in 
OVX+0×E2 rats, but stimulated LH secretion in OVX+2×E2 rats and had no 
effects on LH secretion in OVX+1×E2 rats, as summarised in D. *P < 0.05 vs. 
1-h baseline within the same group; #P < 0.05 vs. 1-h baseline within the 0×E2 
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Fig. 4.4 Effects of NMDA on LH secretion in OVX+0×E2 rats in the presence 
of a NK3R antagonist. Representative LH profiles illustrating the effect of iv 
infusion (arrow) of NMDA (30 mg/kg) on LH secretion in OVX+0×E2 rats  in 
the presence (C) or absence (A) of icv administration (arrow) of SB222200 
(15 nmol), a NK3R antagonist, as well as the icv administration of  
SB222200 (15 nmol) with iv infusion of vehicle (saline) (B). NMDA-induced 
inhibition of LH secretion in OVX +0×E2 rats was blocked by pre-treatment 
of SB222200, a NK3R antagonist, as summarised in D; SB222200 per se had 
no effects on LH secretion. *P < 0.05 vs. 1-h baseline within the same group; 
#P < 0.05 vs. the same 1-h period within the group treated with vehicle and 
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Fig. 4.5 Effects of NMDA on LH secretion in OVX+2×E2 rats in the presence 
of a Kiss1r antagonist. Representative LH profiles illustrating the effect of iv 
infusion (arrow) of NMDA (30 mg/kg) on LH secretion in OVX+2×E2 rats  in 
the presence (C) or absence (A) of icv administration (arrow) of peptide-234 
(3 nmol), a Kiss1r antagonist, as well as the icv administration of  peptide (3 
nmol) with iv infusion of vehicle (saline) (B). NMDA-induced stimulation of 
LH secretion in OVX +2×E2 rats was blocked by pre-treatment of peptide-
234, a Kiss1r antagonist, as summarised in D; Peptide-234 per se had no 
effects on LH secretion. *P < 0.05 vs. 1 h baseline within the same group; #P 
< 0.05 vs. the same 1-h period within the group treated with vehicle and 
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Fig. 4.6 Effects of implantation of different numbers of E2 capsules on 
circulating levels of E2 in OVX rats, comparing to intact female rats. The 
circulating levels of E2 were increased in OVX rats implanted with one E2 
capsule (labelled as 1×E2) compared with that in OVX rats without E2 capsule 
implantation (labelled as 0×E2). The E2 levels were further increased in OVX 
rats replaced with two E2 capsules (labelled as 2×E2) compared with one 
capsule. Furthermore, the circulating levels of E2 in OVX+2×E2 rats were 
lower to that in intact female rats in proestrus phase (labelled as P) but not 
different to that in oestrus phase (labelled as E). However, the E2 levels in 
both OVX+0×E2 and OVX+1× E2 rats were lower to that in oestrus phase. *P 
< 0.05 vs. 0×E2 group; 
#P < 0.05 vs. 1×E2 group; 
£P < 0.05 vs. 1×E2 group, as 
well as 0×E2 group; 




























The results of this study have demonstrated that central administration of a 
selective NK3R agonist potently suppressed LH release in conditions of low 
levels of E2 (OVX without E2 replacement), but stimulated LH release in 
conditions of relatively high levels of E2 (equivalent to oestrus phase in normal 
cycling rats). Furthermore, NK3R agonist had no effects on LH release in 
animals with medium circulating levels of E2 (OVX with one E2 capsule 
replacement). These results support and extend previous studies that showed that 
senktide had a biphasic effects on LH release (Wakabayashi et al. 2010, Navarro 
et al. 2011a), adding that an intermediary state may exist between those two 
phases, given a condition with appropriate E2 levels. Admittedly, the differences 
of circulating E2 levels in those three replacement regimes in the present study 
were very subtle (Fig. 4.6). However, an extensive difference in LH releasing 
ability was induced by this comparably narrow range of E2 levels which might 
provide an explanation for previous studies showing suppressive, null or 
stimulatory effects of senktide on LH release in OVX rodents with or without E2 
replacement (Sandoval-Guzman and Rance 2004, Navarro et al. 2009a, Navarro 
et al. 2011a, Kinsey-Jones et al. 2012). Previous studies from our lab failed to 
observe the null or stimulatory effects of senktide on LH release using a similar 
methodology (Grachev et al. 2012a, Kinsey-Jones et al. 2012). This may be due 
to the seemingly less potent E2 replacement in those studies, with intact pulsatile 
LH release regardless of the E2 replacement regime (Grachev et al. 2012a, 
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Kinsey-Jones et al. 2012). In the present study, LH pulses were presented in the 
low E2 replacement regime, whereas they were markedly attenuated in the 
medium and high E2 replacement groups, reflecting a stronger E2 negative 
feedback control. It should be noted that all of the above E2 levels were either 
equal or below the E2 levels determined in the oestrus phase of the cycle, 
suggesting that in the rat, the switch from an inhibitory to a stimulatory effect of 
senktide on LH release happened below the lowest physiological E2 levels, 
which is in accordance with the predominant stimulatory role of NKB-NK3R 
signalling in normal physiological conditions. 
In the present study, senktide inhibits LH release in the OVX rats, evidently in 
the second post-treatment h as calculated by the AUC of LH profiles (Fig. 4.2). 
This is in agreement with a previous study which showed central administration 
of senktide inhibited LH level in OVX rats 120 min after the treatment onset 
(Navarro et al. 2011a). In addition, senktide inhibits LH pulses in OVX+0×E2 
rats, which is in keeping with previous studies showing prolongation of the LH 
pulse interval throughout the 2-h post-treatment period (Grachev et al. 2012a, 
Kinsey-Jones et al. 2012, Grachev et al. 2014a). These inhibitory effects are 
through activating the NK3R in the ARC, since intra-ARC administration of 
senktide dose-dependently inhibited the pulsatile release of LH, an effect 
blocked by pre-treatment of a NK3R antagonist (Grachev et al. 2012a). 
Furthermore, senktide-induced suppression of pulsatile LH release can be 
blocked by intra-ARC administration of nor-BNI, a κ-opioid receptor antagonist, 
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indicating that NKB-NK3R signalling in the ARC is mediated via Dyn, the 
endogenous ligand for the κ-opioid receptor, to activate κ-opioid receptor, and 
thus suppress the GnRH pulse generator (Grachev et al. 2012a). However, it 
should be noted that κ-opioid receptors are not abundantly expressed in the 
vicinity of GnRH neurones (Mitchell et al. 1997). Therefore, it is hypothesised 
that Dyn neurones affect GnRH secretion via an unknown signalling system 
(Grachev et al. 2014b). Overall, since KNDy neurones in the ARC co-express 
NK3R and Dyn, it is postulated that senktide acts through KNDy neurones to 
suppress the GnRH release (Grachev et al. 2014b), at least when E2 levels are 
low. 
In contrast to its inhibitory effects in low E2 conditions, senktide stimulated LH 
release in a relatively high E2 environment in OVX rats that were implanted with 
two E2 capsules (Fig. 4.2). This is in line with a previous study (Navarro et al. 
2011a) that showed senktide induced LH release in OVX rats replaced with 
proestrus levels of E2. A plethora of studies have indicated that NKB-induced 
LH release is dependent on Kiss1-Kiss1r signalling (Ramaswamy et al. 2010, 
Garcia-Galiano et al. 2012b, Grachev et al. 2012b). In rodents, the Kiss1r 
knockout mice was devoid of senktide-induced LH release, while Kiss1r 
antagonism blocked the senktide-induced release of LH in prepubertal rats 
(Garcia-Galiano et al. 2012b, Grachev et al. 2012b). In addition, morphological 
studies have further strengthened this argument. It was shown that KNDy 
neurones were interconnected with each other bilaterally in the ARC through 
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NK3R (Krajewski et al. 2010). Furthermore, KNDy neurones were shown to 
project to the mPOA and median eminence in rodents (Lehman et al. 2013). 
Although it is not known whether Kiss1r protein is expressed in GnRH terminals, 
Kiss1r mRNA is identified in GnRH neurones by in situ hybridization in rodents 
(Irwig et al. 2004, Han et al. 2005). It is therefore postulated that NKB may act 
through KNDy neurones, which in turn activate GnRH neurones via either 
GnRH cell bodies in the mPOA or GnRH terminals in the medial eminence 
(Navarro 2013, Grachev et al. 2014b). 
Nevertheless, the most intriguing finding of the present study was the null effect 
of the senktide on LH release in the medium E2 replacement regime. An absence 
of LH response to senktide was previously reported in OVX mice primed with 
E2 (Navarro et al. 2009a). It was argued that the levels of NK3R mRNA in the 
ARC were potently inhibited by the increased E2 concentration, leading to the 
lack of effect of senktide on the LH release (Navarro et al. 2011a). However, this 
argument failed to explain the stimulatory effects of senktide in intact female 
rats with similar levels of NK3R mRNA in the ARC (Navarro et al. 2011a). 
Given the paradigm of the present study, the null effect might be due to the 
opposing inhibitory and stimulatory effects of senktide on LH release, or due to 
the unresponsive nature of senktide on LH release at that particular E2 level, 
therefore, providing an expected transitional stage (i.e. the ‘switch’). The 
mechanisms underlying this switch from inhibitory to stimulatory, dependent on 
E2 level, which is in common with many other neuropeptides (Kalra and Kalra 
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1983) and neurotransmitters, remain to be established. 
In the present study, a similar effect of NMDA on LH release as reported for 
senktide was observed. NMDA is an agonist of NMDA receptor, a subtype for 
the neurotransmitter glutamate. Peripheral administration of NMDA potently 
suppressed LH release in the presence of low levels of E2 (OVX without E2 
replacement), whereas stimulated LH release in the presence of relatively high 
levels of E2 (OVX with two E2 capsules; equivalent to oestrus phase in normal 
cycling rats). Furthermore, NMDA had no effects on LH release in the presence 
of intermediary levels of E2 (OVX with one E2 capsule). These data are in 
keeping with previous studies that showed NMDA inhibited or had no effect on 
LH release in OVX rats and increased LH release in proestrus rats or OVX rats 
primed with E2 (Brann and Mahesh 1992, Arias et al. 1993). Comparing the 
effect of NMDA with senktide, the triphasic LH releasing ability and thresholds 
of E2 levels for the switch to happen are similar, which may allude to possible 
common mechanisms and prompted us to investigate the possible correlation 
between those two signalling systems. 
The inhibitory effects of NMDA on LH release in low E2 conditions have 
remained unexplained. The suppressive effects on LH release following 
administration of NMDA in OVX monkeys are accompanied by a concomitant 
increase of circulating levels of cortisol (Reyes et al. 1990). Thus, NMDA may 
activate corticotrophin-releasing factor (CRF), the core of 
hypothalamo-pituitary-adrenal (HPA) axis and a hypothalamic inhibitory 
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regulator on GnRH release (Li et al. 2010), to suppress LH release. Indeed, 
pre-treatment with a CRF antagonist prevents the decrease of LH release in 
response to NMDA (Reyes et al. 1990). However, NMDA was later shown to 
increase cortisol levels to the same degree in OVX monkeys with or without E2 
treatment (Reyes et al. 1991), therefore, making the above argument less 
compelling. In the present study, we provided an alternative route for NMDA to 
suppress LH release in low E2 conditions which is through the NKB-NK3R 
signalling system, since a NK3R antagonist blocked the suppressive effects of 
NMDA on LH release in OVX rats. Although it is not clear where NK3R 
antagonism is acting, it could be speculated that peripheral administration of 
NMDA could act through ARC KNDy neurones to suppress the LH release via 
NKB-NK3R signalling, because (a) KNDy neurones receive inputs from 
non-KNDy glutamatergic fibres arising from other regions (Lehman et al. 2013); 
(b) KNDy neurones in the ARC co-express NKB and NK3R (Lehman et al. 
2010); and (c) activation of NK3R in the ARC inhibits the LH release in OVX 
rats and these effects can by blocked by pre-treatment of Dyn antagonism 
(Grachev et al. 2012a). Thus, we proposed a potent link between glutamate → 
NKB → Dyn signalling systems may underlie the inhibitory effects of NMDA 
on LH release. Of note, NK3R antagonism per se had no effects on LH release, 
which is in agreement with previous studies (Noritake et al. 2011, Grachev et al. 
2012a). This indicates that endogenous NKB may not be involved in controlling 
pulsatile LH release in low E2 conditions. 
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We have also shown that the stimulatory effects of NMDA on LH release were 
through Kiss1-Kiss1r signaling, since peptide-234 blocked the NMDA-induced 
LH secretion in OVX+2×E2 rats. This is in keeping with the study that showed 
that peripheral administration of NMDA activates Kiss1-Kiss1r signalling to 
increase LH release (d'Anglemont de Tassigny et al. 2010). It also concurs with 
an in vitro study that showed that Kiss1 increases glutamatergic transmission 
directly onto GnRH neurones in an E2 dependent manner (Pielecka-Fortuna and 
Moenter 2010). However, NMDA does not seem to act on GnRH neurones 
directly, making the in vitro study less compelling in a physiological condition. 
Our current studies and previous studies support a Kiss1 dependent GnRH/LH 
release by NMDA, which is supported by the fact that KNDy neurones receive 
inputs from non-KNDy glutamatergic fibres (Lehman et al. 2013) and KNDy 
neurones activate GnRH neurones to release GnRH (Navarro 2013). However, 
the present study did not investigate whether the stimulatory effects of NMDA 
on LH release in OVX+2×E2 rats are dependent on the NKB-NK3R siganlling 
system. This is possible since NK3R agonism stimulates LH secretion in the 
presence of relatively high levels of E2 and this stimulation is dependent on 
Kiss1-Kiss1r signalling (Navarro et al. 2011a, Garcia-Galiano et al. 2012b). 
Therefore, we cannot rule out the possibility that NKB-NK3R signalling may 
also mediate the stimulatory action of NMDA on LH relaese. 
In summary, we have presented herein a triphasic LH secretory response to 
senktide, as well as to NMDA, determined by different levels of circulating E2. 
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This is reminiscent of the predominant stimulatory effect of the NKB and 
glutamate signalling systems on the reproductive system in normal physiological 
conditions, and the inhibitory effect in conditions of low E2 such as menopause, 
ovarian failure or ovariectomy. Furthermore, we suggest that peripheral 
administration of NMDA might act on KNDy neurones to affect LH release, by 
providing evidences that NMDA activates the Kiss1-Kiss1r or NKB-NK3R 
signalling systems to stimulate or inhibit LH release respectively, depending on 
the prevailing E2 conditions. This might shed light on the mechanisms of many 
other neurotransmitters or neuropeptides that have presented a similar triphasic 




CHAPTER FIVE: BIPHASIC EFFECTS OF SUBSTANCE P 
ON LH SECRETION IN FEMALE RATS 
5.1 Introduction 
Normal reproductive function requires pulsatile GnRH release controlled by the 
GnRH pulse generator. The precise neural identity of the GnRH pulse generator 
remains to be clarified. Recently, emerging evidence has alluded to the KNDy 
neurones in the ARC as a likely candidate for the intrinsic source of the GnRH 
pulse generator (Lehman et al. 2010). Of the neuropeptides in KNDy neurones, 
NKB belongs to a family of peptides termed tachykinins, which also include 
NKA and substance P (Almeida et al. 2004). Tachykinins bind to three G 
protein-coupled receptors, NK1R, NK2R and NK3R. Although, each tachykinin 
binds preferentially to one of the tachykinin receptors (substance P – NK1R, 
NKA – NK2R, NKB – NK3R), substance P, NKA and NKB can activate any 
one of the receptors (Almeida et al. 2004). 
After its identification as a 11-amino acid peptide (Chang et al. 1971), substance 
P has been shown to be involved in pituitary gonadotrophin secretion with 
numerous effects. Treatments of substance P in a variety of experimental 
paradigms in laboratory animals have been shown to stimulate (Vijayan and 
McCann 1979, Arisawa et al. 1990, Navarro et al. 2015, Simavli et al. 2015), 
inhibit (Vijayan and McCann 1979, Arisawa et al. 1990, Kalra et al. 1992) or 
exert no effects (Eckstein et al. 1980, Kalra et al. 1992, Sahu and Kalra 1992) on 
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circulating LH levels, with no changes in levels of FSH (Vijayan and McCann 
1979, Eckstein et al. 1980). More specifically, central administration (icv) of 
substance P increased tonic LH release in OVX rats/mice with or without E2 
replacement (Vijayan and McCann 1979, Arisawa et al. 1990, Navarro et al. 
2015). Peripheral (iv) administration of substance P inhibited tonic LH secretion 
in OVX rats (Vijayan and McCann 1979, Arisawa et al. 1990) and specific 
nucleus (intra-mPOA) administration of substance P inhibited tonic LH secretion 
in both intact and castrated male rats (Picanco-Diniz et al. 1990). Furthermore, 
icv administration of substance P had no effects on tonic LH release in intact 
female monkeys (Eckstein et al. 1980). Similarly, icv administration of 
substance P did not affect LH secretion in intact male rats or in OVX rats with or 
without E2 replacement (Kalra et al. 1992, Sahu and Kalra 1992). The 
discrepancies among these studies might be due to the differences in the species, 
sex, sexual gonadal levels or methods (route and site) of drug delivery. 
The studies described above showed either a net increase or decrease in mean 
levels of LH in response to substance P. However, they do not address the role 
of substance P in the regulation of pulsatile GnRH/LH release. Earlier studies 
have shown that neurones expressing Tac1 mRNA (encoding substance P and 
NKA) were found in the ARC in rats (Larsen et al. 1993). Furthermore, along 
with its receptor (NK1R, encoded by gene Tacr1), substance P fibres were also 
shown to be concentrated in the ARC in rats (Shults et al. 1984, Buck et al. 1986, 
Hershey et al. 1991). Recent findings have underscored substance P as a 
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potential modulator of the GnRH pulse generator, since substance P is 
co-localised with kisspeptin and NKB in KNDy neurones in the human 
hypothalamus (Hrabovszky et al. 2013). However, in mice, Tac1 mRNA 
measured by in situ hybridization was not co-expressed with Kiss1 mRNA in the 
ARC (Navarro et al. 2015), indicating a possible species difference. Furthermore, 
substance P directly increases the excitability of mouse ARC Kiss1 neurones in 
vitro (de Croft et al. 2013) and the ARC Kiss1 neurones express Tacr1 mRNA 
(Navarro et al. 2015). In addition, Kiss1r knockout mice reversed the 
stimulatory effect of substance P on LH release (Navarro et al. 2015). It is 
therefore reasonable to assume that Kiss1 signalling in the ARC modulates the 
effects of substance P on LH release. 
 
5.2 Aims and objectives 
To test the hypothesis that NK1R signalling in the ARC regulates the release of 
LH in female rats and this regulation is affected by the circulating levels of E2. 
a) To investigate the effects of intra-ARC administration of substance P or 
GR73632, a selective NK1R agonist, on LH release in OVX rats with 
(OVX+2×E2; 36.8 ± 2.4 pg/ml, equal to circulating levels of oestrus phase 
of intact female rats) or without (OVX+0×E2) E2 replacement. 
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b) To determine whether activation of NK1R in the ARC by substance P or 
GR73632 modulates the frequency of pulsatile LH release in OVX rats 
without E2 replacement. 
 
5.3 Materials and methods 
5.3.1 Animals and surgical procedures 
Under general anaesthesia, adult Sprague-Dawley rats were OVX and implanted 
with bilateral guide cannulae directed towards the ARC (see section 2.2.2.5). In 
addition, animals receiving E2 replacement were implanted subcutaneously with 
two Silastic
TM
 E2 capsules (equal to circulating levels of oestrus phase of intact 
female rats; see Chapter 4), while animals without E2 replacement were replaced 
with two Silastic
TM
 capsules filled with arachis oil (see section 2.2). After a 10-d 
recovery period (Fig. 5.1), rats were fitted with two indwelling cardiac catheters 
via the jugular vein, as described in section 2.2.2.6. Experimentation 
commenced 3 d later (Fig. 5.1). Cannula placement was verified by histological 
inspection at the end of the experiment, and animals with cannulae tips located 







Fig. 5.1 Timeline diagram of various surgical and experimental procedures for 
investigating the effects of ARC substance P-NK1R signalling system on LH 
release in OVX rats replaced with different levels of E2. 
 
5.3.2 Experiment 1: Effects of substance P on LH release in OVX rats 
with or without E2 replacement 
On the morning of experimentation, a bilateral internal injection cannula 
(Plastics One) with extension tubing preloaded with substance P (Sigma-Aldrich) 
or vehicle (aCSF) was inserted into the guide cannula and extended 1 mm 
beyond the guide cannula to reach the ARC. The distal end of the tubing was 
extended outside of the cage connected to a 5 µl Hamilton syringe (Waters 
International), thereby allowing remote infusion without disturbing the rat 
during the experiment (see section 2.2.3.3). Rats were also attached via one of 
the two cardiac catheters to the computer-controlled automated blood sampling 
system (see section 2.2.3.1). Once connected, animals were left undisturbed for 
1 h. Blood sampling commenced between 1000 and 1100 h and samples were 
collected every 5 min for 6 h for LH measurement. 
Substance P (10 or 100 pmol in 400 nl aCSF per side, n = 7, 8, respectively) or 








7 d 10 d 3 d 7-14 d
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min after 2 h of controlled blood sampling into OVX+0×E2 rats. In addition, a 
separate group of OVX+2×E2 rats was injected (intra-ARC) with 400 nl aCSF (n 
= 5), 10 pmol substance P (n = 6), or 100 pmol substance P (n = 7). The dose of 
substance P was selected based on our previous study (Grachev et al. 2012a) 
showing that intra-ARC administration of senktide (1 or 10 pmol), a NK3R 
agonist, inhibited the pulsatile LH release. However, our preliminary study with 
1 pmol of substance P failed to show any effects on LH release, which prompted 
us to adopt higher doses (10 and 100 pmol). 
 
5.3.3 Experiment 2: Effects of GR73632, an agonist of NK1R, on LH 
release in OVX rats with or without E2 replacement 
On the morning of experimentation, the rats were attached to the automated 
blood sampling system and equipped with the intra-ARC injection system, as 
described above. After 2-h control blood sampling, GR73632 (10 or 100 pmol in 
400 nl aCSF per side, n = 6, 7, respectively, Tocris Biosciences), a selective 
agonist of NK1R (Hagan et al. 1991), or aCSF (400 nl, n = 6) was administered 
(intra-ARC) over 5 min into OVX+0×E2 rats. Additionally, GR73632 (10 or 100 
pmol in 400 nl aCSF per side, n = 6, 8, respectively) or aCSF (400 nl per side, n 





5.3.4 Statistical analysis 
Detection of LH pulses in OVX+0×E2 rats was established by use of the 
algorithm ULTRA (Van Cauter 1988). The effect of pharmacological agents on 
pulsatile LH secretion was analysed by comparing the mean LH pulse interval in 
the 2-h period preceding treatment with that in two consecutive 2-h 





 2-h post-treatment periods, was divided by the number of LH pulses 
detected in each of these periods to give the appropriate LH pulse interval. The 
significance of the effect of treatments on LH pulse intervals was compared with 
control animals injected with vehicle, at the same time period, as well as with 
mean pulse interval during the 2-h pre-treatment period. The effect of 
pharmacological agents on overall LH release was calculated by comparing the 




 h post-treatment periods with that in the 1-h pre-treatment 
period, using SigmaPlot version 11 (Systat Software). Statistical significance 
was tested using one-way ANOVA followed by Dunnett’s test. All data were 
shown as mean ± S.E.M. P < 0.05 was considered statistically significant. 
 
5.4 Results 
5.4.1 Experiment 1: Effects of substance P on LH release in OVX rats 
with or without E2 replacement 
To investigate the activation of NK1R on LH release in different E2 levels, we 
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examined the effects of intra-ARC administration of substance P on LH 
secretion in OVX rats with or without E2 replacement. Intra-ARC administration 
of substance P caused a dose-dependent inhibition of LH pulse interval in 
OVX+0×E2 rats (Fig. 5.2, G). At the dose of 10 pmol, substance P prolonged the 
LH pulse interval by 44.2% (2-h pre-injection vs. 1
st
 2-h post-injection: 22.4 ± 
1.0 vs. 32.3 ± 1.5 min; P < 0.05), and by 79.4% with 100 pmol substance P, (2-h 
pre-injection vs. 1
st
 2-h post-injection: 23.9 ± 0.7 vs. 42.9 ± 3.0 min; P < 0.05). 
LH pulse frequency recovered after suppression due to substance P, with pulse 
intervals returning to 23.0 ± 0.8 and 25.7 ± 2.1 min during the 2
nd
 2-h period 
after treatment with 10 pmol and 100 pmol substance P, respectively. In the 
control group, infusion of vehicle (aCSF) did not affect the LH pulse frequency. 
Due to the negative feedback effect of E2 with the replacement regime of 2 E2 
capsules, LH pulses were not evident. We therefore calculated the overall LH 
secretion by using AUC and, for comparative purposes, we used this method of 
analysis for both OVX+0×E2 and OVX+2×E2 rats treated with substance P. 
Intra-ARC administration of substance P (100 pmol) reduced AUC of the LH 
profile during the 2
nd
 1-h period after treatment in OVX+0×E2 rats (1-h 
pre-injection vs. 2
nd
 1-h post-injection: 269.2 ± 6.8 vs. 224.4 ± 11.2 ng/ml.min; P 
< 0.05; Figs. 5.2, C and H). By contrast, AUC of the LH profile was increased 
during the 1
st
 h post-administration period in OVX+2×E2 rats (AUC in 1-h 
pre-injection vs. AUC in 1
st
 1-h post-injection: 155.4 ± 5.6 vs. 189.0 ± 3.3 
ng/ml.min; P < 0.05; Figs. 5.2, F and H). However, this stimulation was 
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followed by an inhibition of LH secretion during the 2
nd
 h post-administration 
period (AUC in 1-h pre-injection vs. AUC in 2
nd
 1-h post-injection: 155.4 ± 5.6 
vs. 128.5 ± 7.1 ng/ml.min; P < 0.05; Figs. 5.2, F and H). Both substance P (10 
pmol) and vehicle (aCSF) did not affect the LH secretion measured by AUC in 
OVX+2×E2 rats, as well as in OVX+0×E2 rats (Figs. 5.2, A, B, D, E and H). In 
addition, no misplaced cannulae were found in this set of experiments. 
 
5.4.2 Experiment 2: Effects of GR73632, an agonist of NK1R, on LH 
release in OVX rats with or without E2 replacement 
To investigate whether substance P acts through NK1R to affect the LH secretion, 
we examined the effects of intra-ARC administration of GR73632, a selective 
NK1R agonist, on LH secretion in OVX rats with or without E2 replacement. As 
was observed with substance P, intra-ARC administration of GR73632 caused a 
dose-dependent inhibition of pulsatile LH release in OVX+0×E2 rats (Fig. 5.3, 
G). GR73632 prolonged the LH pulse interval by 49.6% with the 10 pmol dose 
(2-h pre-injection vs. 1
st
 2-h post-injection: 22.4 ± 1.9 vs. 33.5 ± 1.6 min; P < 
0.05), and by 78.5% with the 100 pmol dose (2-h pre-injection vs. 1
st
 2-h 
post-injection, 22.3 ± 1.7 vs. 39.8 ± 3.5 min; P < 0.05). After treatment with 10 
pmol or 100 pmol of GR73632, LH pulse frequency recovered during the 2
nd
 2-h 
post-treatment period, with pulse intervals returning to 21.9 ± 1.2 and 24.9 ± 0.9 
min, respectively. In the control group, infusion of vehicle (aCSF) did not affect 
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the LH pulse frequency. 
Due to the negative feedback effect of E2 with the replacement regime of 2 E2 
capsules, LH pulses were not evident. We therefore calculated the overall LH 
secretion by using AUC and, for comparative purposes, we used this method of 
analysis for both OVX+0×E2 and OVX+2×E2 rats treated with GR73632. 
Intra-ARC administration of GR73632 (100 pmol) reduced the AUC of the LH 
profile in OVX+0×E2 rats (1-h pre-injection vs. 2
nd
 1-h post-injection: 269.0 ± 
6.9 vs. 219.4 ± 11.7 ng/ml.min; P < 0.05; Figs. 5.3, C and H). By contrast, LH 
levels were increased during the 1
st
 h post-administration period in OVX+2×E2 
rats (AUC in 1-h pre-injection vs. AUC in 1
st
 1-h post-injection: 153.8 ± 3.4 vs. 
182.4 ± 9.8 ng/ml.min; P < 0.05; Figs. 5.3, F and H). This simulation was 
followed by an inhibition during the 2
nd
 h post-administration period (AUC in 
1-h pre-injection vs. AUC in 2
nd
 1-h post-injection: 153.8 ± 3.4 vs. 118.0 ± 8.1 
ng/ml.min; P < 0.05; Figs. 5.3, F and H). Both GR73632 (10 pmol) and vehicle 
(aCSF) did not affect the LH secretion measured by AUC in OVX+2×E2 rats, as 
well as in OVX+0×E2 rats (Figs. 5.3, A, B, D, E and H). ARC cannulae were 
found to be misplaced in two OVX+2×E2 rats (Fig. 5.4). GR73632 did not affect 
the LH secretion in those two rats at the dose of 10 pmol (data not shown) or 100 
pmol (AUC in 1-h pre-injection vs. AUC in 1
st
 1-h post-injection vs. AUC in 2
nd
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Fig. 5.2 Effects of substance P on LH release in OVX rats with or without E2 
replacement. Representative LH profiles demonstrating (1) effects of intra-
ARC administration (arrow) of substance P or vehicle (aCSF) on pulsatile LH 
secretion in OVX rats without E2 replacement (labelled as 0×E2) (A-C), and 
(2) effects of intra-ARC administration of substance P or vehicle (aCSF) on 
LH secretion in OVX rats replaced with two E2 capsules (labelled as 2×E2) 
(D-F). Central administration of substance P dose-dependently suppressed 
pulsatile LH release in OVX+0×E2 rats, as summarised in panel G. 100 pmol 
substance P inhibited LH secretion (calculated by AUC) in OVX+0×E2 rats 
(H). Furthermore, 100 pmol substance P stimulated LH secretion in 
OVX+2×E2 rats (H). However, this stimulation was followed by an inhibition 
(H). The effects of substance P on LH secretion are summarised in panel H. 
*P < 0.05 vs. 1-h baseline within the same group, as well as the same 1-h 
period within the vehicle treated group; #P < 0.05 vs. same 1-h period within 
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Fig. 5.3 Effects of GR73632, an agonist of NK1R, on LH release in OVX rats 
with or without E2 replacement. Representative LH profiles demonstrating 
(1) effects of intra-ARC administration (arrow) of GR73632 or vehicle 
(aCSF) on pulsatile LH secretion in OVX rats without E2 replacement 
(labelled as 0×E2) (A-C), and (2) effects of intra-ARC administration of 
substance P or vehicle (aCSF) on LH secretion in OVX rats replaced with 
two E2 capsules (labelled as 2×E2) (D-F). Central administration of GR73632 
dose-dependently suppressed the pulsatile LH release in OVX+0×E2 rats, as 
summarised in panel G. 100 pmol GR73632 inhibited LH secretion 
(calculated by AUC) in OVX+0×E2 rats (H). Furthermore, 100 pmol 
GR73632 stimulated LH secretion in OVX+2×E2 rats (H). However, this 
stimulation was followed by an inhibition (H). The effects of GR73632 on 
LH secretion are summarised in panel H. *P < 0.05 vs. 1-h baseline within 
the same group, as well as the same 1-h period within the vehicle treated 
group; #P < 0.05 vs. same 1-h period within the group treated with 10 pmol 
GR73632 (n = 5-8 per group). 
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Fig. 5.4 Schematic illustration and photomicrograph of the infusion site 
targeted to the ARC. A, schematic illustration showing the target site for 
bilateral cannulation of the ARC. Arrows point to the location of the tips of 
internal cannulae. B, photomicrograph of a coronal brain section in a 
representative animal implanted with a bilateral cannula in the ARC. 
Arrows indicate the tip of the internal cannulae. C-D, schematic drawings of 
the ARC illustrating the individual sites of injection for the experiments 
carried out in OVX+0×E2 and OVX+2×E2 rats, respectively. Numbers in 
each drawing indicate the distance (mm) to Bregma. Open circles show the 






The present study has shown that activation of NK1R in the ARC stimulated LH 
release in conditions of high circulating levels of E2 (equivalent to those 
observed in the oestrus phase of the cycle). In contrast, an inhibitory response 
was observed in conditions of low E2 levels (OVX without E2 replacement). 
These results support previous studies showing a similar biphasic effects of iv 
administration of substance P on LH release (Arisawa et al. 1990) and therefore 
indicate the ARC to be the primary site of action. Although substance P is not 
indicated to cross the blood-brain barrier, it is possible that iv administration 
may still act at the level of the ARC, since this structure, which lies immediately 
dorsal to the ME, is one of the circumventricular organs characterised by an 
incomplete blood-brain barrier and therefore susceptible to the peripheral 
hormone environment (Yamamura et al. 2015). If the above hypothesis is correct, 
then the inhibitory effects of iv administered substance P observed in previous 
studies in OVX rats without E2 replacement (Vijayan and McCann 1979, 
Arisawa et al. 1990) could be explained by the activation of NK1R in the ARC, 
as shown in the present study. However, these biphasic effects were not 
demonstrated in a recent study which showed that the activation of NK1R (icv 
administration) stimulated LH release in OVX mice with or without E2 
replacement (Navarro et al. 2015). These conflicting data may be due to the 
species differences or different routes of drug delivery. Nevertheless, the results 
from an earlier study showed that substance P induced LH release follow icv 
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administration, but inhibited LH release following iv administration in OVX rats 
without E2 replacement (Vijayan and McCann 1979). 
The results of the present study are similar to those examining the role of NK3R 
activation in the regulation of LH release, as described in Chapter 4. Similar to 
NKB, the underlying mechanism for the stimulatory effects of substance P on 
the LH release implicate Kiss1 signalling in the ARC. Recent studies showed 
that substance P fibres innervated Kiss1 neurones in the ARC in sheep and 
monkeys (Bruna et al. 2014, Chrysanthi et al. 2015). Furthermore, Kiss1r 
knockout mice were devoid of substance P-induced LH release and ARC Kiss1 
neurones express NK1R in mice (Navarro et al. 2015). Since intra-ARC 
administration of the NK1R agonists induced LH secretion, as shown in the 
present study, it is reasonable to postulate that substance P may stimulate LH 
release via KNDy neurones in the ARC. 
The present study has also shown that this transitory stimulatory effect was 
followed by an inhibition of LH release. This inhibitory effect was not observed 
with NK3R and NMDA agonists (see Chapter 4), although a tendency towards 
inhibition was evident. The specific location of administration of NK1R agonists 
into the ARC may account for the more obvious inhibitory effect, although the 




We have also shown that intra-ARC administration of the NK1R agonist 
dose-dependently suppressed pulsatile LH release in OVX+0×E2 rats. This 
indicates that substance P may inhibit the GnRH pulse generator in conditions of 
low E2. Morphological studies have demonstrated that substance P may innervate 
KNDy neurones in the ARC which are postulated to be an essential component 
of the GnRH pulse generator (Lehman et al. 2010). It is therefore possible that 
substance P inhibits the pulsatile LH release via the KNDy neurones. 
Furthermore, previous studies have shown that activation of NK3R in the ARC 
suppressed pulsatile LH release (Grachev et al. 2012a, Grachev et al. 2014a). 
The NK3R agonist-induced suppression of LH pulses is thought to be mediated 
via Dyn signalling in the ARC (Grachev et al. 2012a). It is possible that the 
inhibitory effect of NK1R agonism on LH pulses is also mediated through Dyn 
signalling. 
In order to exclude the possibility that substance P act on receptors other than 
NK1R to affect LH release, we used the selective NK1R agonist GR73632 
(Navarro et al. 2015, Ruiz-Pino et al. 2015, Simavli et al. 2015). Previous 
studies have shown GR73632 may be more potent on NK1R compared to 
substance P (Hagan et al. 1991). However, the effects of substance P and 
GR73632 on the dynamics of LH secretion in the present study were very similar. 
This might suggest that substance P may have a stronger affinity with NK1R 
compared with NK2R or NK3R (Seabrook et al. 1995). Compared with NK3R 
agonists (Grachev et al. 2012a), the effects of intra-ARC administration of the 
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NK1R agonists (even with a 10 times higher dose) on LH release in the ARC 
were very modest. This could be due to a more robust expression of NK3R in the 
KNDy neurones compared with NK1R (Navarro et al. 2015). It is possible that 
NK1R signalling may play a less important role in regulating the GnRH pulse 
generator compared with NK3R. This is supported by a recent study showing 
that a 100 times higher dose of NK1R agonists (compared to NK3R agonists) 
was required to induce the MUA volley (an electrophysiological correlate of 
GnRH pulse generator activities) in OVX goats (Yamamura et al. 2015). 
Although the morphological and pharmacological studies supported the potential 
role of NK1R signalling in the regulation of the GnRH pulse generator, the 
physiological significance of substance P in the reproductive system warrants 
cautious interpretation. Nevertheless, a recent study showed that Tac1 knockout 
mice presented a delayed puberty onset without changing the body weight 
(Simavli et al. 2015). An acceleration of the GnRH pulse generator is required 
for the initiation of puberty (Sisk and Foster 2004). It could be inferred that 
substance P may be involved in the acceleration of the GnRH pulse generator 
during the prepubertal stage, which is in keeping with the concurrent increased 
substance P signalling during this period (Simavli et al. 2015). 
In summary, the present study has shown biphasic effects of substance P on LH 
release, depending on the prevailing levels of E2. Furthermore, we determined 
the ARC to be a primary site of action, which suggests that the KNDy neural 
system may be a downstream effector of substance P signalling. 
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CHAPTER SIX: RFRP-3 MODULATES BASAL AND 
STRESS-INDUCED SUPPRESSION OF PULSATILE LH 
RELEASE IN FEMALE RATS 
6.1 Introduction 
GnIH was discovered in birds to be the first hypophysiotrophic hormone to 
directly inhibit the gonadotrophin secretion at the level of the anterior pituitary 
gland (Tsutsui et al. 2000). Its mammal orthologue, RFRP, was later identified 
and characterised in a variety of mammal species, including rodents (Ukena et al. 
2002, Kriegsfeld et al. 2006). However, unlike their avian orthologue, the 
hypophysiotrophic role of RFRP on gonadotrophin release in rodents has been 
extensively questioned since RFRP fibres are sparse or absent in external layer 
of ME (Kriegsfeld et al. 2006, Johnson et al. 2007, Rizwan et al. 2009), and 
RFRP neurones are unable to absorb retrograde tract tracing dye injected 
peripherally (Rizwan et al. 2009). Therefore, it is unlikely that RFRP is released 
into the portal veins to act on anterior pituitary. Instead, RFRP is indicated as a 
hypothalamic neuropeptide since mRNA of both RFRP and GPR147 (RFRP 
receptor) were predominantly expressed in hypothalamus in rodents compared 
with other tissues such as pituitary gland and gonads (Hinuma et al. 2000). 
The RFRP mRNA encodes a polypeptide that is cleaved into two neuropeptides 
(RFRP-1 and RFRP-3) (Hinuma et al. 2000, Ukena et al. 2002, Tsutsui et al. 
2012). Whilst RFRP-1 does not exert an inhibitory effect on the release of 
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gonadotrophins in rodents (Pineda et al. 2010b), numerous studies have 
demonstrated that central administration of RFRP-3 is able to exert an inhibitory 
effect on the HPG axis, principally a robust reduction in mean circulating levels 
of LH (Kriegsfeld et al. 2006, Johnson et al. 2007, Kirby et al. 2009, Pineda et 
al. 2010b, Leon et al. 2014), which suggests RFRP-3 is likely to be the GnIH in 
mammals, but with a different site of action. Furthermore, RFRP-3-induced LH 
suppression may act through the GPR147 receptor, since this inhibitory effect 
was nullified in GPR147 knockout mice (Leon et al. 2014). However, other 
studies investigating the mechanisms underlying this inhibition have yielded 
absence of effect of RFRP-3 on pulsatile LH secretion, including LH pulse 
frequency and amplitude (Murakami et al. 2008, Anderson et al. 2009). These 
above results are at odds with the inhibitory role of RFRP-3 on LH release and 
therefore warranted further investigation. A recent in vitro study used fast-scan 
cyclic voltammetry to directly detect the oxidation of spontaneously secreted 
GnRH at the level of ME in prepubertal male mice (Glanowska et al. 2014). It 
showed that RFRP-3 reduced frequency and amplitude of GnRH pulses 
(Glanowska et al. 2014). Furthermore, 1-adamantanecarbonyl-Arg-Phe-NH2 
trifluoroacetate (RF-9), a RFRP-3 antagonist (Simonin et al. 2006, Pineda et al. 
2010c), induced a significant increase in the frequency of GnRH pulses, but not 
the amplitude (Glanowska et al. 2014). It was therefore suggested that RFRP-3 
may function as a brake on the GnRH pulse generator in prepubertal animals and 
this modulation may be regulated specifically through GnRH pulse frequency 
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and/or amplitude. However, no in vivo study has yet established the role of 
hypothalamic RFRP-3 signalling in the regulation of GnRH pulse generator 
activity in adult mammals. 
It is well known that various stressful stimuli profoundly inhibit the HPG axis 
through suppression of pulsatile GnRH release and therefore pulsatile LH 
release (Ferin 1993), although the underlying mechanisms are not fully 
elucidated. CRF, an important stress modulator, has been implicated in this 
process since CRF antagonist blocks the stress-induced suppression of pulsatile 
LH release (Rivier et al. 1986, Cates et al. 2004, Li et al. 2006). Although 
central administration of CRF decreases the release of GnRH into hypophysial 
portal veins (Petraglia et al. 1987), CRF neurones do not appear to innervate 
GnRH neurones directly, since CRF-R1 (encoding type 1 CRF receptor) mRNA 
do not co-express with GnRH mRNA in rats (Hahn et al. 2003). CRF neurones 
located in major CRF expressing nuclei fail to pick up the retrograde tracer 
injected into the vicinity of the GnRH neurones (Hahn et al. 2003). Alternatively, 
CRF may innervate KNDy neurones in the ARC to modulate the GnRH pulse 
generator. Both CRF-R1 and R2 are expressed in the ARC (Chalmers et al. 1995, 
Van Pett et al. 2000) and central administration of CRF decreases Kiss1 and 
Kiss1r mRNA expression in the ARC (Kinsey-Jones et al. 2009). However, it is 
unknown whether CRF mediate the Kiss1 signalling in the ARC directly, since 
the expression of CRF receptors has not been found in KNDy neurones. It is 
therefore possible that CRF-mediated suppression of the GnRH signalling and/or 
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GnRH pulse generator may involve indirect regulatory mechanisms. The 
inhibitory effects of RFRP-3 on the HPG axis raise the question of whether 
stress-induced suppression of LH release operates through this system. Indeed, 
the identification of CRF neurones and fibres in the DMH (Cummings et al. 
1983) and co-expression of CRF-R1 on RFRP neurones (Kirby et al. 2009) 
using immunohistochemical labelling provides an anatomical structure for the 
interaction between CRF and RFRP signalling systems. Furthermore, CRF 
signalling has been implicated in regulating different types of stressors-induced 
LH suppression in rats since CRF-R1 antagonism blocks restraint-induced LH 
suppression and CRF-R2 antagonism blocks both restraint and LPS-induced LH 
suppression (Li et al. 2006). It is therefore reasonable to speculate that RFRP 
signalling may also play a role in psychological and immunological 
stressors-induced LH suppression. Accordingly, it has been shown that both 
immobilisation and LPS stress increases RFRP mRNA expression in the DMH, 
which is associated with inhibition of LH secretion in rats (Kirby et al. 2009, 
Iwasa et al. 2014). 
RFRP-3 may act as a possible downstream of CRF signalling and a possible 
mediator of the basal and/or stress-induced suppression of the GnRH pulse 
generator. It is reminiscent of another important hypothalamic neuropeptide 
signalling: the endogenous opioid peptides. Endogenous opioid peptides have 
been implicated in the suppression of pulsatile LH release with opioid receptor 
antagonists increasing and opioid receptor agonist suppressing the frequency of 
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the GnRH pulse generator in rats (Kimura et al. 1991, Grachev et al. 2012a, 
Nakahara et al. 2013). Furthermore, opioid receptor antagonists blocked the 
stress-induced suppression of pulsatile LH release in both monkeys and rats 
(O'Byrne et al. 1989, Cagampang and Maeda 1991). Accordingly, CRF-induced 
suppression of LH release can also be mediated via endogenous opioid peptides 
and this mediation may involve the µ-opioid receptor (Gindoff and Ferin 1987, 
Almeida et al. 1988, Rivest et al. 1993). However, it remains unknown whether 
the endogenous opioid peptides mediate the inhibitory effects of RFRP-3 on the 
pulsatile LH release. 
RFRP-3 exerts an inhibitory effect on the HPG axis, which prompted us to 
investigate whether this effect is mediated through specific locations in the brain. 
Morphological evidences have shown that RFRP-3 neurones project into the 
ARC to innervate 35% of Kiss1 neurones and approximate 25% of KNDy 
neurones in the ARC co-express GPR147 mRNA (Poling et al. 2013). 
Furthermore, RFRP-3 has an inhibitory effect on Kiss1 neurones in the ARC, 
since the number of Kiss1 mRNA expressing neurones in the ARC increased by 
60% in GPR147 knockout mice (Leon et al. 2014). Due to the fact that KNDy 
neurones in the ARC have been implicated as the putative GnRH pulse generator, 
it is possible that RFRP-3 inhibit the KNDy neurones in the ARC to suppress the 
pulsatile LH release. 
Alternatively, another major site of action of RFRP-3 at the HPG axis can be the 
mPOA, where most GnRH neurones are located. A number of studies have 
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shown that RFRP-3 fibres form close apposition with 25 to 75% of GnRH 
neurones (Kriegsfeld et al. 2006, Johnson et al. 2007, Rizwan et al. 2012, Ubuka 
et al. 2012). Furthermore, 33% of GnRH neurones in the mPOA co-express 
GPR147 mRNA (Rizwan et al. 2012). RFRP-3-induced LH suppression via 
GPR147 receptor is dependent on the GnRH signaling, since the stimulatory 
effect of RF-9 is blocked by pre-treatment of a GnRH receptor antagonist 
(Rizwan et al. 2012). Furthermore, in vitro electrophysiological studies have 
shown that RFRP-3 directly suppresses the excitability of GnRH neurones and 
blocks the stimulatory action of Kiss1 on GnRH neurones (Ducret et al. 2009, 
Wu et al. 2009). It is therefore evident that mPOA could play an essential role in 
RFRP-3-induced inhibition of LH release through a direct interaction, even 
though this process may not directly involve the GnRH pulse generator located 
in the ARC. 
RFRP have also been implicated in negative feedback control of the 
reproductive axis in females (Kriegsfeld et al. 2006, Leon et al. 2014). Previous 
studies have shown that 25 to 40% of RFRP neurones co-express ER-α receptors 
and peripheral treatment of E2 induce a robust c-Fos expression in RFRP 
neurones (Kriegsfeld et al. 2006, Poling et al. 2012). This suggests a direct 
action of E2 on activities of RFRP neurones. ERα receptors are involved in E2 
negative feedback control of LH secretion and GnRH mRNA expression in mice 
(Dorling et al. 2003). Therefore, E2-induced LH suppression may be mediated 
via RFRP-3 signalling. Indeed, recent studies have shown that the removal of 
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ovaries induced a higher LH level in GPR147 knockout mice compared with 
wild type mice (Leon et al. 2014). It suggests GPR147 plays an inhibitory role in 
LH release when E2 levels are normal. Even though there is a considerable 
amount of evidence for the involvement of RFRP-3 in the E2 negative feedback 
control, few studies have explored the underlying mechanisms. Given its direct 
innervations of both GnRH and KNDy neurones, RFRP-3 may regulate 
E2-induced negative feedback control of GnRH release in the same mode, with 
direct action on GnRH neurones and/or indirect regulation through KNDy 
neurones, which have also been implicated in the E2-induced negative feedback 
control of the HPG axis (d'Anglemont de Tassigny and Colledge 2010, Hameed 
et al. 2011). 
 
6.2 Aims and objectives 
To test the hypothesis that RFRP-3 signalling regulates both basal and 
stress-induced suppression of pulsatile LH release and mediates the E2-induced 
negative feedback control of LH release in female rats. 
1. To determine the role of RFRP-3 signalling in the control of the GnRH pulse 
generator in OVX rats. 
a) To identify the effect of central administered RFRP-3, as well as its 
antagonist RF-9, on the pulsatile release of LH. 
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b) To investigate whether pre-treatment of RF-9 blocks the effect of RFRP-3 
on LH pulses. 
c) To assess whether the effect of central administered RFRP-3 on pulsatile 
LH secretion is modulated through endogenous opioid peptide signalling, and to 
determine the opioid receptor subtypes involved. 
 
2. To elucidate the role of RFRP-3 signalling in stress-induced suppression of 
the GnRH pulse generator in OVX rats. 
a) To determine whether central administration of RF-9 blocks CRF-induced 
suppression of pulsatile LH release. 
b) To determine whether central administration of RF-9 blocks restraint and 
LPS stress-induced suppression of LH pulses. 
 
3. To evaluate the mechanisms and sites of action of RFRP-3 in the negative 
feedback control of E2 on LH secretion. 
a) To test whether the effect of RFRP-3 on pulsatile LH release is mediated 
through the ARC and to determine whether the RFRP-3 signalling in the 
ARC is involved in the E2-induced suppression of LH release by 
administering RRFP-3 and RF-9 into the ARC of both OVX rats with (2 E2 
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capsules; equal to oestrus levels of E2; see Chapter 4) or without E2 
replacement. 
b) To investigate whether the inhibitory effect of RFRP-3 on LH release is 
mediated through the mPOA and to determine whether the RFRP-3 
signalling in the mPOA is involved in the E2-induced suppression of LH by 
administering RRFP-3, as well as RF-9, into the mPOA of both E2 replaced 
and non-E2 replaced OVX rats. 
 
6.3 Materials and methods 
6.3.1 Animals and surgical procedures 
Adult Sprague-Dawley rats were implanted with unilateral icv guide cannulae 
directed towards left lateral cerebral ventricles (see section 2.2.2.4). Rats were 
also OVX without implanting any capsules. After a 10-d recovery period (Fig. 
6.1), rats were all fitted with two indwelling cardiac catheters via the jugular 
vein, as described in section 2.2.2.6. Experimentation commenced 3 d later (Fig. 
6.1). 
A separate group of adult Sprague-Dawley rats were OVX and implanted with 
bilateral guide cannulae directed towards ARC or mPOA (see section 2.2.2.5). In 
addition, animals receiving E2 replacement were implanted subcutaneously with 
two Silastic
TM
 E2 capsules (equal to oestrus levels of E2; see Chapter 4), 
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identified in the present study as ‘OVX+2×E2’ rats. Animals without E2 
replacement were implanted with two Silastic
TM
 capsules filled with arachis oil 
and identified as ‘OVX+0×E2’ rats. Rats were further fitted with two indwelling 
cardiac catheters via the jugular vein after a 10-d recovery period (Fig. 6.1). 
Experimentation commenced 3 d later (Fig. 6.1). 
 
Fig. 6.1 Timeline diagram of various surgical and experimental procedures for 
investigating the role of RFRP-3 signalling in regulating the pulsatile LH release 
and the E2-induced negative feedback control of LH release in female rats. 
 
6.3.2 Experiment 1: Effects of RFRP-3 on pulsatile LH release in OVX 
rats 
An icv injection cannula (Plastics One) with extension tubing preloaded with 
RFRP-3 (Bachem, Germany) was inserted into the guide cannula, with 1 µl of 
air separating the fluid in the tubing from the lateral ventricle system before the 
actual injection. The tip of injection cannula extended 1 mm beyond the guide 
cannula to reach the ventricle. The distal end of the tubing was extended outside 
of the cage connected to a 25 µl Hamilton syringe (Waters International), 









7 d 10 d 3 d 7-14 d
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experiment (see section 2.2.3.3.1). Rats were also attached via one of the two 
cardiac catheters to a computer-controlled automated blood sampling system, 
which allows for the intermittent withdrawal of small blood samples (see section 
2.2.3.1). Once connected, animals were left undisturbed for 1 h before sampling 
commenced between 1000 and 1100 h, and samples were collected every 5 min 
for 6 h.  
To examine the effects of RFRP-3 on pulsatile LH release, RFRP-3 or vehicle 
(aCSF) was infused (icv) over 5 min after 2 h of controlled blood sampling into 
OVX rats. Rats received a single dose of 0.1, 1, or 5 nmol RFRP-3 in 4 µl aCSF 
in each treatment group (n = 5-8 per group) or 4 µl aCSF in the control group (n 
= 6). The doses of RFRP-3 were selected from a previous study (Pineda et al. 
2010b). 
 
6.3.3 Experiment 2: Effects of RF-9 on LH release in OVX rats 
On the morning of experimentation, OVX rats were attached to the automated 
blood sampling system and equipped with the icv injection system, as described 
above. After 2 h of controlled blood sampling, rats were administered (icv) a 
single dose of 0.1, 1, or 10 nmol RF-9 (Sigma-Aldrich) in 4 µl aCSF in each 
treatment group (n = 5-7 per group) or 4 µl aCSF in the control group (n = 5). 




6.3.4 Experiment 3: Effects of RFRP-3 on pulsatile LH release in the 
presence of RF-9 in OVX rats 
On the morning of experimentation, OVX rats were attached to the automated 
blood sampling system and equipped with the icv injection system, as described 
above. After 1 h 45 min of controlled blood sampling, rats received three 
consecutive injections (icv) of RF-9 (10 nmol in 4 µl aCSF, n = 8) or vehicle (4 
µl aCSF, n = 8), each administered over 5 min, 30 min apart, with a further 
injection (icv) of RFRP-3 (5 nmol in 4 µl aCSF) administered 15 min following 
the first injection of RF-9 or aCSF. Additional rats, used as controls, received 
three consecutive injections (icv, 30 min apart) of RF-9 (10 nmol, n = 6) or aCSF 
(4 µl, n = 6) after 1 h 45 min of controlled blood sampling. 
 
6.3.5 Experiment 4: Effects of RF-9 on CRF or stress-induced 
inhibition of pulsatile LH release in OVX rats 
On the morning of experimentation, OVX rats were attached to the automated 
blood sampling system and equipped with the icv injection system, as described 
above. After 1 h 45 min of control blood sampling, rats received three 
consecutive injections (icv) of RF-9 (10 nmol in 4 µl aCSF, n = 8) or vehicle (4 
µl aCSF, n = 6), each administered over 5 min, 30 min apart, with a further 
injection (icv) of CRF (2 nmol in 4 µl aCSF, Sigma-Aldrich), administered 15 
min following the first injection of RF-9 or aCSF. Additional rats, used as 
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controls, received four consecutive injections (icv) of 4 µl aCSF (at 1 h 45 min, 
2 h, 2 h 15 min and 2 h 45 min of blood sampling, n = 5). 
Separate groups of OVX rats prepared as above were used for stress studies. For 
restraint stress studies, rats received three consecutive injections (icv) of RF-9 
(10 nmol in 4 µl aCSF, n = 8) or vehicle (4 µl aCSF, n = 7) after 1 h 45 min of 
controlled blood sampling, each administered over 5 min, 30 min apart. Fifteen 
min after the first injection of RF-9 or aCSF, rats were placed in a restraint 
device for 1 h and blood sampling continued uninterrupted during the 1-h 
restraint and the 3-h post-restraint period (see section 2.2.3.2). Control animals 
(n = 5) received three consecutive injections (icv) of aCSF (4 µl) without being 
restrained. For LPS stress studies, rats received three consecutive injections (icv) 
of RF-9 (10 nmol in 4 µl aCSF, n = 9) or vehicle (4 µl aCSF, n = 8) after 1 h 45 
min of controlled blood sampling. Fifteen min after the first injection of RF-9 or 
aCSF, rats were infused (iv) of LPS (15 µg/kg in 0.2 ml saline, Sigma-Aldrich) 
over 5 min via one of the two cardiac catheters. Additional control rats (n = 5) 
were infused (iv) of saline (0.2 ml) with three injections (icv) of aCSF (4 µl). 
 
6.3.6 Experiment 5: Effects of opioid receptor antagonists on 
RFRP-3-induced inhibition of pulsatile LH release in OVX rats 
On the morning of experimentation, OVX rats were attached to the automated 
blood sampling system and equipped with the icv injection system, as described 
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above. After 1 h 45 min of controlled blood sampling, rats were administered 
(icv) over 5 min with naloxone (30 nmol in 4 µl aCSF, a specific µ-receptor 
antagonist at this dose, n = 11), nor-BNI (6.8 nmol in 4 µl aCSF, a specific 
κ-receptor antagonist, n = 11) or naltrindole (12 nmol in 4 µl aCSF, a 
specific   -receptor antagonist, n = 8). Fifteen min later, rats were further 
administered (icv) with RFRP-3 (5 nmol in 4 µl aCSF). The doses for the 
endogenous opioid receptor antagonists were from one of our previous studies 
(Bowe et al. 2005). Additional control rats were administered (icv) with vehicle 
(4 µl aCSF, n = 6), naloxone (30 nmol, n = 7), nor-BNI (6.8 nmol, n = 6), or 
naltrindole (12 nmol, n = 6) after 1 h 45 min control blood sampling, followed 
by vehicle (4 µl aCSF) 15 min later. 
 
6.3.7 Experiment 6: Effects of intra-ARC administration of RFRP-3 
or RF-9 on LH release in OVX rats with or without E2 
replacement 
On the morning of experimentation, a bilateral internal injection cannula 
(Plastics One) with extension tubing preloaded with vehicle, RFRP-3 or RF-9 
was inserted into the guide cannula and extended 1 mm beyond the guide 
cannula to reach the ARC. The distal end of the tubing was extended outside of 
the cage connected to a 5 µl Hamilton syringe (Waters International), thereby 
allowing remote infusion without disturbing the rat during the experiment (see 
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section 2.2.3.3.2). Rats were also attached to the automated blood sampling 
system, as described above. 
Rats were administered bilaterally (intra-ARC) with vehicle (400 nl aCSF, n = 4), 
RFRP-3 (500 pmol in 400 nl aCSF, n = 6) or RF-9 (1 nmol in 400 nl aCSF, n = 8) 
over 5 min after 2 h of controlled blood sampling in OVX+0×E2 rats. The doses 
used here is 1/10 of the maximal single doses used in the icv studies. In addition, 
a separate group of OVX+2×E2 rats were injected bilaterally (intra-ARC) with 
400 nl aCSF (n = 4), 500 pmol RFRP-3 (n = 6) or 1 nmol RF-9 (n = 6). 
6.3.8 Experiment 7: Effects of intra-mPOA administration of RFRP-3 
or RF-9 on LH release in OVX rats with or without E2 
replacement 
The rats were similarly equipped with the intra-mPOA injection system and 
attached to the automated blood sampling system, as described above. After 2 h 
of controlled blood sampling, vehicle (400 nl aCSF, n = 4), RFRP-3 (500 pmol 
in 400 nl aCSF, n = 6) or RF-9 (1 nmol in 400 nl aCSF, n = 7) were administered 
bilaterally over 5 min (intra-mPOA) into OVX+0×E2 rats. Additionally, vehicle 
(400 nl aCSF, n = 4), RFRP-3 (500 pmol in 400 nl aCSF, n = 6) or RF-9 (1 nmol 
in 400 nl aCSF, n = 6) were administered bilaterally (intra-mPOA) into a 





6.3.9 Statistical analysis 
Detection of LH pulses in OVX rats in experiments 1-5 and OVX+0×E2 rats in 
experiments 6-7 was established by use of the algorithm ULTRA (Van Cauter 
1988). The effects of pharmacological agents on pulsatile LH secretion were 
analysed by comparing the mean LH pulse interval in the 2-h period preceding 
treatment with that in two consecutive 2-h post-treatment periods. The duration 




 2-h post-treatment periods, 
was divided by the number of LH pulses detected in each of these periods to 
give the appropriate LH pulse interval. The effect of pharmacological agents on 
LH pulse amplitude was also calculated in the same time periods used for LH 
pulse frequency. The LH amplitude was calculated from the differences between 
the nadir and apex of each LH pulses. The significance of the effects of 
treatments on LH pulse intervals and amplitude were compared with control 
animals injected with vehicle, at the same time period, as well as with mean 
pulse interval during the 2-h pre-treatment period. The effect of stress (restraint 
or LPS)-induced inhibition of pulsatile LH secretion was calculated by 
comparing the 1
st
 prolonged pulse interval after stress with the mean pulse 
interval during the 2-h pre-stress period, as well as with control animals injected 
with vehicle at the same time points. The post-stress recovery period was 
defined as the remaining observation period after the 1
st
 prolonged LH pulse 
interval. The effects of pharmacological agents on overall LH release were 
calculated by comparing the AUC in two consecutive 2-h post-treatment periods 
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with that in the 2-h pre-treatment period, using SigmaPlot version 11 (Systat 
Software). Statistical significance was tested using one-way ANOVA followed 
by Dunnett’s test. All data were shown as mean ± S.E.M. P < 0.05 was 
considered statistically significant. 
 
6.4 Results 
6.4.1 Experiment 1: Effects of RFRP-3 on pulsatile LH release in OVX 
rats 
To investigate the effects of RFRP-3 on pulsatile LH release, we examined the 
effects of centrally administered RFRP-3 on LH secretion in OVX rats. Central 
administration (icv) of RFRP-3 induced a dose-dependent inhibition of pulsatile 
LH release in OVX rats (Fig. 6.2). Injections of 0.1 nmol RFRP-3 had no 
significant effects on the duration of the LH pulse interval (Figs. 6.2, B and E). 
However, 1 nmol RFRP-3 increased the duration of the LH pulse interval by 27% 
(2-h pre-injection vs. 1
st
 2-h post-injection: 23.8 ± 1.6 vs. 30.2 ± 1.6 min; P < 
0.05; Figs. 6.2, C and E). At the dose of 5 nmol, RFRP-3 increased the duration 
of pulse interval by 70% (2-h pre-injection vs. 1
st
 2-h post-injection: 24.0 ± 1.1 
vs. 40.8 ± 1.6 min; P < 0.05; Figs. 6.2, D and E). Compared with 1 nmol RFRP-3, 
5 nmol RFRP-3 had a significantly (P < 0.05) greater inhibitory effect on the 
pulsatile LH release. Furthermore, 5 nmol RFRP-3 had no effects on the LH 
pulses amplitude (2-h pre-injection vs. 1
st





post-injection: 2.3 ± 0.3 vs. 2.7 ± 0.3 vs. 2.5 ± 0.2 ng/ml; P > 0.05). In the 




6.4.2 Experiment 2: Effects of RF-9 on LH release in OVX rats 
To investigate the effects of RF-9, a RFRP-3 antagonist, on pulsatile LH release, 
we examined the effects of centrally administered RF-9 on LH secretion in OVX 
rats. Central administration (icv) of RF-9 did not affect the pulsatile LH release, 
but resulted in a dose-dependent increase of overall LH secretion, calculated by 
AUC (Fig. 6.3). Injections of 0.1 nmol RF-9 had no significant effects on LH 
secretion (Figs. 6.3, B and F). However, 1 nmol RF-9 significantly increased LH 
secretion by 19% (AUC, 2-h pre-injection vs. 1
st
 2-h post-injection: 556.8 ± 15.7 
vs. 661.8 ± 18.3 ng/ml.min; P < 0.05; Figs. 6.3, C and F). At the dose of 10 nmol, 
RF-9 increased the LH secretion by 42% (AUC, pre-injection vs. 1
st
 2-h 
post-injection: 560.2 ± 19.0 vs. 793.4 ± 45.6 ng/ml.min; P < 0.05) and this 
increase was more potent (P < 0.05) than that of 1 nmol RF-9 (Figs. 6.3, D and 
F). In the control group, vehicle (aCSF) had no effects on LH secretion (Figs. 6.3, 
A and F). Neither of the above doses of RF-9 significantly affected LH pulse 
interval, even with the highest dose (10 nmol) of RF-9 (2-h pre-injection vs. 1
st
 
2-h post-injection: 23.0 ± 1.2 vs. 26.8 ± 1.9; P > 0.05; Fig. 6.3, E). Furthermore, 
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10 nmol RF-9 had no effects on the amplitude of LH pulses (2-h pre-injection vs. 
1
st
 2-h post-injection vs. 2
nd
 2-h post-injection: 2.5 ± 0.2 vs. 2.1 ± 0.3 vs. 2.2 ± 
0.3 ng/ml; P > 0.05). 
 
6.4.3 Experiment 3: Effects of RFRP-3 on pulsatile LH release in the 
presence of RF-9 in OVX rats 
To investigate whether RFRP-3 induced suppression of pulsatile LH release is 
through the receptor GRP147, RFRP-3 (5 nmol) was administered (icv) into rats 
in the presence of RF-9 (30 nmol, icv). The RFRP-3-induced inhibition of 
pulsatile LH secretion was blocked by co-administration of RF-9 (LH pulse 
interval in 1
st
 2-h post injection, vehicle + RFRP-3 vs. RF-9 + RFRP-3: 40.4 ± 
1.8 vs. 27.0 ± 1.4 min; P < 0.05; Figs. 6. 4, B, D and E). Similar to its single 
injection, three sequential injections of 10 nmol RF-9 per se did not affect the 





2-h post-injection: 22.9 ± 1.1 vs. 26.2 ± 1.6 vs. 24.2 ± 0.8 
min; P > 0.05; Figs. 6. 4, C and E). Furthermore, three sequential injections of 
vehicle (aCSF) had no effects on the pulsatile LH release in control rats (Figs. 6. 
4, A and E). Like the single injection, three sequential injections of RF-9 (10 
nmol) increased the overall circulating levels of LH, calculated by AUC 
(pre-injection vs. 1
st
 2-h post-injection: 571.3 ± 16.1 vs. 769.7 ± 37.6 ng/ml.min; 





 2-h post-injection: 590.1 ± 13.3 vs. 498.9 ± 21.2 ng/ml.min; 
P < 0.05), and this suppression was blocked by co-administration of RF-9 (AUC 
in the 1
st
 2-h post-injection, vehicle + RFRP-3 vs. RF-9 + RFRP-3: 498.9 ± 21.2 
vs. 564.2 ± 19.1 ng/ml.min; P < 0.05).    
 
6.4.4 Experiment 4: Effects of RF-9 on CRF or stress-induced 
inhibition of pulsatile LH release in OVX rats 
To investigate the role of RFRP-3 in the stress-induced inhibition of pulsatile LH 
release, we administered CRF (2 nmol, icv), a central component of stress 
response, to OVX rats in the presence of RF-9 (30 nmol, icv). Furthermore, we 
exposed rats to two different stressors (restraint and LPS) in the presence of 
RF-9 (30 nmol, icv) (Fig. 6.5). 
Central administration of CRF inhibited the pulsatile LH release in OVX rats 
(LH pulse interval, 2-h pre-injection vs. 1
st
 2-h post-injection: 24.3 ± 0.5 vs. 44.4 
± 2.4 min; P < 0.05; Figs. 6.5, B and D). This inhibitory effect was significantly 
attenuated by co-administration of RF-9 (LH pulse interval in 1
st
 2-h 
post-injection, vehicle + CRF vs. RF-9 + CRF: 44.4 ± 2.4 vs. 31.8 ± 4.9 min; P < 
0.05), but this blockage was partial (Figs. 6.5, B, C and D). Control rats had no 
effects on the pulsatile LH release (Figs. 6.5, A and D) 
Restraint stress induced an immediate suppression of pulsatile LH release in 
OVX rats (LH pulse interval, 2-h pre-injection vs. 1
st
 prolonged interval 
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post-injection: 22.9 ± 0.5 vs. 49.7 ± 3.5 min; P < 0.05; Figs. 6.5, F and H). This 
inhibitory effect was significantly attenuated by co-administration of RF-9 (1
st
 
prolonged interval post-injection, vehicle + restraint vs. RF-9 + restraint: 49.7 ± 
3.5 vs. 34.1 ± 3.9 min; P < 0.05), even though this blockage was partial (Figs. 
6.5, F, G and H). Similarly, control rats had no effects on the pulsatile LH release 
(Figs. 6.5, E and H). 
Administration of LPS evoked a profound inhibitory effect on the pulsatile LH 
release with the 1
st
 prolonged LH pulse interval lasting over 2 h in OVX rats (1
st
 
prolonged interval post-injection, vehicle + vehicle vs. vehicle + LPS: 23.2 ± 1.0 
vs. 138.8 ± 17.2 min; P < 0.05; Figs. 6.5, J and L). An inhibitory effect was also 
found in the recovery period (LH pulse interval in the recovery period, vehicle + 
vehicle vs. vehicle + LPS:  23.1 ± 1.2 vs. 40.7 ± 3.2 min; P < 0.05; Figs. 6.5, J 
and L). Co-administration of RF-9 decreased LPS-induced 1
st
 prolonged LH 
pulse interval (1
st
 prolonged interval post-injection, vehicle + LPS vs. RF-9 + 
LPS: 138.8 ± 17.2 vs. 78.3 ± 13.0 min; P < 0.05), even though this blockage was 
partial (Figs. 6.5, J, K and L). Furthermore, RF-9 totally blocked the inhibitory 
effects of LPS on the pulsatile LH release in the recovery period (Figs. 6.5, K 





6.4.5 Experiment 5: Effects of opioid receptor antagonists on 
RFRP-3-induced inhibition of pulsatile LH release in OVX rats 
To investigate whether the opioid peptides signalling systems are involved in 
RFRP-3-induced inhibition of pulsatile LH secretion, we administered RFRP-3 
(5 nmol, icv) to OVX rats pre-treated (icv) with naloxone (30 nmol), nor-BNI 
(6.8 nmol) or naltrindole (12 nmol). The RFRP-3-induced inhibition of pulsatile 
LH release was attenuated by co-administration of naloxone (1
st
 2-h 
post-injection, vehicle + RFRP-3 vs. naloxone + RFRP-3: 41.1 ± 2.4 vs. 31.6 ± 
2.1 min; P < 0.05; Figs. 6.6, E, F and I). However, RFRP-3-induced inhibition of 
pulsatile LH secretion was not affected by pre-treatment of nor-BNI or 
naltrindole (1
st
 2-h post-injection, vehicle + RFRP-3 vs. nor-BNI + RFRP-3 vs. 
naltrindole + RFRP-3: 41.1 ± 2.4 vs. 38.3 ± 2.6 vs. 39.6 ± 2.5 min; P > 0.05; Figs. 
6.6, E, G, H and I). Furthermore, administration of opioid receptor antagonists 
alone with vehicle had no effects on the pulsatile LH secretion (Figs. 6.6, A-D). 
 
6.4.6 Experiment 6: Effects of intra-ARC administration of RFRP-3 
or RF-9 on LH release in OVX rats with or without E2 
replacement 
To investigate the role of RFRP-3 signalling in the ARC on LH release in the 
presence of different E2 levels, we examined the effects of intra-ARC 
administration of RFRP-3 or RF-9 on LH secretion in both OVX+0×E2 and 
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OVX+2×E2 rats (Fig. 6.7).  
Intra-ARC administration of RFRP-3 (500 pmol) or RF-9 (1 nmol) had no 
effects on pulsatile LH release in OVX+0×E2 rats (LH pulse interval in RFRP-3 
group, 2-h pre-injection vs. 1
st
 2-h post-injection vs. 2
nd
 2-h post-injection: 22.6 
± 1.2 vs. 24.4 ± 1.2 vs. 23.0 ± 1.1 min; P > 0.05; LH pulse interval in RF-9 group, 
2-h pre-injection vs. 1
st
 2-h post-injection vs. 2
nd
 2-h post-injection: 23.7 ± 0.8 vs. 
26.3 ± 1.4 vs. 22.9 ± 1.1 min; P > 0.05; Figs. 6.7, B, C, and G). Furthermore, 
RFRP-3 and RF-9 had no effects on the LH pulse amplitude. Accordingly, both 
RFRP-3 and RF-9 did not affect the overall LH release (measured by AUC) in 
OVX+0×E2 rats (Figs. 6.7, B, C and H). In the control group, intra-ARC 
administration of vehicle (aCSF) did not affect LH pulse frequency or overall 
LH secretion in OVX+0×E2 rats (Fig. 6.7, A, G and H). 
Intra-ARC administration of both vehicle (aCSF) and RFRP-3 (500 pmol) had 
no effects on overall LH release (measured by AUC) in OVX+2×E2 rats (Figs. 
6.7, D, E and H). However, LH secretion was significantly increased by 
intra-ARC administration of RF-9 (1 nmol) by nearly 1 fold in the 1
st
 2-h 
post-injection period (AUC, 2-h pre-injection vs. 1
st
 2-h post-injection: 301.0 ± 
24.3 vs. 585.9 ± 50.9 ng/ml.min; P < 0.05; Figs. 6.7, F and H). This increase 
recovered to normal in the 2
nd
 2-h post-injection period (AUC, 2-h pre-injection 
vs. 1
st
 2-h post-injection: 301.0 ± 24.3 vs. 389.0 ± 24.6 ng/ml.min; P > 0.05; Figs. 
6.7, F and H). In addition, no misplaced ARC cannulae were found in this set of 




6.4.7 Experiment 7: Effects of intra-mPOA administration of RFRP-3 
or RF-9 on LH release in OVX rats with or without E2 
replacement 
To investigate the role of RFRP-3 signalling in mPOA in LH release in different 
E2 levels, we examined the effects of intra-mPOA administration of RFRP-3 or 
RF-9 on LH secretion in both OVX+0×E2 and OVX+2×E2 rats. 
Intra-mPOA administration of RFRP-3 (500 pmol) had no effects on pulsatile 





 2-h post-injection: 23.0 ± 1.9 vs. 24.5 ± 1.0 vs. 24.7 ± 1.9 
min; P > 0.05; Figs. 6.9, B and G). Accordingly, RFRP-3 did not affect the 
overall LH release (calculated by AUC) in OVX+0×E2 rats (Figs. 6.9, B and H). 
Interestingly, intra-mPOA administration of RF-9 (1 nmol) did not affect the LH 
pulse frequency in OVX+0×E2 rats (LH pulse interval, 2-h pre-injection vs. 1
st
 
2-h post-injection vs. 2
nd
 2-h post-injection: 23.7 ± 1.0 vs. 26.3 ± 1.4 vs. 26.1 ± 
1.7 min; P > 0.05; Figs. 6.9, C and G). However, RF-9 increased the LH pulse 




 post-injection periods (LH pulse amplitude, 2-h 
pre-injection vs. 1
st
 2-h post-injection vs. 2
nd
 2-h post-injection: 2.0 ± 0.1 vs. 3.5 
± 0.5 vs. 4.1 ± 0.1 ng/ml; P < 0.05), and therefore increased the overall LH 
secretion in that 4-h period (AUC, 2-h pre-injection vs. 1
st
 2-h post-injection vs. 
2
nd
 2-h post-injection: 550.8 ± 20.7 vs. 740.3 ± 15.4 vs. 760.1 ± 47.4 ng/ml.min; 
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P < 0.05; Figs. 6.9, C and H). Additional, in the control group, vehicle (aCSF) 
did not affect LH pulse frequency or overall LH secretion in OVX+0×E2 rats 
(Figs. 6.9, A, G and H). 
In OVX+2×E2 rats, intra-mPOA administration of RFRP-3 (500 pmol) did not 
affect the overall LH release (calculated by AUC; Figs. 6.9, E and H). However, 
intra-mPOA administration of RF-9 (1 nmol) significantly increased the overall 




 2-h post-infusion periods (AUC, 2-h 
pre-injection vs. 1
st
 2-h post-injection vs. 2
nd
 2-h post-injection: 332.3 ± 18.3 vs. 
620.9 ± 42.6 vs. 614.9 ± 60.8 ng/ml.min; P < 0.05; Figs. 6.9, F and H). In 
addition, the mPOA cannulae were found to be misplaced in two OVX+2×E2 rats 
(Fig. 6.10). RF-9 (1 nmol) did not affect the LH secretion in those rats (AUC, 
2-h pre-injection vs. 1
st
 1-h post-injection vs. 2
nd
 1-h post-injection: 332.3 ± 18.3 
vs. 360.9 ± 32.6 vs. 344.9 ± 20.8 ng/ml.min, P > 0.05). Intra-mPOA 
administration of vehicle (aCSF) had no effects on overall LH release in 
OVX+2×E2 rats (Figs. 6.9, D and H). 
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Fig. 6.2 Effects of RFRP-3 on pulsatile LH release in OVX rats.  
Representative LH profiles illustrating the effect of icv administration (arrow) 
of RFRP-3  (B-D), or vehicle (aCSF) (A) in OVX rats. Central administration 
of RFRP-3 resulted in a dose-dependent inhibition of pulsatile LH secretion, 
as summarised in panel E. *, P < 0.05 vs. 2-h baseline period within the same 
group, as well as the same 2-h period within the vehicle treated group; #, P < 
0.05 vs. same 2-h period within the group treated with 1 nmol RFRP-3 (n = 5-
8 per group). 
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Fig. 6.3 Effects of RF-9 on LH release in OVX rats. Representative LH 
profiles illustrating effects of icv administration (arrow) of RF-9 (B-D), or 
vehicle (aCSF) (A) in OVX rats. Central administration of RF-9 had no 
significant effects on pulsatile LH secretion in OVX rats, as summarised in 
panel E, while resulted in a dose-dependent increase of LH secretion, 
calculated by AUC, as summarised in panel F. *, P < 0.05 vs. 2-h baseline 
period within the same group, as well as the same 2-h period within the 
vehicle treated group; #, P < 0.05 vs. same 2-h period within the group treated 
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Fig. 6.4 Effects of RFRP-3 on pulsatile LH release in the presence of RF-9 in 
OVX rats. Representative LH profiles illustrating the effect of icv 
administration of 5 nmol RFRP-3 (arrow) in the presence of icv 
administration of 3×10 nmol RF-9 (D) (↓↓↓) or vehicle (aCSF) (B) (↓↓↓), as 
well as that of 3×10 nmol RF-9 (C) (↓↓↓) or vehicle (aCSF) (A) (↓↓↓) 
alone, in OVX rats.  The RFRP-3-induced inhibition of pulsatile LH secretion 
was blocked by pre-treatment of RF-9, as summarised in panel E. *, P < 0.05 
vs. 2-h baseline period within the same group, as well as the same 2-h period 
within the vehicle treated group; #, P < 0.05 vs. same 2-h period within the 
group treated with vehicle + RFRP-3 (n = 6-8 per group). 
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Fig. 6.5 Effects of RF-9 on CRF or stress-induced inhibition of pulsatile LH 
release in OVX rats. Representative LH profiles illustrating the effect of icv 
administration of 2 nmol CRF (arrow), applying of restraint (1 h) (horizontal 
bar) or iv administration of LPS (15 µg/kg) (arrow) in the presence of icv 
administration of 3×10 nmol RF-9 (↓↓↓) (C, G, K) or vehicle (↓↓↓) (B, F, J), 
as well as that of vehicle (A, E, I) alone, in OVX rats. RF-9 partially blocked 
the CRF, restraint, or LPS-induced inhibition of pulsatile LH secretion, as 
summarised in panel D, H, L. *, P < 0.05 vs. 2-h baseline period within the 
same group, as well as the same 2-h or 1st prolongation period within the 
vehicle treated group; #, P < 0.05 vs. same 2-h period, 1st prolongation period, 
or recovery period within the group treated with CRF or stress in the presence 
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Fig. 6.6 Effects of opioid receptor antagonists on RFRP-3-induced inhibition 
of pulsatile LH release in OVX rats. Representative LH profiles illustrating 
effects of icv administration (arrow) of 5 nmol RFRP-3 in the presence of icv 
administration (↓) of specific opioid receptor antagonists [µ-receptor 
antagonist: 30 nmol naloxone, (F); κ-receptor antagonist: 6.8 nmol nor-BNI, 
(G); δ-receptor antagonist: 12 nmol naltrindole, (H)] or vehicle (aCSF) (E), 
as well as that of endogenous opioid receptor antagonists (same dose as 
above) alone (B-D), in OVX rats. Naloxone partially blocked the RFRP-3-
induced inhibition of pulsatile LH secretion, as summarised in panel I. *, P < 
0.05 vs. 2-h baseline period within the same group, as well as the same 2-h 
period within the vehicle treated group; #, P < 0.05 vs. same 2-h period 
within the group treated with RFRP-3 in the presence of vehicle, nor-BNI or 
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Fig. 6.7 Effects of intra-ARC administration of RFRP-3 or RF-9 on LH 
release in OVX rats with or without E2 replacement. Representative LH 
profiles demonstrating (1) effects of intra-ARC administration (arrow) of 
vehicle (aCSF), RFRP-3 or RF-9 on pulsatile LH secretion in OVX rats 
without E2 capsule replacement (labelled as 0×E2) (A-C), and (2) effects of 
intra-ARC administration (arrow) of vehicle (aCSF), RFRP-3 or RF-9 on LH 
secretion in OVX rats replaced with two E2 capsules (labelled as 2×E2) (D-F). 
Intra-ARC administration of both RFRP-3 and RF-9  had no effects on the 
pulsatile LH release in OVX+0×E2 rats, as summarised in panel G. 
Furthermore, intra-ARC administration of RF-9 stimulated LH secretion in 
OVX+2×E2 rats, but not in OVX+0×E2 rats, as summarised in panel H. *P < 
0.05 vs. 2-h baseline within the same group, as well as the same 2-h period 
within group treated with corresponding vehicle (n = 4-8 per group). 
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Infusion site:  AP  - 3.3 mm 
                            ML  0.5 mm 
                            DV  -10.2 mm 
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Fig. 6.8 Schematic illustration and photomicrograph of the infusion site 
targeted to the ARC. A, schematic illustration showing the target site for 
bilateral cannulation of the ARC. Arrows point to the location of the tips of 
internal cannulae. B, photomicrograph of a coronal brain section in a 
representative animal implanted with a bilateral cannula in the ARC. 
Arrows indicate the tips of the internal cannulae. C-D, schematic drawings 
of the ARC illustrating the individual sites of injection for the experiments 
carried out in OVX+0×E2 and OVX+2×E2 rats, respectively. Numbers in 
each drawing indicate the distance (mm) to Bregma. Open circles show the 
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Fig. 6.9 Effects of intra-mPOA administration of RFRP-3 or RF-9 on LH 
release in OVX rats with or without E2 replacement. Representative LH 
profiles demonstrating (1) effects of intra-mPOA administration (arrow) of 
vehicle (aCSF), RFRP-3 or RF-9 on pulsatile LH secretion in OVX rats 
without E2 capsule replacement (labelled as 0×E2) (A-C), and (2) effects of 
intra-mPOA administration (arrow) of vehicle (aCSF), RFRP-3 or RF-9 on 
LH secretion in OVX rats replaced with two E2 capsules (labelled as 2×E2) 
(D-F). Intra-mPOA administration of both RFRP-3 and RF-9  had no effects 
on the pulsatile LH release in OVX+0×E2 rats, as summarised in panel G. 
However, intra-mPOA administration of RF-9 stimulated LH secretion in 
both OVX+0×E2 and OVX+2×E2 rats, as summarised in panel H. *P < 0.05 vs. 
2-h baseline within the same group, as well as the same 2-h period within the 
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Fig. 6.10 Schematic illustration and photomicrograph of the infusion site 
targeted to the mPOA. A, schematic illustration showing the target site for 
bilateral cannulation of the mPOA. Arrows point to the location of the tips 
of internal cannulae. B, photomicrograph of a coronal brain section in a 
representative animal implanted with a bilateral cannula in the mPOA. 
Arrows indicate the tips of the internal cannulae. C-D, schematic drawings 
of the mPOA illustrating the individual sites of injection for the experiments 
carried out in OVX+0×E2 and OVX+2×E2 rats, respectively. Numbers in 
each drawing indicate the distance (mm) to Bregma. Open circles show the 






In the present study we provide evidence to suggest that RFRP-3 signalling 
regulates the frequency of the GnRH pulse generator, since central 
administration of RFRP-3 via icv cannulae induced a dose-dependent inhibition 
of pulsatile LH release in OVX rats. This is in agreement with previous studies 
that showed that central administration (icv) of 5 nmol RFRP-3 induced a 
suppressive effect on mean LH secretion in OVX rats (Pineda et al. 2010b). It is 
also in keeping with several other studies showing inhibitory effects of central 
administered RFRP-3 on mean LH release in rodents (Johnson et al. 2007, Leon 
et al. 2014). However, the present study is the first to indicate that these effects 
may relate to the inhibition of GnRH pulse generator frequency. This inhibitory 
effect on pulsatile LH release was not shown in previous studies that monitored 
LH pulses (Murakami et al. 2008, Anderson et al. 2009). These studies used 
comparable doses of RFRP-3 to those of the current study, however, no effects 
on the LH pulse frequency, amplitude or mean LH concentration were reported 
(Murakami et al. 2008, Anderson et al. 2009), which is at odds with the 
inhibitory role of RFRP-3 in the HPG axis. This may be due to the differences in 
experimental animal strains or gonadal steroid milieu. Murakami et al. (2008) 
used OVX Wistar rats and Anderson et al. (2009) used OVX Sprague-Dawley 
rats with E2 replacement, whereas we used OVX Sprague-Dawley rats without 
E2 replacement. Furthermore, we collected blood samples more frequently and 
for a longer period, which may have helped to reveal the modest inhibitory effect 
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of RFRP-3 as shown in the present study. 
Central administration of RF-9 per se increased LH secretion (measured by AUC) 
in OVX rats in a dose-dependent fashion, which is in keeping with previous 
studies (Pineda et al. 2010c). Furthermore, the present study has shown that 
RF-9 did not affect the frequency of LH pulses, at least not with the doses used. 
This unchanged LH pulse frequency by central administered RF-9 in OVX rats 
may indicate a lack of endogenous RFRP-3 tone on the GnRH pulse generator in 
hypoestrogenic conditions. Furthermore, we have shown that RF-9 blocks the 
inhibitory effects of RFRP-3 on pulsatile LH release in OVX rats. Since RF-9 
was identified as one of GPR147 receptor antagonist (Hinuma et al. 2000, 
Pineda et al. 2010c), it indicates that exogenous RFRP-3 act on GPR147 
receptor to suppress pulsatile LH release. This is in keeping with recent studies 
showing that the inhibitory effects of RFRP-3 on LH release are abrogated in 
GPR147 knockout mice (Leon et al. 2014). However, the present study further 
implicates the GnRH pulse generator as the underlying mechanism for this 
blockade effect. Of note, RF-9 was reported as a potent and selective antagonist 
of receptors for both RFRPs and neuropeptide FF, a related peptide in the same 
family of RFRPs. Since central administration of RFRP-1 and neuropeptide FF 
had no effects on LH secretion in OVX rats (Pineda et al. 2010b), the 
stimulatory effects of RF-9 were likely mediated through the blockade of 
RFRP-3’s actions. However, a recent study from Allan Herbison’s group 
reported that RF-9 could directly excite the electrical activity of GnRH neurons, 
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and that this stimulation was not observed in Kiss1r knockout mice (Liu and 
Herbison 2014). It is therefore possible that RF-9 function as a GPR147 
antagonist, as well as a Kiss1r agonist on GnRH neurones. This is supported by 
another more recent study showing that the stimulatory effect of RF-9 on LH 
release was significantly blunted in Kiss1r knockout mice and selective rescue of 
Kiss1r expression in GnRH neurones restored the stimulatory effect of RF-9 on 
LH release (Min et al. 2015). Similarly, it has been shown that RF-9-induced LH 
secretion is blocked by a Kiss1r antagonist in female rats (Sahin et al. 2015). 
Therefore, substantial evidence has accumulated very recently to indicate that 
RF-9 can function as a Kiss1r agonist which will definitely complicate the 
interpretation for the findings of the present study. However, previous studies 
have shown that iv administered Kiss1 did not affect the frequency of the GnRH 
pulse generator monitored electrophysiologically by measurement of MUA 
volleys in the ARC of OVX rats, although it induced a concomitant heightened 
LH secretion (Kinsey-Jones et al. 2008). Therefore, activation of Kiss1r by RF-9, 
if possible, does not necessarily induce an increased LH pulse frequency. 
The present study has also shown that central (icv) administration of RFRP-3 or 
RF-9 had no effect on the amplitude of LH pulses. LH pulse amplitude could be 
subject to regulations at various levels in the HPG axis. First, the amplitude of 
LH pulses can be affected by the frequency of the GnRH pulses due to the 
amount of releasable LH in the pituitary glands (Clarke and Cummins 1985). 
Therefore, high frequency GnRH pulses lead to low LH pulse amplitude, 
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whereas low frequency lead to high pulse amplitude (Clarke and Cummins 1985, 
Wu et al. 1987). Second, RFRP-3 may modulate the amplitude of GnRH pulses 
by acting directly on GnRH neurones. Indeed, an in vitro study showed that 
RFRP-3 could suppress the amplitude of GnRH pulses (Glanowska et al. 2014). 
Therefore, this inhibitory effect may abrogate the stimulatory effects on LH 
pulse amplitude induced by the decreased LH pulse frequency, which may 
provide an explanation for the unaltered LH pulse amplitude following central 
administration of RFRP-3 in the present study. The same rationale could apply to 
RF-9. Finally, these inhibitory/stimulatory effects of RFRP-3/RF-9 could be due 
to interactions at the level of pituitary. Previous studies have implicated RFRP-3 
signalling in the regulation of gonadotrophs in anterior pituitary since peripheral 
injection (iv) of RFRP-3 inhibited, whereas RF-9 stimulated, LH secretion in 
rodents (Murakami et al. 2008, Pineda et al. 2010c, Poling et al. 2014). 
Furthermore, exposure to RFRP-3 suppressed LH secretion from pituitary 
explants of rodents (Pineda et al. 2010b, Leon et al. 2014). This suppression was 
due to the GPR147 receptor expressed in the pituitary, since it was blocked by 
co-administration of RF-9 and was absent in pituitary explants from GPR147 
knockout mice (Pineda et al. 2010b, Leon et al. 2014). However, it should be 
noted that RFRP-3 is unlikely to function as a hypophysiotrophic neuropeptide 
due to the absence of RFRP fibres in the external layer of ME (Kriegsfeld et al. 
2006, Johnson et al. 2007, Rizwan et al. 2009). Nor does RFRP-3 function as a 
para/autocrine regulating neuropeptide, since only GPR147 but not RFRP 
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mRNA was displayed in the pituitary (Hinuma et al. 2000). Therefore, the 
mechanisms underlying the regulation of RFRP-3 at the anterior pituitary in 
rodents remain to be elucidated. 
We have also shown that RF-9 partially blocked both restraint (psychological 
stressor) and LPS (immunological stressor)-induced inhibition of pulsatile LH 
release. If these blocade effects are via the antagonism of GPR147, RFRP-3 
might be involved in the suppression of the HPG axis by different stressors. This 
is in agreement with previous studies which showed that hypothalamic Rfrp 
mRNA expression was up-regulated in response to acute psychological and 
immunological stress in rats (Kirby et al. 2009, Iwasa et al. 2014). Other recent 
studies have also implicated RFRP-3 signalling in chronic psychological stress 
and metabolic stress-induced reproductive dysfunctions (Batool et al. 2014, 
Leon et al. 2014, Geraghty et al. 2015). The present study adds to our 
understanding of the underlying mechanism of RFRP-3 signalling to mediate 
stress-induced suppression of the HPG axis, by showing a modulation via the 
GnRH pulse generator. Furthermore, it should be noted that psychological stress 
did not affect Rfrp mRNA expression in sheep (Papargiris et al. 2011) and 
immunological stress did not affect GnIH mRNA expression in birds (Lopes et 
al. 2012). These data indicate that species differences may exist in the 
RFRPs/GnIH signalling systems in response to stress. 
Stress-induced suppression of the HPG axis involves a variety of neuropeptides. 
It is well established that the CRF signalling system is a potent inhibitor of the 
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GnRH pulse generator and is involved in both LPS and restraint stress-induced 
suppression of pulsatile LH release (Li et al. 2010). Yet, the role of RFRP-3 
signalling in mediating these stress responses is unknown. The present study has 
shown that CRF-induced suppression of LH can be reversed by the RFRP-3 
antagonist. Therefore, RFRP-3 may be one of the downstream mediators of 
CRF-induced suppression of LH. Indeed, CRF-R1 are found on RFRPs neurones 
(Kirby et al. 2009) and central administration of CRF induced increased 
neuronal activity in DMH where RFRP-3 neurones are located (Imaki et al. 
1993). Furthermore, different types of stressors activate specific CRF receptor 
subtypes. Whilst restraint-induced suppression of GnRH pulse generator 
frequency is mediated via both CRF-R1 and CRF-R2, metabolic and 
immunological stress are only mediated via CRF-R2 (Li et al. 2006). Therefore, 
it is postulated that CRF-R2 is also expressed in RFRP-3 neurones. Indeed, 
previous studies have shown that CRF-R2 was expressed in DMH (Van Pett et al. 
2000). Furthermore, RF-9 only partially blocked the inhibitory effects induced 
by CRF as well as restraint and LPS stress. This is not surprising since the CRF 
signalling system may operate through other downstream mediators such as 
GABA and endogenous opioid peptides to affect pulsatile LH release (Li et al. 
2010). 
The present study has shown that the µ-opioid receptor mediates, at least in part, 
the effect of RFRP-3 on the pulsatile LH release since opioid antagonist 
naloxone partially blocks RFRP-3-induced suppression of LH pulse frequency. It 
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was also shown that antagonism of κ-receptor with nor-BNI or  -receptor with 
naltrindole had no effects on RFRP-3-induced inhibition of pulsatile LH release. 
This is in keeping with a previous study that showed only µ-opioid receptor 
antagonist partially blocked the GnIH-induced food intake in chickens, but not 
with κ- and  -receptor antagonists (Tachibana et al. 2008). Thus, it is tempting 
to speculate that endogenous opioid peptides may modulate various 
physiological or pharmacological traits of the GnIH/RFRP-3 signalling system, 
and this modulation may be via the µ-opioid receptor which is expressed on 
GnRH neurones (Zheng et al. 2005). It has been suggested that among the 
various endogenous opioid peptides in the brain, β-endorphin show high affinity 
for the µ-opioid receptor (Tachibana et al. 2008). Furthermore, β-endorphin is 
involved in the inhibitory effects of pulsatile GnRH secretion (Ogata et al. 2009). 
Therefore, it is possible that RFRP-3 neurones may project to β-endorphin 
containing neurones. As shown in the present study, CRF-induced suppression of 
LH release was also blocked by RFRP-3 antagonist. Furthermore, CRF or 
stress-induced suppression of LH release can also be reversed by naloxone 
(Gindoff and Ferin 1987, O'Byrne et al. 1989), which indicates that endogenous 
opioid peptides may be the downstream effectors of both CRF/stress and 
RFRP-3 signalling systems. Taken together, it is reasonable to speculate that 
CRF, RFRP-3 and endogenous opioid neuropeptides may form a sequential link 
to modulate stress-induced suppression of LH secretion. 
We further investigated the specific locations for RFRP-3 signalling to exert its 
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inhibitory effects on the pulsatile LH release. Administration of RFRP-3 in the 
ARC or mPOA was unable to affect the pulsatile release of LH in OVX+0×E2 
rats. Administration of RF-9 in the ARC or mPOA did not affect the frequency 
of LH pulses in OVX+0×E2 rats, even though RF-9 in the mPOA induced an 
increase of overall LH secretion measured by AUC. Likewise, a previous study 
in sheep showed that icv administration of RF-9 induced a dramatic increase in 
LH release, but icv administration of RFRP-3 had no effects on LH release 
(Caraty et al. 2012). A possible explanation for this discrepancy could be the 
potential action of RF-9 on Kiss1r, as discussed above. Indeed, it has been 
shown that intra-mPOA administration of Kiss1 induced a robust LH secretion in 
OVX rats (Li et al. 2009b). However, the dynamics of stimulated LH secretion 
are quite different: Kiss1 action in the mPOA induced an immediate surge-like 
secretion of LH, whereas RF-9 elicited a more gradual and sustained increase in 
the amplitude of LH pulses which lasted more than 4 h after the intra-mPOA 
injection. The present study has also shown that RFRP-3 signalling in the ARC 
was not involved in the pulsatile LH release. It indicated that the suppression of 
pulsatile release of LH by icv administered RFRP-3, as shown in the present 
study, may not involve the GnRH pulse generator in the ARC directly. Although 
morphological studies have implicated RFRP-3 neurones via direct interactions 
with Kiss1 neurones in the ARC (postulated to be one component of the GnRH 
pulse generator) (Poling et al. 2013), RFRP-3 may be able to mediate its effects 
on the GnRH pulse generator indirectly through other signalling pathways, such 
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as endogenous opioid peptides. Taken together, the results of the present study 
dispute the ARC and mPOA as the site of action by which centrally administered 
RFRP-3 inhibits the pulsatile release of LH in OVX rats. This inhibitory effect 
may involve intermediate signalling systems which could eventually affect the 
GnRH secretion. 
The present study has also shown that RF-9 acts in both the ARC and mPOA to 
induce a profound secretion of LH in OVX+2×E2 rats. This indicates that RF-9 
had a more robust stimulatory effect in the presence of raised E2 levels, which is 
in accordance with the inhibitory role of RFRP-3 in E2 negative feedback control 
of gonadotrophins (Kriegsfeld et al. 2006, Leon et al. 2014). The present study 
is in keeping with previous studies which showed that E2 supplementation 
augmented the LH secretion induced by RF-9 in intact female rats (Pineda et al. 
2010c). We further indicated that both the mPOA and ARC are involved in this 
augmentation induced by E2. This is in keeping with the notion that inhibitory 
effects of E2 on the HPG axis involve multiple brain sites including the mPOA 
and ARC (Herbison 1998). The present study has also shown that RFRP-3 
administered into mPOA or ARC did not inhibit the LH release in OVX+2×E2 
rats. This may due to the enhanced endogenous RFRP-3 tone in these locations 
which could block any effects of exodogenous RFRP-3 signalling. Previous 
studies have shown that the expression of RFRP mRNA in the DMH did not 
vary between intact, OVX and OVX+E2 rats (Quennell et al. 2010). Neither did 
the expression of GPR147 mRNA in the mPOA or ARC fluctuate among these 
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groups (Quennell et al. 2010). It is therefore likely that the enhanced RFRP-3 
inhibitory tone during E2-induced negative feedback control may be due to the 
augmented RFRP-3 function in the mPOA and ARC. 
In summary, the results of the present study provide evidence of a suppressive 
effect of RFRP-3 on pulsatile LH release in female rats. This effect may be 
mediated via endogenous opioid peptides. Furthermore, RFRP-3 antagonism 
partially blocks CRF/stress-induced suppression of pulsatile LH release, which 
indicates that RFRP-3 is an important stress modulator on the HPG axis. Finally, 
these data also suggest that RFRP-3 signalling in the mPOA and ARC may be 




CHAPTER SEVEN: KISS1 AND GABAB RECEPTOR 
SIGNALLING IN THE MEA MODULATES LH 
SECRETION IN FEMALE RATS 
7.1 Introduction 
Extra-hypothalamic structures have long been indicated as important modulators 
of HPG axis. Among them, the amygdala has been implicated in regulating 
various reproductive functions, including ovulation, oestrous cyclicity, 
gonadotrophin secretion and sexual behaviour (Beltramino and Taleisnik 1978, 
Bagga et al. 1984, Chateau et al. 1984, Salamon et al. 2005). The MeA has been 
shown to exert an inhibitory effect on the reproductive axis. Indeed, electrical 
stimulation of the MeA delays puberty onset in female rats (Bar-Sela and 
Critchlow 1966). Conversely, lesioning of MeA advances puberty onset (Li et al. 
2015). Furthermore, lesioning of MeA increases circulating LH levels (Lawton 
and Sawyer 1970) and prevents the stress-induced suppression of pulsatile LH 
release (Lin et al. 2011). Neuroanatomical studies have shown evidence of direct 
projections from the MeA to the hypothalamic regions that regulate reproductive 
hormone release such as Kiss1-rich ARC and AVPV, and GnRH-rich mPOA 
(Hahn and Coen 2006, Usunoff et al. 2009, Keshavarzi et al. 2014). MeA may 
exert its inhibitory effect on the reproductive system via these projections. 




Recently, Kiss1-Kiss1r signalling has been identified in the MeA (Lee et al. 
1999, Clarkson et al. 2009). Previous studies regarding the physiological 
functions of Kiss1 signalling have mainly focused on two regions of the 
hypothalamus; the ARC and AVPV. Numerous studies have indicated that ARC 
and AVPV Kiss1 signalling are involved in LH pulse and surge generation, 
respectively. Knockdown of Kiss1 in the ARC decreases LH pulse frequency, 
while knockdown of Kiss1 in the AVPV reduces the incidence of LH surges in 
female rats (Beale et al. 2014, Hu et al. 2015). Knockdown of Kiss1 in the ARC 
and AVPV both resulted in a disruption of oestrous cyclicity in female rats 
(Beale et al. 2014, Hu et al. 2015). However, Kiss1 signalling is not restricted to 
hypothalamic regions. Both Kiss1 neurones and fibres are found in 
extra-hypothalamic regions such as the MeA (Clarkson et al. 2009). Furthermore, 
Kiss1r mRNA is also expressed in the MeA (Lee et al. 1999). It was shown that 
the expression of Kiss1 mRNA in the MeA is regulated by the stages of oestrous 
cycles of female rats and the levels of sex steroids of both sexes (Kim et al. 
2011). The expression of Kiss1 mRNA in the MeA was highest at proestrus and 
amplified by sex steroids in castrated rats of both sexes (Kim et al. 2011). The 
enhanced Kiss1 signalling in the MeA by E2 treatment appears to be regulated 
by ER-dependent pathways, since nonaromatisable androgens do not modulate 
Kiss1 expression in the MeA (Kim et al. 2011). Indeed, both ERα and ERβ 




In addition to its regulation by gonadal steroids, MeA Kiss1 expression is 
modulated by GABA neurotransmitter. The majority of hypothalamic and MeA 
Kiss1 neurones express GABAB receptor (Di Giorgio et al. 2014). In adult mice 
of both sexes, Kiss1 signalling in the MeA is under tonic inhibitory regulation 
by GABAergic signalling, since knockout of GABAB receptor amplified the 
expression of Kiss1 mRNA in the MeA and increased the frequency of pulsatile 
GnRH release (Catalano et al. 2010, Di Giorgio et al. 2014). This inhibitory 
effect of GABAB receptor signalling on Kiss1 signalling was not found in the 
ARC or the AVPV in adult mice (Di Giorgio et al. 2014). Therefore, GABAB 
receptor signalling appears to modulate the Kiss1 signalling by a regional 
specific manner. These studies have heightened interest in the role of amygdala 
Kiss1 signalling. However, unlike hypothalamic Kiss1 signalling, whether the 
Kiss1 signalling in the MeA plays a role in regulating reproductive function 
including ovulation, oestrous cyclicity, or gonadotrophin secretion is still 
unknown. 
The interactions between Kiss1 and GABAergic signalling systems appear to be 
reciprocal. Various studies have indicated that Kiss1 signalling can modulate 
central GABAergic signalling with different effects. Kiss1 can increase 
GABAergic transmission directly to GnRH neurones and also potentiate the 
postsynaptic response of GnRH neurones to GABA (Pielecka-Fortuna and 
Moenter 2010, Ronnekleiv and Kelly 2013). However, other studies have 
showed Kiss1 can decrease the release of GABA in the mPOA (Neal-Perry et al. 
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2009) and block GABAB receptor mediated inhibitory effect on GnRH neuronal 
activity (Zhang et al. 2009). Furthermore, recent studies have suggested that 
Kiss1 might possibly modulate GABAergic signalling in the MeA. Peripheral 
administration of Kiss1 increased LH secretion concomitant with reduced 
neuronal activity in the amygdala measured by magnetic resonance imaging 
(MRI) (Comninos et al. 2015). GABA is the chief inhibitory neurotransmitter in 
the mammalian central nervous system. GABAergic neurones form an 
interconnected local inhibitory network in the MeA and constitute the majority 
of projections out from this region (Keshavarzi et al. 2014). Therefore, 
peripheral administered Kiss1 might affect the GABAergic signalling in the 
MeA to induce the LH release. 
 
7.2 Aims and objectives 
1. To test the hypothesis that Kiss1 signalling in the MeA regulates both the 
pulsatile and surge modes of LH release in female rats. 
a) To determine the effect of intra-MeA administered Kiss1r agonist and 
antagonist on pulsatile LH secretion in OVX rats. 
b) To assess the effect of chronic administered Kiss1r antagonist on 




2. To test the hypothesis that the stimulatory effects of peripherally administered 
Kiss1r agonist on LH secretion is mediated via the GABAB receptor in the MeA 
in OVX rats. 
 
7.3 Materials and methods 
7.3.1 Animals and surgical procedures 
Adult Sprague-Dawley rats were OVX and implanted with bilateral guide 
cannulae directed towards the MeA (see section 2.2.2.5). An additional group of 
rats used as controls were OVX and implanted with unilateral icv guide cannulae 
directed towards the left lateral cerebral ventricle (see section 2.2.2.4). After a 
10-d recovery period (Fig. 7.1, A), rats were fitted with two indwelling cardiac 
catheters via the jugular vein, as described in section 2.2.2.6. Experimentation 
commenced 3 d later (Fig. 7.1, A). 
A separate group of adult female rats were chronically implanted bilaterally with 
cannulae (28 gauge, Plastics One) directed towards the MeA: coordinates for 
implantation were 3.4 mm lateral, 3.14 mm posterior to bregma, and 8.6 mm 
below the surface of the dura according to the Rat Brain Atlas of Paxinos and 
Watson (Paxinos G 1986). An osmotic mini-pump (Model 1002, Alza Corp) was 
attached to the left cannula with silicone tubing, and implanted subcutaneously 
in the interscapular space. This was repeated for the right cannulae. The Kiss1r 
antagonist peptide-234 (Sigma-Aldrich; n = 10) or aCSF (n = 7) was delivered 
203 
 
bilaterally via the osmotic mini-pump at the rate of 0.25 µl/h for a 14-d period. 
The dose of peptide-234 used was 0.33 nmol/µl (2 nmol/d for each side). An 
additional group of female rats used as controls were implanted a cannula (28 
gauge, Plastics One) directed towards the left lateral cerebral ventricle: the 
coordinates for implantation were 1.5 mm lateral, 0.6 mm posterior to bregma, 
and 4 mm below the surface of the dura according to the Rat Brain Atlas of 
Paxinos and Watson (Paxinos G 1986). An osmotic mini-pump (Model 2002, 
Alza Corp) was attached to the cannula. To compare with bilaterally 2 nmol/d 
intra-MeA administration of peptide-234, peptide-234 (4 nmol/d) was 
administered via the mini-pump to the ventricle system. After a 3-d recovery 
period (Fig. 7.1, B), rats were fitted with two indwelling cardiac catheters via the 
jugular vein, as described in section 2.2.2.6. Experimentation commenced 2 d 








Fig. 7.1 Timeline diagram of various surgical and experimental procedures for 
investigating the role of MeA Kiss1 signalling in regulating the release of LH 
and the role of MeA GABAB receptor signalling in mediating the release of LH 
induced by Kiss1. 
 
7.3.2 Experiment 1: Effects of intra-MeA administration of Kiss1r 
agonist or antagonist on LH release in OVX rats 
On the morning of experimentation, a bilateral internal injection cannula 
(Plastics One) with extension tubing preloaded with aCSF, Kp-10 
(Sigma-Aldrich) or peptide-234 was inserted into the guide cannula and 
extended 1 mm beyond the guide cannula to reach the MeA. The distal end of 
the tubing was extended outside of the cage connected to a 5 µl Hamilton 
syringe (Waters International), thereby allowing remote infusion without 
disturbing the rat during the experiment (see section 2.2.3.3). Rats were also 
attached via one of the two cardiac catheters to the computer-controlled 





















were left undisturbed for 1 h. Blood sampling commenced between 1000 and 
1100 h and samples were collected every 5 min for 6 h for LH measurement. 
Kp-10 or vehicle (aCSF) was infused (intra-MeA) over 5 min into OVX rats 
after 2 h of controlled blood sampling. Rats received a single dose of 100 pmol 
or 1 nmol Kp-10 in 400 nl aCSF (n = 9 per treatment group), bilaterally. Control 
rats received 400 nl aCSF (n = 7). Peptide-234 (50 pmol) was administered in 
400 nl aCSF over 5 min after 2 h of controlled blood sampling and then the same 
dosage was repeated on two further occasions at an interval of 30 min (n = 9). 
The above dosage was selected based on our previous studies investigating the 
Kiss1 signalling in the ARC (Li et al. 2009b). 
Additional group of OVX rats implanted with icv cannulae were used as controls 
to rule out the possibility that Kp-10 administered into the MeA may have 
diffused into the lateral cerebral ventricle to exert its effect via that route. Rats 
were attached to the automated blood sampling system and equipped with the 
icv injection system on the morning of experimentation, as described in Chapter 
4. Kp-10 (200 pmol in 4 µl aCSF) was infused via the icv cannulae over 5 min 
into OVX rats (n = 6) after 2 h of controlled blood sampling. This dose was 




7.3.3 Experiment 2: Effects of chronic intra-MeA administration of 
Kiss1r antagonist on oestrous cyclicity and the proestrus LH 
surges in intact female rats 
After the implantation of the osmotic mini-pump filled with peptide-234 or 
aCSF (see section 7.3.1), rats (17 rats from the experiment of chronic intra-MeA 
administration of peptide-234/aCSF via mini-pump and 5 rats from the 
experiment of chronic icv administration of peptide-234/aCSF via mini-pump) 
were monitored daily (0900-1000 h) for normal ovarian cyclicity by means of 
vaginal cytology for 22 d. Normal ovarian cyclicity in this study was defined as 
having at least 2 consecutive normal cycles, which last for 4-5 d with 1-2 d of 
oestrus (Hu et al. 2015). 
At least 2 d after the implantation of cardiac catheters (see section 7.3.1), rats 
that were shown to be in proestrus were attached via one of the two cardiac 
catheters to the computer-controlled automated blood sampling system (see 
section 2.2.3.1). Blood sampling commenced at 1300 h and samples (25 µl) were 
collected every 30 min for 7 h for LH measurement. 
 
7.3.4 Experiment 3: Effects of peripheral administration of Kiss1r 
agonist on LH release in the presence of intra-MeA 
administration of GABAB receptor antagonist in OVX rats 
On the morning of experimentation, OVX rats were attached to the automated 
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blood sampling system and equipped with the intra-MeA injection system, as 
described above. After 1 h 45 min of controlled blood sampling, rats received 
three consecutive injections (intra-MeA) of GABAB antagonist CGP35348 (1.2 
nmol in 400 nl aCSF, n = 6) or vehicle (400 nl aCSF, n = 6), each administered 
over 5 min, 30 min apart, with a further injection (iv) of Kp-10 (50 nmol in 0.2 
ml saline), administered 15 min following the first injection of CGP35348 or 
aCSF. Additional rats, used as controls, received three consecutive injections 
(intra-MeA, 30 min apart) of CGP35348 (1.2 nmol, n = 4) after 1 h 45 min of 
controlled blood sampling with a further injection of saline (0.2 ml) after the 
first injection of CGP35348. The dose of CGP35348 was based on our previous 
studies investigating GABAergic signalling in the mPOA (Lin et al. 2012). 
 
7.3.5 Statistical analysis 
Detection of LH pulses in OVX rats in experiment 1 was established by use of 
the algorithm ULTRA (Van Cauter 1988). The effects of pharmacological agents 
on pulsatile LH secretion were analysed by comparing the mean LH pulse 
interval in the 2-h period preceding treatment with that in the 1-h post-treatment 
and 2-4-h post-treatment period. The duration (min) of the 2-h pre-treatment, 1-h 
post-treatment and 2-4 h post-treatment period, was divided by the number of 
LH pulses detected in each of these periods to give the appropriate LH pulse 
interval. The effects of pharmacological agents on overall LH release in 
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experiment 1 were calculated by comparing the average AUC per h in the 1-h 
and 2-4-h post-treatment periods with that in the 2-h pre-treatment period, using 
SigmaPlot version 11 (Systat Software). In experiment 2, the percentage of rats 
exhibiting LH surges/normal oestrus cyclicity were calculated by the number of 
rats showing LH surges/normal oestrus cycles divided by the number of overall 
rats. In experiment 3, the effects of pharmacological agents on overall LH 




 2-h post-treatment 
period with that in the 2-h pre-treatment period. Statistical significance for the 
percentage of normal oestrous cyclicity and the percentage of rats exhibiting LH 
surges was examined by Fisher’s test. All other results were analysed by 
one-way ANOVA followed by Dunnett’s test. All data were shown as mean ± 
S.E.M. P < 0.05 was considered statistically significant. 
 
7.4 Results 
7.4.1 Experiment 1: Effects of intra-MeA administration of Kiss1r 
agonist or antagonist on LH release in OVX rats 
To investigate the role of Kiss1 signalling in the MeA in pulsatile LH release, we 
examined the effects of intra-MeA administered Kp-10 or its antagonist, 
peptide-234, on LH secretion in OVX rats. Intra-MeA administration of Kp-10 
induced a dose-dependent increase in overall LH levels calculated by AUC (Figs. 
7.2, B, C and F). 100 pmol Kp-10 increased the overall LH levels per h by 17.2% 
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during the 1-h post-infusion period (AUC per h, 2-h pre-injection vs. 1-h 
post-injection: 286.7 ± 3.8 vs. 336.0 ± 13.2 ng/ml.min; P < 0.05) and by 69.5% 
with 1 nmol Kp-10 (AUC per h, 2-h pre-injection vs. 1-h post-injection: 286.4 ± 
11.0 vs. 485.5 ± 37.9 ng/ml.min; P < 0.05). By contrast, intra-MeA 
administration of peptide-234 inhibited the overall LH levels during the 2-4-h 
post-infusion period (AUC per h, 2-h pre-injection vs. 2-4-h post-injection: 290 
± 18.8 vs. 209.7 ± 17.5 ng/ml.min; P < 0.05; Figs. 7.2, D and F). Furthermore, at 
the dose of 100 pmol, Kp-10 did not affect the LH pulse frequency (Figs. 7.2, B 
and E). However, 1 nmol Kp-10 induced a profound and prolonged increase in 
LH secretion that precluded reliable LH pulse detection in this treatment group. 
By contrast, intra-MeA administration of peptide-234 inhibited the LH pulse 
frequency in OVX rats (LH pulse interval, 2-h pre-injection vs. 2-4-h 
post-injection: 22.0 ± 0.8 vs. 55.3 ± 5.6 min; P < 0.05; Figs. 7.2, D and E). In the 
control group, vehicle (aCSF) did not affect the pulsatile LH release or overall 
LH secretion (Figs. 7.2, A, E and F). In addition, the MeA cannulae were found 
to be misplaced in one rat (Fig. 7.5) in which both Kp-10 and peptide-234 did 
not affect the LH secretion. Furthermore, icv administration of Kp-10 (200 pmol) 
did not affect the LH secretion in OVX rats (AUC per h, 2-h pre-injection vs. 1-h 






7.4.2 Experiment 2: Effects of chronic intra-MeA administration of 
Kiss1r antagonist on oestrous cyclicity and the proestrus LH 
surges in intact female rats 
To investigate the role of Kiss1 signalling in the MeA on the surge mode of LH 
secretion, we examined the effects of intra-MeA administered Kiss1r antagonist 
peptide-234 on oestrous cyclicity and LH secretion in intact female rats. Chronic 
intra-MeA administration of peptide-234 (2 nmol/d bilaterally) reduced the 
incidence of normal oestrous cyclicity in female rats by 61.4% (aCSF vs. 
peptide-234, 71.4% vs. 10.0%, P < 0.05; Figs. 7.3, A and B). Furthermore, 
peptide-234 reduced the percentage of rats showing spontaneous LH surges by 
65.7% (aCSF vs. peptide-234, 85.7% vs. 20%, P < 0.05; Fig. 7.3, E). Only 1 out 
of 10 animals exhibited an LH surge at proestrus in the peptide-234 treatment 
group, whereas 6 out of 7 showed LH surges in the aCSF control group. 
Representative examples of LH surges in control and treatment groups are 
provided in Figures 7.2, C and D. No misplaced cannulae were found in this set 
of experiments (Fig. 7.5). Furthermore, in additional rats chronically 
administered (icv via a mini-pump) peptide-234 (4 nmol/d), 4 out of 5 exhibited 






7.4.3 Experiment 3: Effects of peripheral administration of Kiss1r 
agonist on LH release in the presence of intra-MeA 
administration of GABAB receptor antagonist in OVX rats 
To investigate the role of GABAB receptor signalling in the MeA in 
Kiss1-induced LH secretion, we examined the effects of iv administered Kp-10 
in the presence of intra-MeA administration of the GABAB receptor antagonist 
CGP35348 on LH secretion in OVX rats. Intra-MeA administration of 
CGP35348 attenuated the rise in overall LH secretion induced by iv Kp-10 (Fig. 





 h post-administration periods (P < 0.05). This increase 
was significantly attenuated by co-administration of CGP35348 during the 2
nd
 
2-h post-administration period (AUC in 2
nd
 2-h post-injection, vehicle + Kp-10 
vs. CGP35348 + Kp-10: 786.4 ± 31.2 vs. 680.1 ± 32.2 ng/ml.min, P < 0.05; Figs. 
7.4, B, C and D). CGP35348 per se did not affect the overall LH secretion (Figs. 
7.4, A and D). In addition, the MeA cannulae were found to be misplaced in one 
rat (Fig. 7.5). In that rat, CGP35348 did not seem to affect the LH secretion 
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Fig. 7.2 Effects of intra-MeA administration of Kiss1r agonist or antagonist 
on LH release in OVX rats. Representative LH profiles illustrating effects of 
intra-MeA administration (arrow) of Kp-10 (B-C), peptide-234 (D) or vehicle 
(aCSF) (A) in OVX rats. Kp-10 (100 pmol) had no significant effects on 
pulsatile LH secretion in OVX rats. However, peptide-234 (3×50 pmol) 
inhibited the pulsatile LH release, as summarised in panel E. Furthermore, 
Kp-10 induced a dose-dependent increase of LH secretion, calculated by 
AUC, as summarised in panel F. By contrast, peptide-234 inhibited the LH 
secretion. *, P < 0.05 vs. 2-h baseline period within the same group, as well 
as the same 2-h period within the vehicle treated group; #, P < 0.05 vs. same 
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Fig. 7.3 Effects of chronic intra-MeA administration of Kiss1r antagonist on 
oestrous cyclicity and proestrus LH surge in intact female rats. (A) 
Representative oestrous cycle profiles of rats administered (intra-MeA, 
bilaterally) vehicle (aCSF, 4 µl/d) or peptide-234 (2 nmol/d); P = proestrus, E 
= oestrus, M = metoestrus, D = dioestrus. Peptide-234 reduced the percentage 
of rats showing normal oestrous cyclicity, as summarised in panel B. (C, D) 
Representative LH surge profiles in rats administered (intra-MeA, bilaterally) 
aCSF or peptide (2 nmol/d), respectively. The percentage of rats exhibiting 
spontaneous LH surges was reduced by peptide-234, as summarised in panel 
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Fig. 7.4 Effects of peripheral administration of Kiss1r agonist on LH release 
in the presence of intra-MeA administration of GABAB antagonist in OVX 
rats. Representative LH profiles illustrating the effect of iv administration of 
50 nmol Kp-10 (arrow) in the presence (C) or absence (B) of intra-MeA 
administration of 3×1.2 nmol CGP35348 (↓↓↓), as well as that of 3×1.2 
nmol CGP35348 (A) (↓↓↓) alone, in OVX rats. The Kp-10-induced LH 
secretion was blocked by pre-treatment of CGP35348, as summarised in 
panel D. *, P < 0.05 vs. 2-h baseline period within the same group, as well as 
the same 2-h period within the vehicle treated group; #, P < 0.05 vs. same 2-h 
period within the group treated with vehicle + Kp-10 (n = 4-6 per group). 
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Fig. 7.5 Schematic illustration and photomicrograph of the infusion site 
targeted to the MeA. A, schematic illustration showing the target site for 
bilateral cannulation of the MeA. Arrows point to the location of the tips of 
internal cannulae or 28 gauge cannulae. B, photomicrograph of a coronal 
brain section in a representative animal implanted with a bilateral cannula 
in the MeA. Arrows indicate the tips of the internal cannulae. C-D, 
schematic drawings of the MeA illustrating the individual sites of injection 
for the experiment 1&3 and 2, respectively. Numbers in each drawing 
indicate the distance (mm) to Bregma. Open circles show the right injection 






The present study investigated whether Kiss1 signalling in the MeA affects LH 
secretion. We found that intra-MeA administration of Kiss1r agonist, Kp-10, 
caused a dose-dependent increase of LH secretion in OVX rats. Previous studies 
have shown that intra-mPOA and intra-ARC administered Kp-10 induce a robust 
LH secretion (Li et al. 2009b). A lower dose of Kp-10 was required in the 
mPOA and ARC to induce a comparable LH secretory response compared with 
the MeA (Li et al. 2009b). This may be due to a less robust expression of Kiss1r 
mRNA in the MeA compared with the mPOA or ARC (Lee et al. 1999). In order 
to rule out the possibility that Kp-10 injected into the MeA may have leaked 
from this site into the ventricular system to have an affect on Kiss1r in the ARC 
or mPOA, we injected the same dose of Kp-10 into the ventricular system. It 
was shown that icv administration of 200 pmol Kp-10 did not affect LH 
secretion in OVX rats. This is also in agreement with previous studies showing 
that icv administration of 100 or 300 pmol Kp-10 did not stimulate LH secretion 
(Thompson et al. 2004, Pheng et al. 2009). This is a critical observation since it 
strongly indicates that the Kp-10 administered into the MeA exerted its effect 
locally and not via leakage into the ventricular system to target hypothalamic 
sites. 
The present study has also shown that intra-MeA administration of Kiss1r 
antagonist peptide-234 profoundly suppresses LH pulse frequency. Again, icv 
administration of the same dose of peptide-234 did not affect the LH secretion, 
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indicating a localised site of action to the amygdala. These data suggest that 
Kiss1-Kiss1r signalling in the MeA can regulate the GnRH pulse generator 
frequency. Previous studies have implicated MeA in the regulation of the GnRH 
pulse generator. Lesioning of the MeA did not affect basal pulsatile LH release, 
whereas it blocked psychological stress-induced suppression of LH pulse 
frequency (Lin et al. 2011). It is therefore possible that the MeA may be 
sensitive to psychological stimuli and function as an upstream ‘inhibitory brake’ 
on the hypothalamic GnRH pulse generator. The psychological stress-induced 
suppression of LH pulses was associated with a decrease in Kiss1 mRNA 
expression in the mPOA and ARC (Kinsey-Jones et al. 2009). Given the 
inhibitory effect of Kiss1r antagonism in the MeA on the pulsatile LH release, it 
is possible that Kiss1 signalling in the MeA is involved in stress-induced 
suppression of pulsatile LH release. However, the neuroanatomical circuitry 
underlying this remains to be elucidated. It has been shown that the majority of 
projections from the MeA to the hypothalamus are GABAergic (Keshavarzi et al. 
2014), which is in keeping with inhibitory role of MeA on the reproductive axis. 
Numerous studies have indicated that GABA signalling plays an important 
inhibitory role in the regulation of GnRH release. Local infusion of GABA into 
the mPOA or ARC suppressed the pulsatile LH release (Jarry et al. 1991, 
Ferreira et al. 1996). Therefore, Kiss1-Kiss1r signalling in the MeA may affect 
the extrinsic projections of GABAergic signalling to affect the pulsatile LH 
release. Indeed, it has been shown that Kiss1 signalling can affect the 
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GABAergic signalling since direct injections of Kiss1 inhibit GABA release in 
the mPOA (Neal-Perry et al. 2009). More studies will be needed to investigate 
the potential effect of the MeA Kiss1 signalling on the GABAergic signalling. 
However, it should be noted that the present study has also shown that 
intra-MeA administration of Kp-10 (100 pmol) did not affect the pulsatile LH 
release. Unfortunately, we cannot analyse the LH pulsatility following the 
injection of higher dosage of Kp-10 due to the dramatic increase of LH levels. 
This dramatic increase of LH release may be due to a massive increase of LH 
pulse frequency. However, a caveat may exist since previous studies have shown 
that iv administered Kp-10 did not affect the frequency of GnRH pulse generator 
(reflected by the frequency of MUA volleys) in OVX rats, despite its dramatic 
stimulatory effects on the LH secretion (Kinsey-Jones et al. 2008). Taken 
together, Kiss1 signalling in the MeA appears to be an important regulator of the 
GnRH pulse generator and warrants further investigation. 
Kiss1 signalling in the MeA fluctuates during the oestrous cycle, with high 
expression of Kiss1 mRNA at proestrus stage, when circulating levels of E2 are 
highest (Kim et al. 2011). ERs are highly expressed in the MeA (Simerly et al. 
1990, Greco et al. 2001). Treatment with E2 dramatically increased the 
expression of Kiss1 mRNA in the MeA of OVX rats (Kim et al. 2011). This 
indicates that E2 positively regulates Kiss1 signalling in the MeA, which mirrors 
that of Kiss1 signalling in the AVPV. Therefore, we ventured to investigate the 
role of Kiss1 signalling in the MeA on spontaneous LH surges generation and 
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oestrous cyclicity in rats. The present study has shown that intra-MeA 
administration of Kiss1r antagonist reduced the percentage of animals showing 
spontaneous LH surges and normal oestrous cyclicity. In contrast, the majority 
of rats administered the same dose of Kiss1r antagonist via an icv route showed 
normal spontaneous LH surges and oestrous cyclicity. This suggests that the 
effect of intra-MeA administered Kiss1r antagonist on the LH surges and 
oestrous cyclicity is unlikely to be due to leakage into the ventricular system. 
The effect of Kiss1r antagonism in the MeA is in line with a recent study 
showing that knockdown of Kiss1 signalling in the AVPV of rats resulted in 
abnormal oestrous cyclicity and a reduction in the occurrence of spontaneous LH 
surges (Hu et al. 2015). The disrupted oestrous cyclicity was characterised by an 
increased time spent in oestrus and metoestrus stages of the cycle (Hu et al. 
2015), which is in line with the present study. Similarly, Kiss1, Kiss1r or Kiss1 
ERα knockout mice move between oestrus and dioestrus stages but remain 
anovulatory (Chan et al. 2009, Mayer et al. 2010). This may suggest that 
animals get stuck in the preovulatory phases as the E2-Kiss1-GnRH signalling 
cascade essential for the LH surge and as a result ovulation is inhibited. 
Furthermore, lesioning of the MeA blocked ovulation (Bagga et al. 1984) and 
disrupted normal oestrous cyclicity (Li et al. 2015) in rats. Taken together with 
the present study, Kiss1 signalling in the MeA may be key component in the 
signalling pathways that initiate spontaneous LH surges. 
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The present study also investigated the role of GABAB receptor signalling in the 
MeA in Kiss1-induced LH secretion. Injection of GABAB receptor antagonist 
into the MeA attenuated peripherally administered Kp-10-induced LH secretion. 
This suggests that Kp-10-induced LH secretion is partially dependent on the 
GABAB receptor signalling in the MeA. We can not rule out the possibility that 
Kp-10 may also require GABAA receptor to induce LH secretion. Recent studies 
have shown that increased LH secretion in response to peripherally administered 
Kp-10 was associated with a marked reduction of neuronal activity in the MeA 
measured by MRI (Comninos et al. 2015). It is possible that this reduction could 
represent an inhibition of the GABAergic neuronal activities in the MeA, since 
most neurones in the MeA are GABAergic (Mugnaini and Oertel 1985, 
Keshavarzi et al. 2014). Furthermore, the majority of projections out of the MeA 
to reproductive related hypothalamus nucleus are GABAergic (Keshavarzi et al. 
2014). Therefore, this inhibited GABAergic signalling is speculated to 
eventually lead to the activation of GnRH neurones and resultant LH release via 
a disinhibition of inhibitory effect. It is important to consider that MRI 
measurement cannot distinguish directly between activation of one population of 
neurones and deactivation of another, and hence represents an overall net effect. 
Additionally, peripherally administered Kp-10 is not thought to cross the 
blood-brain barrier (Herde et al. 2011). It has been reported that iv 
administration of Kp-10 induced neuronal activity in the supraoptic nucleus to 
release oxytocin (Scott and Brown 2011). The mechanism for this modulation is 
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unknown, but could possibly be due to the activation of an afferent vagal 
pathway (Scott and Brown 2011). Similarly, the inhibited neuronal activities in 
the MeA in response to peripherally administered Kp-10 (Comninos et al. 2015) 
may be via an indirect route, which remains to be elucidated. 
In summary, the present study has shown that Kiss1 signalling in the MeA is 
involved in both LH pulse and LH surge generation. Our data provide evidence 
that Kiss1 in the MeA is also an essential regulator of the reproductive system, 
integrating limbic circuits with the modulation of the HPG axis. Furthermore, 
Kiss1-induced LH secretion is partially dependent on GABAB signalling in the 
MeA, which indicates an indirect pathway may exist for Kiss1 signalling to act 




CHAPTER EIGHT: GENERAL DISCUSSION 
Sexual maturation involves a series of neuroendocrine developments that lead to 
the activation of the HPG axis. This activation is initiated by an acceleration of 
the GnRH pulse generator, which results in the accelerated pulsatile release of 
GnRH, the principle central stimulator of gonadotrophins. This phenomenon has 
been found across mammalian species, from rodents to primates and including 
humans (Watanabe and Terasawa 1989, Sisk et al. 2001, Harris and Levine 2003, 
McCartney 2010, Li et al. 2012). The timing of sexual maturation appears to be 
tightly regulated by the activity of the GnRH pulse generator. Recent studies 
have implicated Kiss1 and NKB signalling in the process of sexual maturation. It 
has been shown that humans with inactivating mutations in genes encoding 
KiSS1, KiSS1r, NKB or NK3R lack pubertal development (de Roux et al. 2003, 
Seminara et al. 2003, Topaloglu et al. 2009, Topaloglu et al. 2012). 
The first aim of this project was to examine the role of NKB-NK3R signalling in 
regulating the timing of puberty onset and the dynamic release of LH in the 
prepubertal stage of rats. It has been demonstrated in the present study that 
chronic central administration of NK3R antagonist results in a significant delay 
in the timing of puberty onset, which is in keeping with the phenotype of human 
genetic mutations (see section 3.3.2). Interestingly, it has been shown that 
NK3R-null mice display normal timing of puberty onset, although with disrupted 
oestrous cycles and reduced gonadal weight (Yang et al. 2012). Similarly, the 
pharmacological tools using NK3R agonists or antagonists have yielded 
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conflicting results in rodent studies (Gill et al. 2012, Navarro et al. 2012, 
Nakahara et al. 2013). This could be due to differences in the dosage or the 
routes of administration. Furthermore, it has been shown in the present study 
that NK3R antagonism reduced the accelerated increase of pulsatile LH release 
in prepubertal rats, which may underlie the delay in puberty onset (see section 
3.3.3). It has previously been shown that chronic infusion of NK3R agonist 
advances puberty onset, but only with a tendency to increase pulsatile LH 
release in female rats (Nakahara et al. 2013). Taken together, NKB-NK3R 
signalling might regulate the timing of sexual maturation by modulating the 
activity of GnRH pulse generator. Furthermore, blockade of the Dyn receptor 
resulted in advanced puberty onset, which is associated with increased pulsatile 
LH release (Nakahara et al. 2013). These studies further strengthened the 
speculation that the oscillation of NKB/Dyn in the ARC produces pulsatile mode 
of GnRH release, as well as the notion that the GnRH pulse generator regulating 
the timing of sexual maturation is partially comprised of KNDy neurones. 
KNDy neurones in the ARC form an interconnected network (Krajewski et al. 
2010) and ARC NKB/Kiss1 neurones express NK3R (Burke et al. 2006, Navarro 
et al. 2009a). It has been speculated that NKB could exert stimulatory effects on 
KNDy neurones via NK3R to evoke synchronised bursting activities among 
KNDy neurons, whereas Dyn could extinguish these stimulatory effects 
(Okamura et al. 2013). 
The timing of sexual maturation is readily affected by nutritional status. Positive 
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energy balance leads to precocious puberty onset, while negative energy balance 
delays puberty. These shifts also appear to be in accordance with the activity of 
the GnRH pulse generator. Food restriction delays puberty onset (Cheung et al. 
1997, Navarro et al. 2012) and inhibits the pulsatile LH release (Bergendahl et al. 
1998, Nagatani et al. 2000, Forbes et al. 2009). In contrast, feeding with a high 
fat diet induces precocious puberty which is accompanied by an earlier onset of 
increased frequency of pulsatile LH release (Li et al. 2012). It has been shown in 
the present study that NK3R antagonism delayed the over-nutrition-induced 
precocious puberty in rats (see section 3.3.2). This delay is associated with a 
decreased frequency of pulsatile LH release (see section 3.3.4). This indicates 
that NK3R signalling might regulate the timing of sexual maturation in states of 
over-nutrition by increasing the activity of GnRH pulse generator. This 
speculation fits the model that oscillation of NKB/Dyn signalling in the ARC 
produces pulsatile mode of GnRH release. Modulating this oscillation via NK3R 
signalling alters the pulsatile mode of GnRH release and therefore shifts the 
timing of sexual maturation in different nutritional status. This is indirectly 
supported by previous studies showing that food deprivation delayed the puberty 
onset in rats which is associated with decreased expression of ARC Tac2 and 
Tacr3 mRNA (Navarro et al. 2012). Treatment of NK3R agonists during food 
restriction could restore the normal timing of puberty onset (Navarro et al. 2012). 
Although little is known about the role of Dyn in regulating puberty onset in 
different nutritional states, previous studies have established that Dyn plays a 
225 
 
role in integrating nutrition and reproduction (Daniel et al. 2013). It was shown 
that icv administration of Dyn increased food intake in sheep (Baile et al. 1987, 
Della-Fera et al. 1990). If each NKB/Dyn oscillation in the ARC could result in 
a pulse of Kiss1 release, altering the Kiss1 signalling system may affect the 
timing of sexual maturation in conditions of different nutritional status. It has 
been shown that food deprivation delayed puberty onset in rats with decreased 
expression of hypothalamic Kiss1 mRNA (Castellano et al. 2005). This delay 
could be reversed by treatment of Kiss1r agonists (Castellano et al. 2005). Taken 
together, it can be speculated that the central mechanisms underlying the shifts 
of timing of sexual maturation in nutritional status might ultimately relay on the 
ARC KNDy signalling systems which could accelerate the pulsatile GnRH 
release to initiate puberty. It is certain that more studies will be needed to 
support this conclusion. 
In order to further study the mechanisms underlying the effects of NK3R 
agonism on LH release, we used pharmacological tools of administering NK3R 
agonists into conscious adult female rats and assessed the dynamic changes in 
pulsatile LH release. Central administration (icv) of NK3R agonists induced a 
triphasic effects on LH release dependent on the oestradiol steroid milieu of the 
rats (see Chapter 4). More specifically, NK3R agonism induced an inhibitory 
effect on LH release in OVX rats with no replacement (circulating E2 levels: 
12.7 ± 1.5 pg/ml), no effect with one E2 capsule replacement (circulating E2 
levels: 23.8 ± 2.0 pg/ml), and a stimulatory effect with two E2 capsules 
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replacement (circulating E2 levels: 36.8 ± 2.4 pg/ml). These various effects have 
been individually described in previous studies (Navarro et al. 2009a, Corander 
et al. 2010, Navarro et al. 2011a, Kinsey-Jones et al. 2012), but this is the first 
time where all three effects have been shown in a single study. It suggests that 
the effects of NK3R signalling on LH release are dependent on critical 
circulating levels of the sex steroid. In this respect, previous studies have yielded 
conflicting results, with some showing the reversal from an inhibitory to a 
stimulatory effect of NK3R agonism on LH secretion in OVX rats after E2 
treatment (equivalent to E2 levels of proestrus), whereas others displayed the 
inhibitory effects without or with E2 treatment (equivalent to E2 levels of diestrus) 
(Navarro et al. 2011a, Grachev et al. 2012a). It has been shown in the present 
study that different regiments of E2 replacement produced significant differences 
in circulating E2 levels (see section 4.4.5). However, the differences of 
circulating levels of E2 in the three replacement regimes used in the present 
study were very subtle. This may provide an explanation for the differences 
observed among previous studies: subtle variations in the circulating gonadal 
steroid milieu among studies could result in significant differences of LH 
secretion in response to NK3R agonism. 
Numerous studies investigating the underlying mechanisms for the stimulatory 
effects of NKB on LH release have implicated the Kiss1-Kiss1r signalling 
system. The stimulatory effect of NK3R agonism on LH release in OVX rats 
treated with E2 replacement is associated with up-regulated activities of Kiss1 
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neurones in the ARC (Navarro et al. 2011a). In ovary-intact prepubertal female 
rats, NK3R agonism induced LH release is dependent on the Kiss1r (Grachev et 
al. 2012b). Similar results have been found in prepubertal monkeys 
(Ramaswamy et al. 2011). Therefore, NK3R agonism might activate the Kiss1 
to stimulate GnRH release. 
The mechanisms underlying the inhibitory effects of NK3R agonism on LH 
release in hypoestrogenic conditions are less clear. Morphologic evidence 
indicated that NKB might directly influence GnRH secretion at the level of the 
ME, since close apposition of NKB GnRH fibres are observed in the ME and 
GnRH neurones express NK3R (Krajewski et al. 2005). However, intravenous 
administration of NK3R agonists, which should theoretically reach the ME, did 
not suppress the pulsatile release of LH in OVX rats replaced with low levels of 
E2 (Grachev et al. 2014b). Therefore, the inhibitory effect of NK3R agonism 
might involve indirect routes via intermediary signalling systems. Dyn is a 
well-established inhibitory effector on LH release and is co-expressed with 
NK3R in the ARC neurones (Burke et al. 2006). The inhibitory effect of NK3R 
agonism on pulsatile LH release in OVX rats treated with low levels of E2 is 
blocked by Dyn receptor antagonism in the ARC (Grachev et al. 2012a). 
Therefore, ARC Dyn signalling appears to regulate the inhibition of LH release 
by ARC NK3R agonism. However, the expression of Dyn receptor mRNA have 
not been detected in GnRH neurones (Mitchell et al. 1997, Sannella and 
Petersen 1997). Therefore, Dyn might not be the only intermediary signalling 
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system that regulates the inhibitory effect of NK3R agonism. Other unknown 
signalling systems that express Dyn receptor will have to relay the effect of Dyn 
to GnRH neurones. 
A model has been presented in which NKB is probably the upstream regulator of 
GnRH release; with stimulation via Kiss1 and inhibition via Dyn signalling 
(Navarro et al. 2011a, Grachev et al. 2014b). This suggests that within a low-E2 
environment (such as that in OVX rats), activation of NK3R recruits a Dyn 
signalling mechanism to suppress the LH pulses, whereas in ovary-intact 
prepubertal female rats and diestrus adult female rats, activation of NK3R 
stimulates the release of Kiss1 to increase LH release. The present study further 
suggests that an expected transitional stage might exist between these two stages, 
as activation of NK3R did not affect the LH release in OVX rats replaced with 
middle levels of E2, i.e. replaced with one E2 capsule. The underlying 
mechanisms for this non-responsive stage remain unclear. We speculate that this 
might be due to the opposing effects of both inhibitory and stimulatory of NK3R 
agonism on LH release, or an unresponsive state of the NK3R at that particular 
level of E2. 
The triphasic effects of NK3R agonism on LH release are reminiscent of 
activation of NK1R on LH release, since previous studies have shown that 
NK1R activation with substance P induced inhibitory, null or stimulatory effects 
on LH release in a variety of experimental paradigms (Vijayan and McCann 
1979, Arisawa et al. 1990, Kalra et al. 1992). Therefore, the effects of NK1R 
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agonism on LH release might similarly be modulated by the circulating levels of 
E2. Indeed, the present study has shown that activation of NK1R in the ARC 
induced inhibitory effects on LH release in OVX rats without E2 replacement, 
while stimulated LH release in OVX rats replaced with two E2 capsules (see 
Chapter 5). This indicated that the biphasic effects of NK1R activation on LH 
release are dependent on the circulating levels of E2. Although we did not study 
the effects of NK1R agonism on LH release in OVX rats replaced with single E2 
capsule, it is reasonable to speculate that a similar transition stage might exist 
between stimulation and inhibition.  
Since we administered the NK1R agonists directly into the ARC, this indicates 
that the biphasic effects of NK1R agonism on LH release are probably mediated 
in this brain region. Since the expression of Tacr1 (encoding NK1R) mRNA has 
been found in ARC Kiss1 neurones (Navarro et al. 2015), it is possible that 
activation of NK1R in the ARC is modulated through the ARC KNDy neurones. 
The stimulatory effects of substance P on LH release are indicated to be 
dependent on the Kiss1r signalling system. It has been shown that Kiss1r 
knockout mice nullified the stimulatory effects of NK1R agonism on LH release 
(Navarro et al. 2015). It was also shown in previous studies that substance P can 
directly increase the excitability of mouse ARC Kiss1 neurones (de Croft et al. 
2013). Taken together, it is possible that NK1R agonists activate the ARC Kiss1 
neurones to induce LH release, just like NK3R activation. However, the 
underlying mechanisms for the inhibitory effects of NK1R agonism on the 
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pulsatile LH release are not understood. Intra-ARC administration of NK3R 
agonists induced inhibition of the pulsatile LH release and is modulated by the 
Dyn (Grachev et al. 2012a). Since the NK1R is also expressed on KNDy 
neurones, NK1R agonism might also activate the ARC Dyn signalling to inhibit 
the pulsatile LH release. Indeed, it has been shown that substance P and NKB 
can activate KNDy neurones with similar fashions (de Croft et al. 2013). More 
studies will be needed to address this speculation. 
Both Kiss1 and GnIH/RFRP-3 belong to the peptide family named RFamide 
peptides, which has been characterised as a major regulator of GnRH neurones 
(Parhar et al. 2012). Kiss1 plays an important role in stimulating the HPG axis, 
whereas GnIH/RFRP-3 has been shown to inhibit various aspects of 
reproductive functions, including the gonadotrophin release (Kriegsfeld et al. 
2006, Johnson et al. 2007). However, previous studies have not established the 
role of RFRP-3 in the regulation of pulsatile LH release. It has been shown in 
the present study that icv administration of RFRP-3 dose-dependently inhibited 
LH pulse frequency in OVX rats (see section 6.4.1). This suggests that the 
inhibitory effects of RFRP-3 on LH release are through inhibiting the GnRH 
pulse generator. Therefore, RFRP-3 might be able to regulate the KNDy 
signalling systems in the ARC. However, intra-ARC administration of RFRP-3 
did not affect the pulsatile LH release in OVX rats (see section 6.4.6). This 
indicates that RFRP-3 signalling is not capable of affecting the ARC KNDy 
neurones directly. Recent studies suggest that 25% of ARC Kiss1 neurones 
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express GPR147, the receptor for RFRP-3, and 35% of ARC Kiss1 neurones 
receive fibre inputs from RFRP neurones (Poling et al. 2013). However, it is not 
known what percentage of Kiss1 neurones both express GPR147 and are 
innervated by RFRP-3, which casts doubt on the functional importance of the 
above morphological observations. Taken together, these data do not support the 
postulate that RFRP-3 directly acts on the ARC KNDy neurones to affect the 
pulsatile LH release. Nevertheless, endogenous RFRP-3 signalling has an 
inhibitory effect on ARC Kiss1 neurones, since the number of Kiss1 mRNA 
expressing neurones in the ARC increased by 60% in GPR147 knockout mice 
(Leon et al. 2014). Therefore, intermediate signalling systems might exist to 
relay this inhibitory effect. It has been shown in the present study that the 
suppression of pulsatile LH release by icv administered RFRP-3 can be partially 
blocked by icv administered µ-opioid receptor antagonist (see section 6.4.5). 
Therefore, µ-opioid receptor and its endogenous ligand might function as the 
intermediate signalling systems. β-endorphin, one of the endogenous ligand for 
the µ-opioid receptor has been shown to mediate effects on various reproductive 
functions, including the inhibition of sexual behaviour and gonadotrophin 
release (Pfaus and Gorzalka 1987, Bonavera et al. 1993). It has been shown that 
central administration (icv) of β-endorphin can inhibit the pulsatile release of LH 
in castrated male rats (Kinoshita et al. 1980). Therefore, the inhibitory effects of 
RFRP-3 on pulsatile LH release might be mediated via β-endorphin neurones. 
Indeed, it has been shown that β-endorphin neurones are located in the ARC in 
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rats (Finley et al. 1981), where both RFRP-3 receptor and fibres have been 
found (Kriegsfeld et al. 2006, Poling et al. 2013). Future studies will be needed 
to investigate whether the ARC β-endorphin neurones co-express with GPR147 
and are innervated by RFRP-3 fibres. Furthermore, β-endorphin neurones might 
not directly innervate ARC KNDy neurones since very moderate levels of 
µ-opioid receptors mRNA have been detected in the ARC (Mansour et al. 1995). 
Other intermediate signalling systems that express µ-opioid receptors might 
further relay the effects from β-endorphin to the KNDy neurones. Indeed, 
β-endorphin fibres have been found in many neuroendocrine important regions 
including the mPOA, the bed nucleus of the stria terminalis (BNST) and MeA, 
where dense expression of µ-opioid receptors have been found (Finley et al. 
1981, Mansour et al. 1995). Taken together, icv administered RFRP-3 may affect 
the GnRH pulse generator indirectly via multiple intermediate signalling systems 
such as the β-endorphin signalling. 
It has been shown in the present study that the antagonism of Kiss1r in the MeA 
reduced the pulsatile LH release in OVX rats (see section 7.4.1). The expression 
of Kiss1 mRNA in the MeA can be affected by the stage of oestrous cycles in 
rats, as well as the levels of sex steroids in both sexes (Kim et al. 2011). 
Therefore, the MeA Kiss1-Kiss1r signalling may play an important role in 
regulating the reproductive axis. Previous studies have implicated the MeA in 
the regulation of the LH release, although the data are controversial. Both MeA 
lesioning and stimulation have been shown to induce LH secretion in rats 
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(Lawton and Sawyer 1970, Beltramino and Taleisnik 1978). Other studies have 
shown that lesions of the MeA had no effect on LH release in rodents 
(Eleftheriou et al. 1970, Docke et al. 1983). These conflicting data might be due 
to the different experimental paradigms used. Nevertheless, these studies only 
measured mean circulating levels of LH. A more recent study monitoring LH 
pulses has shown that lesioning of MeA has no effects on the pulsatile LH 
release in OVX rats (Lin et al. 2011). However, lesioning of the MeA blocks 
restraint stress-induced suppression of pulsatile LH release (Lin et al. 2011). 
This suggests that the MeA Kiss1 per se is not involved in the generation of LH 
pulses, but mediates, at least in part, the suppression the GnRH pulse generator 
frequency in response to psychological stressors. Hypothalamic Kiss1 signalling 
has been implicated in the psychological stress-induced suppression of the 
GnRH pulse generator. Restraint stress reduced the expression of Kiss1 mRNA 
in both the mPOA and the ARC, which was associated with an inhibition of 
pulsatile LH release (Kinsey-Jones et al. 2009). It is plausible that psychological 
stressors might also affect Kiss1-Kiss1r signalling in the MeA, although further 
studies will be required to establish this. It has been shown in the present study 
that the blockade of Kiss1-Kiss1r signalling in the MeA reduced the frequency 
of LH pulses, which is in keeping with the postulate that psychological stress 
might down-regulate Kiss1-Kiss1r signalling in this limbic brain structure to 
suppress the GnRH pulse generator. The underlying mechanisms for the MeA 
Kiss1-Kiss1r signalling in the regulation of GnRH pulse generator activity are 
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unknown. It has been shown that the MeA projects directly to the ARC where 
the GnRH pulse generator is located (Coolen and Wood 1998, Usunoff et al. 
2009). However, these projections are very sparse, indicating a rather limited 
level of interaction between these brain regions. Alternatively, MeA may affect 
other brain regions that regulate the GnRH pulse generator. It has shown that 
MeA has extensive direct projections to the mPOA and the BNST (Canteras et al. 
1995, Coolen and Wood 1998), both of which have been implicated in regulating 
the pulsatile GnRH release. Intra-mPOA administration of a wide range of 
neuropeptides, including CRF, GABA and calcitonin gene-related peptide, 
suppresses pulsatile LH release (Jarry et al. 1991, Li et al. 2009a, Kinsey-Jones 
et al. 2010). Therefore, an unknown neurocircuit relay via the mPOA to the ARC 
to modulate the GnRH pulse generator might exist. Likewise, it has been shown 
that intra-BNST administration of noradrenaline and CRF inhibit the pulsatile 
LH release (Yamada et al. 2006, Li et al. 2011). Furthermore, extensive 
projections have been found from the BNST to the ARC (Dong and Swanson 
2006). Taken together, the mPOA and the BNST might relay the effects of MeA 
Kiss1-Kiss1r signalling to the GnRH pulse generator in the ARC. 
In summary, the main topic of the studies presented in this thesis invovles the 
role of various neuropeptides in regulating the pulsatile release of GnRH (Fig. 
8.1) which is essential for initiating puberty and maintaining normal 
reproductive functions. The core of this regulation is the KNDy neurones in the 
ARC, which are thought to represent part of the neural construct of the GnRH 
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pulse generator. KNDy neurones express NK3R and project to each other to 
form an interconnected network. The synchronized activation of KNDy neurones 
via NKB-NK3R signalling may produce pulsatile release of Kiss1 at the level of 
the mPOA and/or the ME to activate GnRH neurones to release GnRH pulses. 
Other neuropeptide signalling systems may directly or indirectly act on KNDy 
neurones to affect the pulsatile release of GnRH. KNDy neurones express NK1R, 
the receptor for substance P which may therefore act directly on KNDy neurones 
in the ARC to alter LH pulse frequency. RFRP-3 neurones found predominantly 
in the DMH are known to directly project to the KNDy neurones. However, a 
direct action of RFRP-3 on the KNDy neurones was not observed in present 
studies, in terms of altered LH pulse frequency, which suggests that other 
unknown signalling system may mediate the suppressive effect of RFRP-3 on 
the pulsatile release of GnRH. Finally, Kiss1 signalling in the MeA profoundly 
modulates the pulsatile release of GnRH, although the neurochemical phenotype 
and trajectory of the functional anatomical connections between the MeA and 
the mPOA and/or the ARC remain to be established.    
Fig. 8.1 Schematic diagram demonstrating the neural signalling systems 
regulating the pulsatile release of GnRH. The ARC KNDy neurones 
functionally interconnect with each other via NK3R, and project to GnRH 
neurones cell bodies in the mPOA and terminals in the ME. Kiss1 activates 
GnRH neurones via Kiss1r to release GnRH pulses at the level of the ME. 
Substance P may act on the KNDy neurones via NK1R. Furthermore, RFRP-
3 neurones in the DMH may act on KNDy neurones and/or GnRH neurones 
via GPR147. However, the present study suggests that other unknown 
signalling systems may mediate the suppressive effect of RFRP-3 on pulsatile 
release of GnRH. Finally, Kiss1 signalling in the MeA modulates pulsatile 
release of GnRH possibly via neural projections, of unknown neurochemical 















The preceding experimental work has answered a number of important questions 
regarding the role of Kiss1, NKB, substance P and RFRP-3 in regulating the 
timing of puberty onset and LH release. The future directions of work which 
could follows on from the present study include: 
1. Elucidating the mechanisms underlying the timing of puberty onset in 
over-nutritional status. 
Is Dyn involved in the regulation of the pulsatile LH release and timing of 
puberty onset in over-nutritional status? 
In the present study, we have shown that NK3R antagonism delayed the puberty 
onset and decreased the frequency of pulsatile LH release in female rats fed with 
high fat diet. We speculated that this may reflect the model that oscillation of 
NKB/Dyn in the ARC controls the pulsatile mode of GnRH release, which 
regulates the timing of puberty onset in over-nutritional status. However, little is 
known about the role of Dyn in the regulation of puberty onset in 
over-nutritional status. To address this, prepubertal female rats fed with a high 
fat diet should be chronically administered (icv) with Dyn. Furthermore, the 





2. Elucidating the neuronal pathways involved in the substance P-induced 
suppression of the GnRH pulse generator. 
Is Dyn involved in the suppression of pulsatile LH release induced by intra-ARC 
administered substance P? 
In the present study, we have shown that intra-ARC administration of substance 
P can suppress the pulsatile release of LH in OVX rats without E2 replacement. 
However, the underlying mechanisms are still unknown. It is speculated that, 
similar to NKB, the inhibitory effects on pulsatile LH release by substance P are 
modulated by the ARC Dyn signalling. To address this, Dyn receptor antagonist 
should be directly administered into the ARC and the suppressive effect of 
substance P on pulsatile LH release assessed. 
 
3. Elucidating the role of the MeA Kiss1 in regulating the sexual 
maturation. 
Does the MeA Kiss1 affect the timing of puberty onset and the pulsatile LH 
release? 
It is well-established from lesion studies that the MeA affect the timing of 
puberty onset in female rats. The MeA Kiss1 might be involved in this process. 
We have shown that intra-MeA administration of a Kiss1r antagonist suppressed 
the pulsatile release of LH. However, it is unknown whether the MeA Kiss1 can 
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also affect the GnRH pulse generator during the sexual development. To address 
these questions, prepubertal female rats should be chronically administered with 
Kiss1r antagonist into the MeA. The effects on pubertal timing and dynamic of 
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